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Introduction 
Annually, more than 1 million patients are treated worldwide for skeletal 
complications in the fields of orthopedic surgery, plastic and reconstructive 
surgery, dental implantology, maxiollofacial surgery and neurosurgery. These bone 
defects can be caused by congenital skeletal abnormalities, trauma, oncologic 
surgery and failures of physiologic osteosynthesis.  
A good bone graft has four main characteristics: it is (1) bioactive, which leads to 
the ability to bond to bone tissue without the intervention of fibrous tissue, (2) 
osteoconductive, thus able to guide bone tissue growth along the surface and into 
pores, (3) osteoinductive, i.e. capable of inducing differentiation of pluripotent 
stem cells into bone-forming osteoprogenitor cells, and (4) it stimulates 
osteogenesis, i.e. formation of bone by osteoblastic cells within the graft.  
The use of autologous bone grafts is the gold standard in treating bone defects. 
Different donor sites are available depending on the application. For example, free 
vascularized bone flaps can be harvested from the radial forearm, fibula, iliac crest 
and scapula, and for non-vascularized bone autografts donor bone can be obtained 
from the iliac crest, rib, distal radius and olecranon [1]. Despite the advantageous 
clinical efficacy of autologous bone, transplantation with autologous bone grafts 
has also several drawbacks: low availability of transplantable tissue, donor site 
morbidity, and rapid depletion of the osteogenic capacity of the graft [2, 3]. 
Besides autologous bone graft, other treatment modalities can be used, such as 
allografts (i.e. human cadaveric bone obtained via the bone bank). Allografts are 
associated with many complications, including risk of viral transmission, bacterial 
infections, malignancy, toxins and systemic disorders like rheumatoid arthritis and 
autoimmune diseases. and are therefore not frequently used [4, 5]. 
An alternative for autologous grafts and allografts are the synthetic biomaterials. 
Synthetic biomaterials can be used as a scaffold or carrier material in the field of 
tissue engineering. The aim of bone tissue engineering research is to develop a 
functional bone substitute to regenerate damaged or lost bone tissue. The general 
approach in tissue engineering is to develop a material composed of one or a 
combination of (1) a scaffold and/or carrier, (2) biological compounds (growth 
factors and/or bioactive molecules), and (3) cells.  
In the last decade, different materials have been described, including bioactive 
glass, polymers and calcium phosphate (CaP) based ceramics or cements [6]. The 
silica-based bioactive glasses (BGs) are a group of synthetic biomaterials with the 
unique ability to bond to living bone by forming a biologically active bone-like 
apatite layer on their surface [7-10] that acts as a template for calcium phosphate 
precipitation and directs new bone formation [7, 10, 11]. Additionally, it has been 
reported that BG has stimulatory effects on the osteogenesis and 
neovascularisation by attracting osteoprogenitor cells and by stimulating the 
differentiation into matrix-producing osteoblasts [7-11] and by stimulating the 
secretion of angiogenic factors [12, 13], respectively. CaP-based materials are of 
major interest in the bone regenerative therapies because they show a similar 
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biological composition as natural bone mineral. In addition, they are non-toxic, 
biocompatible, and allow direct bone bonding without intervening soft tissue 
layers. CaP-based materials can be prepared in the form of granules, blocks or 
cements. 
CaP ceramics can be classified according to the crystal phase, e.g. hydroxyapatite 
(HA), β-tricalcium phosphate (β-TCP), biphasic calcium phosphate (BCP), 
amorphous calcium phosphate (ACP), carbonated apatite (CA), and calcium 
deficient hydroxyapatite (CDHA). A list of abbreviations of CaP-crystals with 
chemical formula and Ca/P-ratio is given in Table 1 [14]. 
CaP ceramics have a compressive strength (300 to 900 MPa) and tensile strength 
(40 to 300 MPa) similar or higher than those of cortical bone. However, due to the 
lack of elasticity the material is very brittle and therefore not suitable for load-
bearing applications. Other disadvantages of CaP ceramics are their low 
degradation rate [14] and relatively poor handling properties. CaP ceramics are 
available in a fixed form and, therefore, the material is difficult to shape into the 
dimensions of the bone defect. These negative properties of CaP ceramics might be 
improved by using CaP cements (CPC). 
 
Calcium phosphate cements  
CPC consist of a powder phase of calcium and phosphate salts, which after mixing 
with an aqueous solution will form an injectable paste at body temperature. The 
advantage of using CPC as a bone substitute material is that it has a similar 
chemical composition, the same calcium and phosphate ions ratio as the mineral 
phase of bone. In addition, the cement paste can be directly injected in bone 
defects, which leads to less invasive and a faster surgery (Figure 1) as compared to 
ceramic bone substitutes that have to be shaped to the defect dimensions during 
operations, which is more labor intensive [15-17]. For clinical application, a certain 
initial and final setting time of the CPC is required.  
  
 
Figure 1 CPC injection in a femoral condyle defect in a rabbit. (A) femoral condyle defect, (B) 
injection of the CPC, (C) CPC after in situ setting. 
 
The clinical meaning of the final setting time relates to the time necessary to set 
the cement sufficiently so it can be touched without damaging it. For clinical 
application, it means that after mixing, the cement must be applied before the 
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initial setting time, and that the wound needs to be closed after the final setting 
time.  
Self-setting CPC was first described by Brown and Chow (1986) and consisted of 
only CaP compounds (i.e. tetracalcium phosphate monoxide (TTCP) and dicalcium 
phosphate dehydrate (DCPD)). Their study aimed at the development of slurries for 
remineralizing carious lesions. Studies on the reaction of TTCP + DCPD to 
hydroxyapatite (HA) resulted in the finding that some of the aqueous pastes harden 
in time. This inadvertent discovery resulted in a new type of self-hardening 
cements consisting only of CaP [15]. 
In general, it has been demonstrated that different CPC compositions are non-toxic, 
biocompatible and osteoconductive [15-17] in different animal models, for 
example in dogs [18, 19],  goats [20, 21], and rabbits [22]. Multiple studies have 
reported that a temporal increase of newly formed bone can be seen in different 
CPC [16, 21, 23] indicating that CPC are promising candidates for bone 
regeneration. Several CPC formulations have been approved by the Federal Drug 
Administration for clinical use. Examples of these commercially available CPC are 
BoneSource, Cementek® and Calcibon®. In Table 2, a list of commercially 
available CPC is given [14]. 
 
CPC biodegradability  
The replacement of a biomaterial by living bone is preferred because this avoids 
potential complications later on, such as inflammation, stiffness, pain and bacterial 
seeding. To obtain replacement of bone, new bone formation and resorption of the 
material, e.g. biodegradation of the material, is required. The rate of material 
degradation and newly formed bone should optimally be in perfect balance to 
maintain mechanical stability (integrity of the ceramic scaffold) and allow a gradual 
takeover of mechanical strength by newly-formed bone tissue. 
Biodegradation of CaP-based material can occur via two processes, namely (1) 
extracellular liquid dissolution, and (2) disintegration into small particles that can 
be intracellularly digested or transported to other adjacent tissues. The first 
process depends on the solubility product of the formed CaP biomaterial, while the 
second process is mainly dependent on the solubility product of the connecting 
agents of the powder particles after crystallization [24]. 
The biodegradation of the material is dependent on different factors, including the 
final product of the cement setting. For example, apatite is a more stable 
compound, and therefore the degradation rate is slower as compared to brushite 
[25]. Due to the slower degradation rate, the material has a relatively good 
mechanical stability, albeit insufficient for load-bearing applications. On the other 
hand, a less stable compound like brushite leads to a faster biodegradation. In 
addition, the CaP chemical composition itself can influence the material 
degradation. This is exemplified by an approach in which calcium sulphate (CS) was 
added to CPC, composed of TTCP and DCPA. Although biocompatible, CS is less 
suitable for bone substitution because of its rapid resorption.  
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Table 1 Abbreviations of CaP-compounds with corresponding chemical formula and Ca/P-
ratio 
Abbreviation Name Formula Ca/P-ratio 
ACP Amorphous calcium 
phosphate 
- 1.25<x<1.55 
BCP Biphasic calcium 
phosphate 
Ca3(PO4)2 + 
Ca10(PO4)6(OH)2 
1.50<x<1.67 
CA Carbonated apatite, 
dahlite 
Ca5(PO5,CO3)3 1.67 
CDHA Calcium deficient 
hydroxyapatite 
Ca10-x(HPO4)x(PO4)6-
(OH)2-x 
1.50<x<1.67 
DCPA Dicalcium phosphate 
anhydrous, Monetite 
CaHPO4 1.00 
DCPD Dicalcium phosphate 
dihydrate, Brushite 
CaHPO4•2H2O 1.00 
HA Hydroxyapatite Ca10(PO4)6(OH)2 1.67 
MCPM Monocalcium 
phosphate 
monohydrate 
Ca(H2PO4)2•H2O 0.50 
OCP Octacalcium 
phosphate  
Ca8H2(PO4)6•5H2O 1.33 
pHA Precipitated 
hydroxyapatite 
Ca10-x(HPO4)x(PO4)6-
x(OH)2-x 
1.50<x<1.67 
α-TCP α-Tricalcium 
phosphate 
α-Ca3(PO4)2 1.50 
β-TCP β-Tricalcium 
phosphate 
β-Ca3(PO4)2 1.50 
TTCP Tetracalcium 
phosphate  
CaO•Ca3(PO4)2 2.00 
 
Interestingly, a mixture of CS, TTCP and DCPA leads to a good biocompatibility and 
enhanced degradability and bone ingrowth as compared to CPC consisting of only 
TTCP and DCPA [26]. In addition, the chemical composition of the CPCs plays also a 
role in the active resorption of the cement. For example, it has been reported that 
a cement produced by a mixture of sodium calcium phosphate, Na3Ca6(PO4)5, 
tetracalcium phosphate and β-tricalcium phosphate powder and malic acid or citric 
acid have a different relationship regarding the number of osteoclasts on the 
cement [27]. Since osteoclastic activity can be a marker for the evaluation of 
bioresorbabillity, it was suggested that cement mixed with malic acid is more 
promising for bone substitution in an active manner than cement mixed with citric 
acid. Also, the patient plays an important role in material degradation. Depending 
on the patient’s age, sex, and general metabolic health condition, the speed of 
degradation can be different. 
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Table 2 Details of currently available commercially available calcium phosphate cements  
 
In addition, the implantation site influences scaffold biodegradation and bone 
formation in the vicinity of the scaffold. For example, ceramic material placed in a 
femoral or cranial defect will be exposed to different environments, including 
differences in biomechanical loading, surrounding tissue and blood/nutrient supply. 
Besides the environment, the origin of the bone tissue (long bone formation 
(femur) is endochondral, while cranial bone formation is intramembranous) may 
play a role in degradation and bone formation due to distinctive signaling 
properties [28]. Other factors involved in the biodegradability are porosity of the 
material, crystallinity (crystal size, crystal perfection and grain size), particle size of 
the CaP powder, and liquid/powder ratio [24, 29, 30]. These factors influence each 
Cement Constituents End 
product 
Setting 
time 
Compression 
strength 
(MPa) 
Porosity 
Biobon  
(α-BSM)® 
ACP, DCPD Poorly 
crystallin
e, HA, 
Ca/P=1.4
5 
15-20 min 
(37°C) 
12 50-60% 
Micro 
Biopex® 75% α-TCP, 18% 
TTCP, 5% DCPD 
2% HA 
HA 8 min 80 Micro 
Bone  
sourceTM 
TTCP, DCPD HA, 
Ca/P=1.6
7 
10-15 min 
(37°C) 
36 Micro 
Calcibon® 61% α-TCP, 26% 
DCPA, 10% 
CaCO3 
3% pHA 
Calcium 
deficient 
CA 
Ca/P=1.5
3 
2-4 min 
(37°C) 
60-70 44%  
Micro 
Cementek® α-TCP, TTCP, 
Ca(OH)2 
HA, 
Ca/P=1.6
4 
40 min 20 50%  
Micro 
ChronOS 
inject® 
44% β-TCP, 21% 
MCPM, 31% β-
TCP granules, 
5% 
MgHPO4*3H2O 
Brushite 
(DCPD) 
12 min 3 Micro 
MimixTM α-TCP, TTCP,  
Citric acid 
HA (37°C) 22 Micro 
Norian-
SRS® 
MCPM, α-TCP, 
CaCO3 
Dahlite 
(CA) 
Ca/P=1.6
7 
12 h 28-55 Very 
low 
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other, and are influenced by the chemical composition of the material. For 
example, CaP compounds that transform into relatively highly crystalline 
hydroxyapatite after hydration will be essentially non-resorbable in vivo [24]. 
 
CPC porosity 
CPC contains an intrinsic high nano/sub-micron-sized porosity. Several parameters, 
including particle size of the powder phase [29] and liquid/powder ratio [30] can 
affect the creation of this type of porosity and, hence, material degradation, and 
consequently allow bone ingrowth. Nanoporosity is an important parameter to be 
controlled in CPC materials because it enables fluid flow within the material and 
can affect protein adsorption. In contrast to nano/sub-micron-sized porosity, 
macroporosity enables tissue ingrowth and is the key factor for CPC degradation 
and its substitution by new bone tissue. 
 
Macroporosity 
Macropores have been built into biomedical materials since the early 1970s [31, 
32]. Resorbability of a material is an important clinical property; it is preferred that 
the CPC will degrade in a short period of time parallel to new bone tissue 
formation. Pores of a suitable diameter and an adequate interconnectivity are 
essential for bone tissue ingrowth and for enhancing CPC degradation. Debates 
about the adequate pore size for bone replacement materials are still ongoing. 
Researchers have suggested that a pore size larger than 100 μm is sufficient for 
tissue ingrowth [33, 34], whereas other investigations conclude that larger pores 
(up to 500 μm) have to be preferred [35]. Although highly porous materials will 
lead to a faster degradation, an adequate balance between degradation and 
structural integrity should be found. Figure 2 gives an overview of typical porous 3D 
structures. 
 
Interconnectivity 
Besides bone ingrowth in the cement pores, interconnectivity is a key factor for 
new tissue formation within the cement. When the pores form an interconnected 
network, cellular and vascular penetration will be favored, ensuring new tissue 
formation in all void areas of the implanted material. Furthermore, variations in 
interconnectivity will lead to modifications in the architecture and mechanical 
properties of the CPC. A suitable balance between pore size, pore volume, 
interconnectivity and structural integrity is a major issue in the development of 
CPC-based bone substitution materials. 
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Figure 2 μCT images of composite discs with different CPC/biodegradable polymer ratio after 
burning out the polymer component. A higher amount of biodegradable polymer leads to an 
increase in porosity of the scaffold material. Bar represents 1 mm. 
 
Enhancement of macroporosity  
In general, the degradation rate of plain CPC is limited (Figure 3). For a better bone 
regeneration, different methods have been used to induce macroporosity in CPCs, 
such as inclusion of water-soluble additives, foam-forming agents, fabrication of 
scaffolds by additive manufacturing technologies and biodegradable polymeric 
microspheres. 
 
Water-soluble additives 
The inclusion of water-soluble additives in CPCs is a common approach to induce 
macroporosity. Also known as the particle leaching technique, it is often used to 
create porosity in other bone substitute materials such as pre-set ceramics or 
polymeric scaffolds. Saccharides such as sucrose, pectin, chitosan or mannitol as 
well as the salts sodium chloride and sodium phosphate are water-soluble 
compounds to generate macroporosity in CPCs. For example, sucrose is a 
disaccharide derived from glucose and fructose. Sucrose crystals of specific sizes 
have been included in CPC, and macroporosity is generated after dissolution of the 
crystals during incubation of the samples in aqueous media [36]. In addition, A 
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more novel technique is the creation of microspheres from a saccharide. Pectin is a 
water-soluble polysaccharide that, in the form of microspheres, has been recently 
introduced in CPC to create round pores after degradation [37]. 
 
 
Figure 3 Histological sections of a femoral condyle of a rat injected with plain CPC or CPC 
with biodegradable polymer, after 4 and 12 weeks of implantation time. In the plain CPC 
implant, degradation and bone ingrowth is limited and restricted to the edges of the defect. 
In contrast, CPC with biodegradable polymer shows an increase in implant degradation and 
bone ingrowth from 4 weeks implantation onwards. Methylene blue and basic fuchsin 
staining. Bar represents 500 μm. 
 
Foam-forming agents 
A different approach to enhance porosity in CPC is to combine it with an agent that, 
by foaming, will generate gas bubbles that will lead to the generation of pores. 
Hydrogen peroxide bubbling [38], or the creation of CO2 bubbles from sodium 
bicarbonate during the cement setting [39, 40], are examples of foam-forming 
methods to generate porosity. 
Acetic and citric acids have been investigated as porogens by the gas-foaming 
technique. The final cement presents good injectable properties and higher 
porosity when combined with citric acid [41]. Furthermore, citric acid has also been 
used in combination with sodium bicarbonate as effervescent agents to generate 
porosity [42]. 
A similar technique is to mix the cement paste with a foam obtained previously 
from a foaming agent. A foam from the natural protein albumin has been used in 
this approach, generating macroporous scaffolds with promising in vivo results [43-
45]. Following this procedure, no potentially toxic gas is liberated after 
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implantation of the cement, since the foam is generated before mixing it with the 
cement paste. 
 
Additive manufacturing techniques 
Rapid prototyping is an advanced manufacturing technique that allows the 
automatic construction of physical objects using additive manufacturing 
technology. Using this concept, CPC scaffolds with highly controlled internal pore 
architectures have been obtained [46, 47]. Stereolitography is another additive 
manufacturing process which has been applied for CaP scaffold fabrication with a 
controlled internal channel architecture [48]. However, a major drawback of these 
techniques is that the scaffolds have to be fabricated prior to implantation in the 
body, meaning that this approach is not suitable for injectable and/or minimally 
invasive procedures. 
 
Surfactants 
Sodium dodecyl sulphate (SDS) [49] has been applied within CPC because of its air-
entrapping properties. Similar to other surfactants, SDS presents a low surface 
tension. Air bubbles are incorporated during the mixing of the powder and the 
liquid component of the cement. These bubbles become covered by a sheath of 
SDS molecules, creating macroporosity after the CPC solidification. Alternatively, 
cetyltrimethyl ammonium is a surfactant that has been applied as CPC porosity 
inducer [50]. 
 
Biodegradable polymers 
Approximately 30% of bone is composed of organic compounds, of which 90 to 
95% is collagen. Consequently, natural polymers are being widely studied in 
relation to bone tissue engineering. Collagen presents a slow degradation rate, 
which makes it unsuitable as porosity inductor for CPCs. In contrast, gelatin is a 
natural enzymatically degradable polymer derived from collagen with a faster 
degradation rate. For these reasons, gelatin has been used in the form of 
microspheres to generate macroporosity in CPCs after its degradation [51-53].  
Besides natural polymers, there is a wide range of synthetic polymers that can be 
used to induce macroporosity in CPCs. The synthetic polymers poly(epsilon-
caprolactone) and poly(l-lactic acid) have been used as fibers to enhance resistance 
of CaP materials in a first stage and porosity after polymer degradation [54].   
Poly(DL-lactic-co glycolic acid) (PLGA) is employed for the production of 
microspheres to be embedded in CPC material and generate porosity after polymer 
hydrolytic degradation [55-57]. In addition, the enzymatically degradable 
poly(trimethylene carbonate) (PTMC) has been processed also in the form of 
microspheres and introduced in CPCs, generating interconnected macroporosity 
and minimal inflammatory response [58, 59].  
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In Figure 4, an overview of gelatin, PTMC and PLGA inclusion and degradation in 
CPC is shown. 
 
 
Figure 4 CPC/PLGA, CPC/gelatin and CPC/PTMC samples. The different characteristics of the 
polymers lead to differences in material degradation of the CPC.  
 
Combinations 
Finally, it has to be mentioned that, in several studies, more combinations of the 
previously mentioned methods have been investigated to generate porosity in 
CPCs. For example, CO2 foaming has been used to induce porosity in combination 
with PLGA-microparticles embedded in CPC for the creation of secondary porosity 
at a later time point [60]. Furthermore, mannitol crystals have been used to 
generate early macroporosity in combination with slower resorbable chitosan 
fibers that will improve the mechanical properties of the cement at initial time 
points, but subsequently will degrade, enhancing the already generated 
macroporosity after mannitol dissolution [61, 62]. 
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CPC as a (drug) delivery system 
Besides the role as a bone substitute, CPC can be used as a carrier for local and 
controlled drug release. This makes the material very attractive because it enables 
(i) directed bone healing, and (ii) treatment of the potential disease underlying the 
bone defect. Examples of skeletal diseases to treat are bone tumors, osteoporosis 
or osteomyelitis [63]. 
Several aspects need to be considered regarding the incorporation of drugs to CPC. 
First of all, it needs to be verified that the setting reaction and hardening 
mechanisms and physico-chemical properties do not alter after the addition of 
drugs. Secondly, the drug release kinetics in vitro needs to be characterized, e.g. by 
in vitro release experiments with radioiodinated drugs of interest [64]. 
Subsequently, a release profile is obtained by measuring in time the remaining 
activity in a gamma counter. This needs to be followed by an assessment of the in 
vivo efficacy of the drug delivery carrier [64], after which the clinical use must be 
evaluated [63]. The efficacy needs to be analyzed because the activity of the drugs 
and/or bioactive molecule might be lost due to the chemical reactions during 
cement setting, and therefore the drug and/or bioactive molecule will have no 
clinical effect [65, 66]. The incorporation of the drugs or other bioactive molecules 
can be in the liquid phase [67] and/or powder phase [68] of the CPC. 
 
Loading growth factors and/or bioactive molecules 
As mentioned before, CPC degradation is slow and can be increased by the 
incorporation of macroporosity to CPC via polymer microparticle addition [39, 51, 
57, 69, 70]. If the porosity of the material increases in time, then the release profile 
of the drugs will not only be dependent on the diffusion through the material. 
Increasing the porosity is therefore not only beneficial for the material degradation, 
but also for the release profile of incorporated drugs. 
Another advantage of the inclusion of polymers is that these polymers can serve as 
a carrier system to obtain a more sustained release of drugs and/or bioactive 
molecules. For example, It is shown that a sustained release of recombinant human 
bone morphogenetic protein-2 (rhBMP-2) from PLGA-microparticles resulted in 
more and faster bone formation in rabbit calvarial defects as compared to 
immediate release of rhBMP-2 [71]. In addition, other CPC carrier systems based on 
different polymeric microparticles such as gelatin [72] or the natural occurring 
pectin have demonstrated to be beneficial for the retention of drugs [37]. 
The drugs and/or bioactive molecules can be either absorbed on the surface of the 
microparticle after microparticle fabrication, or entrapped in the microparticles 
during the microparticle fabrication. Different types of molecules can be loaded or 
entrapped in the microparticles, including antibiotics, anti-inflammatory drugs [73, 
74],  and growth factors [75-78].  In addition, these delivery systems can be used to 
deliver non-proteinaceous compounds (e.g. genes [79, 80]), and even cells [81].  
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Growth factor delivery 
Bone healing is a complex physiological process that is initiated and controlled by 
growth factors, such as members of the transforming growth factor (TGF) 
superfamily, which includes TGF-β that plays a significant role in the repair of skin 
and bone [75], as well as Bone Morphogenetic Proteins (e.g. BMP-2), which play an 
important regulatory role in many steps of bone morphogenesis [76]. BMPs seem 
to play an important role in increasing the material degradation and bone forming 
capacity of CPC. For example, it has been reported that addition of BMP-2 to the 
PLGA-microparticles in CPC composites placed in a rat critical sized cranial defect 
model significantly increases the degradation and the bone forming capacity of the 
material as compared with plain CaP/PLGA cement composites, from 4-weeks 
implantation period onwards (Figure 5) [77]. Another study reported that injectable 
rhBMP-2/CPC stimulated bone formation and blood vessel ingrowth after two 
months in vertebroplasty, as compared to rhBMP-2 /polymethylmethacrylate 
(PMMA) bone substitute [82]. In addition, an effect of rhBMP-2 has been observed 
in an equine model, where surgically osteotomies and ostectomies of the accessory 
metatarsal bones were induced. The rhBMP-2/CPC increased early bone formation 
as compared to non-treated bone defects [83]. 
 
 
Figure 5 Histological sections of cranial defects, consisting of either (1) plain CPC, or (2) CPC 
loaded with BMP-2, after 12 weeks. CPC/PLGA shows limited ingrowth of bone after 12 
weeks of implantation. In the CPC/PLGA loaded with BMP-2, more bone formation is 
observed. Methylene blue and basic fuchsin staining. Bar represents 625 μm.  
 
Another example of a growth factor used to induce material degradation and bone 
formation is TGF-β. It have been demonstrated that addition of TGF-β to CPCs 
within the liquid component is released in a bioactive form and still capable of 
stimulating the differentiation of preosteoblastic cells in vitro [84] and results in 
vivo in an increased bone formation when implanted in 5-mm rat cranial defects 
[78]. However, depending on the loading of the TGF-β and the chemical 
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composition, different results may be obtained. For example, addition of TGF-β to 
gelatin microparticles in CPC composites significantly accelerated implant 
degradation, and only a tendency toward increased bone ingrowth 12 weeks 
postoperatively as compared to plain CaP/gelatin cement composites was observed 
[85]. 
Bone is a highly vascularized tissue, and therefore the formation of new blood 
vessels, angiogenesis, is essential for bone regeneration [86]. Thus, besides an 
important role for BMPs, angiogenesis stimulating factors seem to play an essential 
role in bone formation. 
Vascular endothelial growth factor (VEGF) is a potent angiogenic growth factor, 
which is known to stimulate blood formation from several studies [87, 88]. The 
half-life time of VEGF is less than 1 hour following in vivo injection [89], and 
therefore a carrier system is required to have a controlled release of the growth 
factor. The method of delivery seems to influence the efficacy of VEGF. For 
example, when VEGF is directly injected in vivo, poorly perfused fragile capillaries 
without connection to the pre-excisting circulation as well as agiomas are observed 
[90]. In contrast, sustained release of VEGF results in the formation of regularly 
organized vasculature [91]. The CPC/polymer microsphere carrier system is a 
promising candidate for sustained release VEGF, and has shown to promote 
vascularization within these bone substitute materials [92]. In addition, local 
sustained VEGF release from carrier biomaterials improved the healing of non-
critical sized bone defects [93]; however, this is contradictionary with another 
study which reported no difference in bone formation when VEGF was released 
locally from a carrier system [94]. The different VEGF release kinetics may be a 
result of differences in carrier system, VEGF concentration and animal model used. 
To mimic bone healing in a more natural fashion, a combination of different growth 
factors, such as angiogenic and osteogenic growth factors, may be beneficial. It is 
reported that dual delivery of VEGF and BMP-2 loaded on different scaffold 
materials can increase both capillary density and bone formation ectopically [95], 
whereas it leads to more bone formation orthotopically as compared to single 
delivery of BMP-2 [94]. The dual delivery of BMP-2 and fibroblast growth factor 
(FGF) by a CPC carrier has also been reported to more substantially induce new 
bone formation [96, 97]. 
 
Other products and/or molecules 
Either from a biological point of view as well as considering cost effectiveness, 
research is focusing on the reduction of included growth factors or replacement of 
the growth factors by less expensive, alternative molecules. Previous studies on 
alternative molecules with angiogenic and osteogenic activity revealed some 
agents, which effectively increased bone formation, such as statins [98], isoflavone 
derivates [99], copper ions [100], TAK-778 [101] and Icariin [102]. Instead of 
delivering bioactive molecules, it is possible to deliver cells via CaP scaffolds [103]. 
In particular, the delivery of stem cells is promising because stem cells are 
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undifferentiated cells with the capacity to differentiate into one or more cell types, 
and have the ability of self-renewal [104]. In addition, the delivery of genetic 
material (e.g. DNA, RNA) can induce bone formation [79]. It has been reported that 
adenoviral vectors can be incorporated in synthetic CPC to provide locally effective 
and sustained release of genetic material [105]. The delivery of a plasmid encoding 
vascular endothelial growth factor(165) (pVEGF165) via collagen/CaP carrier 
resulted in vivo in an increase in bone volume [80]. Besides the delivery of plasmids 
encoding growth factors, the delivery of numerous signaling molecules involved in 
bone development and regeneration, such as the transcription factors Runt-related 
transcription factor 2 (Runx2) and Osterix, show promise for the regeneration of 
bone in vivo [106]. 
 
Performance of CPC in compromised conditions 
As mentioned before, CPCs represent reliable candidates for the substitution of 
bone due to their similar chemical composition compared to the mineral phase of 
bone and their biocompatibility and osteoconductive properties. Several different 
formulations of CPC including biodegradable polymeric microparticles have been 
studied and demonstrated to be non-toxic, biocompatible and osteoconductive 
[15, 16, 107] in different animal models for example in rabbits [22], dogs [18, 19], 
and goats [21, 108]. However, the outcome of those studies is based on 
performance of CPCs in healthy individuals and therefore does not provide 
information on CPC performance in a compromised situation, such as in 
osteoporotic patients.  
In osteoporotic conditions, the balance between bone formation (i.e. osteoblasts) 
and bone resorption (i.e. osteoclasts) is disturbed. This disturbance leads to a 
decrease in bone mass (i.e. osteopenia) and a decline in bone micro-architecture, 
which leads to an enhanced fragility of the skeleton and hence an increased risk of 
fractures [109]. The occurrence of osteoporosis is strongly related to hormonal 
changes since the lack of estrogen induce the increase of osteoclastogenesis and 
osteoclastic activity [110]. It is assumed that in the world population over 50 years 
of age, 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture 
indicating the requirement for bone substitute materials in osteoporotic patients. 
To study osteoporosis, different animal models have been used such as rodents, 
dogs, sheep and goats [111]. Osteoporosis can be introduced either via chemical 
stimulation, for example by the administration of prednisolone to rabbits [112] or 
via an ovariectomy in female animals or an orchidectomy in male animals [109, 
111]. The removal of the ovaries or testis induces a decline in estrogen and 
androgen levels, respectively, which leads to reduced BMD and BMC. The most 
well-established osteoporosis animal model is the ovariectomized (OVX) rat. 
Following OVX, a rapid decrease in bone mass and strength occurs which mimics 
the bone changes following oophorectomy or menopause in humans [109]. In 
Figure 6 the bone architecture of healthy and OVX rats is depicted. 
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In view of the differences in bone morphology and metabolism between 
osteoporotic patients and healthy humans, the biological performance of CPC in 
osteoporotic patients may also be different. For example, it has been reported that 
calcium sulphate-based bone substitute materials are resorbed faster and possess 
an altered performance in a spine model in osteoporotic rats compared to healthy 
control animals. In addition, it has been reported that under osteoporotic 
conditions the cement-mediated bone augmentation is altered compared to 
healthy controls [113]. However, up to date no information on the performance of 
CPC (either supplemented with additives) is available. 
 
 
Figure 6 Histological sections of femoral condyle of healthy and osteoporotic rats. Bone (+)  
and trabecular spacing (*) are indicated. Bar represents 500 μm. 
 
Objectives of this thesis 
The general objective of the current thesis was to evaluate the potential 
improvement of different additives regarding the biological performance of CPC. To 
that end, the influence of porogen addition (i.e. PLGA-microparticles) on the 
biological performance of CPC was evaluated firstly, after which the effect on CPC 
performance of various incorporated biologically active additives (i.e. BG and BMP-
2) was explored. Furthermore, the differences between the biological performance 
of CPC in healthy and osteoporotic conditions was evaluated. 
 
The following research questions were addressed: 
1. To what extent can addition of PLGA-microparticles improve the biological 
performance of CPC/PLGA (Chapter 2)? 
2. Can the biological performance of CPC be improved by the addition of bioactive 
glass (Chapter 3)?  
3. Does the solubility of BMP-2 influence the bioactivity, release profile of and 
osteoinductive properties of CPC scaffold material (Chapter 4)? 
4. Does the BMP-2 loading method to CPC influence the release kinetics and 
osteoinductive potential of CPC (Chapter 5)? 
5. What are the differences in biological performance of CPC between 
osteoporotic and healthy rats (Chapter 6)? 
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Introduction 
Calcium phosphate (CaP) cements represent a promising candidate material for 
bone substitution in dentistry, orthopedics, and reconstructive surgery, due to their 
biocompatibility and osteoconductive properties, as well as the potential to use 
minimally invasive surgery because of their injectability [1, 2]. However, an 
important disadvantage of CaP cements is the slow degradation rate of the 
material and control thereof [3]. 
CaP cements contain an intrinsic nanoporosity (pore size 10 nm - 100 nm), which is 
insufficient to substantially enhance material degradation for clinical benefit or 
tissue ingrowth [4, 5]. Microporosity (pore size 1 - 50 μm) or macroporosity (pore 
size > 50 μm) can be introduced inside CaP cement, by using different approaches, 
in order to enhance material degradation. The use of sodium bicarbonate to obtain 
CO2-gas bubbles during cement setting has demonstrated to create macroporosity 
[6], however with poor control over pore distribution. In contrast, mixing water-
soluble crystals [7, 8]  or biodegradable polymer microparticles (e.g. gelatin [9] or 
poly(D,L-lactic-co-glycolic) acid (PLGA) [10-13]) as porogens homogeneously 
through the cement powder has demonstrated to be a feasible method to obtain a 
homogeneous microporosity after in situ crystal leaching or microparticle 
degradation, respectively. 
PLGA is biocompatible, non-toxic and its degradation properties can be modified by 
changing different parameters such as molecular weight or the lactic to glycolic 
acid ratio [14]. The degradation of PLGA depends on hydrolysis, where polyglycolic 
acid degrades faster than polylactic acid. In the form of microparticles, PLGA can 
have a role as porogen in CaP/PLGA composites [11, 12, 15]. Moreover, PLGA-
microparticles have been proposed as a carrier for the delivery of drugs and/or 
growth factors into bone defects to direct biological responses [16-20]. The 
molecular weight (MW) of PLGA is influencing the degradation of the 
microparticles and thus the obtained porosity for bone tissue ingrowth. It is 
demonstrated that relatively high molecular weight (MW ~40kDa) PLGA-
microparticles lead to a slower material degradation in vivo compared to PLGA-
microparticles with lower molecular weight (MW ~5 kDa) [21].  
Although the biological data of composites containing PLGA-microparticles of a 
MW of 5kDA are encouraging [21], no data are available on the temporal 
progression of bone defect closure. In addition, it was hypothesized that a further 
acceleration of in vivo material degradation might be achievable by adding a higher 
amount of PLGA-microparticles. Consequently, the rationale for the current study 
was to evaluate the bone regenerative effect of CaP/5kDa PLGA-cement composite 
material in a temporal fashion (i.e. implantation for 4, 8 and 12 weeks) and with 
variation in PLGA-microparticle amount (i.e. 20 vs. 30 wt.%) in critically-sized 
cranial defects in rats. 
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Materials and Methods 
Materials 
CaP cement consisted of 85% alpha tri-calcium phosphate (α-TCP), 10% dicalcium 
phosphate anhydrous (DCPA) and 5% precipitated hydroxyapatite. The cement 
liquid applied was a sterilized 2 wt.% aqueous solution of Na2HPO4. Poly(DL-lactic-
co-glycolic acid) (PLGA) (Purasorb®, Purac, Gorinchem, The Netherlands) with a 
lactic to glycolic acid ratio of 50:50 and a molecular weight (Mw) of 4.54 ± 0.02 
kg/mol was used for microparticle preparation. 
 
Preparation of PLGA-microparticles 
To prepare PLGA-microparticles, a double-emulsion-solvent-extraction technique 
(water-in-oil-in-water) was used, as described before [13]. Microparticles were 
produced by adding 500 μl of distilled water to 1400 mg PLGA in 2 ml 
dichloromethane. The mixture was emulsified using a Turrax® emulsifier for 60 
seconds at 6000 rpm. Then 6 ml 0.3% aqueous poly(vinyl alcohol) (PVA, Acros 
Organics, Geel, Belgium) solution was added and emulsified for another 60 sec at 
6000 rpm to produce the second emulsion. The emulsion was transferred to a 
stirred beaker, after which 394 ml 0.3% PVA solution and 400 ml of 2% isopropylic 
alcohol solution was added slowly. After 1 hour of stirring, the microparticles were 
allowed to settle for 15 min and the solution was decanted. Then, the 
microparticles were washed and collected through centrifugation at 1500 rpm for 5 
min, lyophilized  and stored at -20°C until use. The size distribution of the 
microparticles was determined by image analysis (Leica Qwin®, Leica 
Microsystems). The microparticles were imaged by scanning electron microscopy 
(SEM; JEOL6310 at 15kV). 
 
Preparation of CaP/PLGA composites [21] 
PLGA-microparticles were homogeneously mixed with the CaP cement powder at 
20 or 30 wt.% resulting in two experimental composite formulations, i.e. C20% and 
C30%, respectively. In a 2-ml syringe (BD PlastipakTM, Becton Dickinson S.A., 
Madrid, Spain) with closed tip,  2 wt.% Na2HPO4 was added to the CaP/PLGA in a 
liquid/powder ratio of 0.35 and mixed for 20 seconds using a mixing apparatus 
(Silamat®, Vivadent, Schaan, Liechtenstein). After mixing, the composite cements 
were immediately injected in Teflon molds (7.8 mm in diameter and 1.8 mm thick). 
After overnight setting at room temperature, the pre-set composites were 
removed from the molds and analyzed using SEM. The pre-set composites were 
sterilized by gamma radiation with 25 kGy (Isotron B.V., Ede, The Netherlands) and 
stored at -20°C until use. 
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Characterization of the pre-set CaP/PLGA composites 
Porosity measurements 
The microporosity (i.e. additional porosity after PLGA-microparticles degradation) 
and total porosity (i.e. intrinsic porosity + microporosity) were determined by 
measuring the weight of pre-set composite discs with and without PLGA-
microparticles and similar composite discs that received a heat-treatment to burn 
out PLGA. To burn out the polymer CaP/PLGA composites (n=9) were placed in a 
furnace at 650°C for 2 h. Subsequently, microporosity and total porosity were 
calculated using the following equations [13]:  
 
 
 
Microcomputed tomography 
To visualize the pre-set composite materials, the materials were placed in a furnace 
at 650°C for 2 h to burn out the polymer. Subsequently, microcomputed 
tomography was used at a voltage of 100 kV and an intensity of 98 μA with a 
resolution of 3.8 μm (Skyscan-1072 X-ray microtomograph, TomoNT version 3N.5, 
Skyscan®, Belgium). PLGA-microparticles appear as pores in the CaP cement disc. 
 
Surgical procedure 
Forty-eight healthy young adult (8 weeks old) male Wistar rats, weighing 295 r 29 g 
were used as experimental animals. National guidelines for the care and use of 
laboratory animals were observed. The research was reviewed and approved by 
the Experimental Animal Committee of the Radboud University (RUDEC 2008-108). 
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia 
Organique Fine Limited, Avonmouth, Bristol, UK) via intubation. To minimize post-
operative discomfort, buprenorfine (Temgesic£;Reckitt Benckiser Health Care 
Limited, Schering-Plough, UK) was administered intraperitoneally (0.02 mg/kg) 
directly after the operation and subcutaneously for two days after surgery. 
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To insert the implants, the rats were immobilized on their abdomen and the skull 
was shaved and disinfected with chlorhexidine. A longitudinal incision was made 
from the nasal bone to the occipital protuberance. To minimize pain, Lidocaine HCL 
1% (B. Braun, Melsungen, Germany) was dripped onto the periosteum before 
incision and exposure of the parietal bone. A critical sized bone defect was created 
by marking the defect outline with a dental trephine drill (outside diameter 8.0 
mm, ACE dental implant system, Brockton MA, USA) after which a full thickness 
bone defect was created by removing cortical bone with an ultrasonic device 
(Piezosurgery, Mectron, Carasco, Italy) with caution for the underlying dura mater 
and sagittal sinus and using constant cooling with sterile saline. Due to the 
ultrasonic frequency, the device only cuts hard tissues in a highly precise and safe 
manner without damaging soft tissues. Pre-set implants were placed in the created 
defects, after which the wound was closed in two layers with resorbable Vicryl® 4-0 
(Johnson&Johnson, St.Stevens-Woluwe, Belgium). 
The animals were housed in pairs. In the initial postoperative period, the intake of 
water and food was monitored. Further, the animals were observed for signs of 
pain, infection and proper activity. At the end of the implantation time, the rats 
were sacrificed by CO2 suffocation. 
 
Implant retrieval and histological preparations 
Implants were retrieved after a 4, 8 or 12 week implantation period. The implants 
with surrounding tissue were excised and fixed in phosphate-buffered 
formaldehyde solution (pH 7.4). Subsequently, the tissue blocks were dehydrated 
in increasing ethanol concentrations (70-100%) and embedded in 
methylmethacrylate. Perpendicularly in the middle of the implants, thin sections 
(10 μm) were prepared using a microtome with diamond blade (Leica 
Microsystems SP 1600, Nussloch, Germany) [22]. Three sections of each implant 
were stained with methylene blue and basic fuchsin and examined using light 
microscopy (Leica Microsystems AG, Wetzlar, Germany). 
 
Histological and Histomorphometrical evaluation 
All histological sections (three sections per implant) were quantitatively scored 
using computer-based image analysis techniques (The Leica® Qwin Pro-image 
analysis system, Wetzlar, Germany). From digitalized images (magnitude 5x), the 
amount of remaining cement and newly-formed bone were determined within two 
regions of interest, i.e.: (1) ROI 1, positioned within the original area as occupied by 
the implant, and (2) ROI 2, situated directly under ROI1 in order to measure bone 
bridging (Figure 1). Material degradation was related to the amount of remaining 
implant and was determined by measuring the area percentage implant material 
within ROI1. The amount of newly-formed bone was determined in μm2 and 
allocated as bone ingrowth (newly-developed bone within ROI1) and total newly-
formed bone (newly-developed bone within ROI1+ROI2). Bone bridging was 
CHAPTER 2 
 40 
determined by measuring the length of the implant (μm) cross-section that was 
associated with bone overgrowth and expressed as percentage of the total length 
of the original implant (width of ROI1; Figure 1). To compare the amount of newly-
formed bone with the native amount, the native amount of cranial bone (μm2) 
within ROI1 of three non-operated control animals was determined and averaged. 
 
 
Figure 1 Schematic overview of histological and histomorphometrical evaluation. Two 
regions of interests (ROI) were created; ROI 1, positioned within the original area as 
occupied by the implant, and ROI 2, situated directly under ROI1. Within ROI 1, the amount 
of remaining implant was measured as a value of material degradation. The amount of 
newly-formed bone was determined in ROI 1 as bone ingrowth and ROI 1 + ROI 2 as amount 
of total newly-formed bone. Bone bridging was determined by measuring the length of the 
implant (μm) cross-section that was associated with bone overgrowth and expressed as 
percentage of the total length of the original implant (width of ROI1=100% bridging).  
 
Statistical Analysis 
Statistical analyses of implant degradation and bone formation measurements 
were performed using SPSS, version 16.0 (SPSS INC., Chicago, Illinious USA). The 
statistical comparisons were performed using a one-way analysis of variance 
(ANOVA) with a Tukey multiple comparison post-test. Differences were considered 
significant at p-values less than 0.05. 
 
Results 
Materials characterization 
The preparation of PLGA-microparticles with the double-emulsion-solvent-
extraction technique resulted in microparticles with an average size of 20.6 ± 4 μm. 
The size distribution is shown in Figure 2A. Morphological examination using SEM 
revealed that the microparticles had a spherical appearance with smooth surfaces 
(Figure 2B). 
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Figure 2 (A) The size distribution PLGA-microparticles prepared by the double-emulsion-
solvent-extraction technique (n=350). The microparticles had an average size of  20.6 ± 4 μm 
(B) SEM picture of PLGA-microparticles. Original magnification 500x , bar represents 10 μm. 
 
For the preparation of pre-set CaP/PLGA composites, the amount of PLGA (wt.%) 
was set at 20% (C20%) or 30% (C30%). The morphological form of C20% and C30% 
as visualized using microCT is presented in Figure 3A and B. Surface examination 
with SEM showed homogenous distribution of PLGA-microparticles within the 
implant material of both experimental groups. C30% showed an increased amount 
of particles at the surface as compared with C20% (Figure 3C and D). 
The porosity measurements demonstrated porosity values of 27.5% (micro) and 
64.5% (total) for C20% and 41.7% (micro) and 71.5% (total) and for C30% (Table 1). 
 
General observation of the experimental animals 
From the total of 48 animals available for surgery, 5 animals were sacrificed by CO2 
suffocation during the surgery as a consequence of extensive blood loss from the 
sagittal sinus. The remaining 43 animals recovered uneventfully from the surgical 
procedure and remained in good health. No signs of wound complications were 
observed post-operatively and macroscopic signs of inflammation or adverse tissue 
responses were absent during the course of the experiment. At the end of the 
experiment, a total of 43 implants were retrieved of which 38 were included for 
analyses. The exclusion of 2 implants from analysis was due to implant fracturing 
during histological processing, while 3 implants were excluded as they were found 
to be moved out of the cranial defect and were positioned above the bone wall of 
the cranial defect. An overview of the number of implants placed, retrieved, and 
used for evaluation is presented in Table 2. 
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Figure 3 Microcomputed tomography images of (A) C20% and (B) C30%. μCT reconstruction 
of segments (1 mm3) of the two experimental composites show the volumetric appearance 
of both groups. PLGA-microparticles appear as pores in the CaP cement (bar represents 0.25 
mm). SEM surface examinations of (C) C20% and (D) C30% revealed homogenously 
distributed PLGA-microparticles in both groups and an apparently higher amount of particles 
in C30% (bar represents 10 μm). 
 
Table 1 The porosity values obtained with the porosity measurements of the two 
experimental groups 
 C20% C30% 
Intrinsic porosity 51.1 ± 1.4 51.1 ± 1.4 
Microporosity 27.5 ± 2.6 41.7 ± 1.4 
Total porosity 64.5 ± 1.2 71.5 ± 0.7 
 
Table 2 Number of implants placed, retrieved and used for histomorphometrical analyses 
  Implants placed    Implants retrieved     Implants used 
       for analysis 
 
Week 4 8 12 4 8 12 4 8 12 
         
C20% 7 7 7 7 7 7 7 7 6** 
C30% 7 7 8 7 7 8    5** 7  6*, ** 
*Deviation from number of implants retrieved due to fracturing of implants during the 
histological processing or ** due to misplacement of the implant in cranial defect. 
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Descriptive light microscopy 
Figure 4 presents an overview of histological sections of the different formulations 
(C20% and C30%) after implantation periods of 4, 8 and 12 weeks. 
Upon visual inspection, the integrity of the implants was maintained throughout 
the entire implantation periods. The PLGA-microparticles were degraded and 
formed pores throughout the entire implant from 4 week implantation period 
onwards for C20% (Figure 5a and b) and C30% (Figure 5c and d). CaP degradation 
was generally limited, although CaP degradation at the implant periphery could be 
observed after 12 weeks of implantation, especially for the C30% formulation. 
After a 4-week implantation period, the contact of the implant with the original 
defect edge was absent in all specimens and the existing gap was occupied with 
fibrous tissue. With increasing implantation period, new bone was formed between 
the original defect edges and the implants. At 12 weeks of implantation, direct 
bone contact was observed between the CaP cement and cranial bone for all 
specimens. Further, newly-formed bone was observed at the dura side of all 
implants of both groups already after 4 weeks implantation, which showed an 
increase with implantation period. 
No bone formation was observed in the center of the implants in any of the 
sections.  However, peripherally located PLGA-pores showed ingrowth of bone, 
fibrous tissue and bone marrow-like tissue which increased with implantation 
period. Bone ingrowth was most obvious in the C30% group after 12 weeks of 
implantation. None of the specimens revealed significant signs of inflammation. 
 
Histomorphometrical evaluation 
Implant degradation (Figure 6) was assessed using surface area measurement (%) 
of ROI1 that was occupied by implant material. Implant degradation was very 
limited without significant temporal progress for both C20% (n>6, from 95.1 ± 1.3% 
at week 4 to 94.8 ± 2.1% after 12 weeks, Table 3) and C30% (n>5, from 91.5 ± 2.9% 
at week 4 to 89.4 ± 4.4% after 12 weeks, Table 3). On the other hand, statistically 
significant differences in implant degradation were observed between C20% and 
C30% at each individual implantation period (week 4 p=0.014, week 8 p=0.006 and 
week 12 p=0.026, Table 4).  
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Figure 4 Representative histological sections of cranial defects of the two experimental 
groups, C20%  and C30% after 4, 8 and 12 weeks. Bar represents 500 μm. Higher 
magnification of C20% show limited ingrowth of bone after 12 weeks of implantation; in the 
C30% ingrowth of bone after 12 weeks of implantation is observed. Methylene blue and 
basic fuchsin staining. Bar represents 100 μm. 
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Figure 5 Magnified histological sections showing (A and C) degraded peripherally located and 
(B-D) centrally located PLGA-microparticles in C20% and C30%, respectively. Methylene blue 
and basic fuchsin staining. Bar represents 50 μm. 
 
 
 
Figure 6 Results of histomorphometrical evaluation of C20% and C30% in critical size cranial 
defects. The amount of remaining implant after 4, 8 and 12 weeks of the two experimental 
groups (n>5) are expressed as percentage of ROI1 (i.e. a standardized region of interest 
within the boundaries of the implant). Error bars represent means ± standard deviation.  
* = p < 0.05. 
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Bone formation was determined by measurement of the area (μm2) of bone within 
ROI1 and ROI2. Within the individual margins of both ROI1 and ROI2, bone 
formation showed a tendency to increase with implantation time, although no 
significant differences were observed between different time periods (for C20% 
(n>6) ROI1 (p=0.122) ranged from 56100.0 ± 35320.1 μm2 to 160414.4 ± 130655.6 
μm2 after 12 weeks and ROI2 (p=0.367) from 242244.2 ± 175432.4 μm2 to 525351.5 
± 541371.6 μm2 after 12 weeks; for C30% (n>5) ROI1 (p=0.100) ranged from 
135005.8 ± 83266.4 μm2 to 457085.4 ± 320027.1 μm2 after 12 weeks and ROI2 
(p=0.055) from 239145.3 ± 70833.7 μm2 to 460518.0 ± 196864.0 μm2 after 12 
weeks, Table 3) or between both groups at each individual implantation period (for 
ROI1 p=0.102, p=0.627, p=0.108 and for ROI 2 p=0.971, p=374, p=0.805 at week 4, 
8 and 12 respectively, Figure 7a and b, Table 4). 
On the other hand, total bone formation (i.e. bone formation within ROI1 + ROI2) 
demonstrated to significantly increase with implantation time for C30% (4wks vs. 
12 wks p=0.029; 8wks vs. 12 wks p=0.036, n>5; total bone ranged from 374151.1 ± 
116841.1 μm2 to 917603.3 ± 365808.3 μm2 after 12 weeks, Figure 7c, Table 3), 
whereas no significant differences were observed between both groups (week 4 
p=0.460, week 8 p=0.756, week 12 p=0.478; Figure 7c, Table 4). 
Bone bridging tended to increase with implantation time for both groups, without 
significant (intra- and inter-group) differences (for C20% intra-group p=0.184 and 
for C30% intra-group p=0.087, Table 3; for C20% vs C30% week 4 p=0.345, week 8 
p=0.382 and week 12 p=0.635, Table 4; Figure 8). Bone bridging during the entire 
experiment ranged from 40.0 ± 25.5% to 65.0 ± 20.0% for C20% (n>6), and from 
51.8 ± 7.8% to 70.5 ± 16.2% for C30% (n>5). 
Relative to the average amount of calvarial bone present in healthy animals (n=3), 
the CaP/PLGA composite materials demonstrated to achieve bone formation after 
12 weeks of implantation up to 19.5 ± 14.7% for the C20% (n>6) and 22.4 ± 8.9 % 
for the C30% (n>5) . A significant time-dependent increase in bone formation was 
observed only for C30% (p=0.036), whereas no significant differences were 
observed between both groups at individual time periods (p>0.05) (Figure 9). 
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Figure 7 Bone regenerative capacity in C20% and C30% at 4, 8 and 12 week implantation 
period. (A) Bone formation is measured within the boundaries of the original implant (ROI1) 
and (B) directly underneath the implant (ROI2). Bone formation is similar at all time in both 
experimental groups. (C) A temporal increase of total bone formation (ROI1 + ROI2) was 
observed for C30% (4wks vs. 12 wks p=0.029; 8wks vs. 12 wks p=0.036). Error bars represent 
means ± standard deviation. * = p < 0.05; n>5. 
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Figure 8 Bone bridging capacity in C20% and C30% at 4, 8 and 12 weeks implantation period. 
Bone bridging was determined by measuring the length of the implant (μm) cross-section 
that was accompanied with bone growth and expressed as percentage of the total length of 
the original implant. 12 weeks postoperatively none of the defects was completely closed. 
Error bars represent means ± standard deviation (n>5). 
 
 
 
Figure 9 Overview of the temporal total bone formation for C20% and C30% compared to 
the initial amount of native bone. A temporal increase of total bone related to the native 
initial bone was observed for 12 weeks postoperatively in C30%. 12 weeks postoperatively 
none of the defects was completely closed. Methylene blue and basic fuchsin staining. Bar 
represents 500 μm. * = p < 0.05; n>5. 
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Table 3 Overview of the histomorphometrical evaluation comparing in time the effect of the 
two experimental groups C20% and C30% 
a Grouping Variable; Time, Rem. Impl.; Remaining Implant, BF ROI 1; Bone formation in ROI 1,  
BF ROI 2; Bone formation in ROI 2, TB; Total bone formation (ROI 1 + ROI 2), Bridging; Bone 
Bridging. 
 
Discussion 
In this study, the influence of various amounts of PLGA-microparticles within pre-
set CaP/PLGA cement discs on temporal degradation and bone ingrowth was 
evaluated in critical size cranial defects in rats. It was hypothesized that gradual 
cement degradation would occur after PLGA degradation and that a higher PLGA-
content accelerates cement degradation as well as bone formation. The main 
findings show that discs containing 30 wt.% PLGA degraded significantly faster than 
20 wt.% PLGA-equivalents, albeit that overall degradation was minimal for both 
types of cement discs. After twelve weeks of implantation, the total amount of 
newly-formed bone was ~20% of the native amount of calvarial bone in healthy 
animals for both experimental groups. Furthermore, bone formation and bone 
bridging demonstrated to be unaffected by amount of PLGA, although a significant 
temporal increase in total bone formation was observed only for cement discs 
containing 30 wt.% PLGA. 
  
 Week 4 Week 8 Week 12 p-value (ANOVA)a 
C20% 
Rem. Imp. (%) 
 
95.1 
 
94.7 
 
94.8 
 
0.919 
BF ROI 1 (um2) 56100.0 147688.5 160414.4 0.122 
BF ROI 2 (um2) 242244.2 345724.5 525351.5 0.367 
TB (um2) 298344.1 493413.0 685765.9 0.276 
Bridging (%) 40.0 55.0 65.0 0.184 
C30% 
Rem. Impl.  (%) 
 
91,521 
 
87.6 
 
89.4 
 
0.302 
BF ROI 1 (um2) 135005.8 199148.7 457085.4 0.100 
BF ROI 2 (um2) 239145.3 234034.4 460518.0 0.055 
TB (um2) 374151.1 433183.1 917603,3 0.020 
Bridging (%) 51.8 42.0 70,5 0.087 
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Table 4 Overview of the histomorphometrical evaluation comparing C20% and C30%  
a Grouping Variable; groups, Rem. Impl.; Remaining Implant, BF ROI 1; Bone formation in ROI 
1,  BF ROI 2; Bone formation in ROI 2, TB; Total bone formation (ROI 1 + ROI 2), Bridging; 
Bone Bridging. 
 
In the present study, a full thickness critical-sized cranial defect was created by 
removing cortical bone with an ultrasonic device. The device only cuts hard tissue 
in a highly precise manner without damaging soft tissues due to the ultrasonic 
frequency. Therefore, the procedure creates a defect in a more safe manner with 
caution for the underlying dura mater and sagittal sinus compared to the trephine 
bur method. However, at 4 weeks of implantation, the bone/implant contact after 
creating the defect with an ultrasonic device was found to be less optimal 
compared to the trephine bur method as used by Bodde et al.  (2008) [18]. Bone 
formation and material degradation is dependent on initial bone/implant contact 
and previous studies have demonstrated that the placement of pre-set CaP/PLGA 
cement discs results in complete fusion of the implant with the calvarial bone 
tissue without an intervening fibrous tissue layer [12, 21]. Consequently, initial 
bone/implant contact might be compromised when the cranial defect is prepared 
    C20%     C30%   p-value  
 
 
Average SD  Median Average  SD Median (ANOVA)a  
Week 4 
Rem. 
Imp   
(%) 
 
95.1 
 
1.3 
 
95.3 
 
91.5 
 
2.9 
 
91.2 
 
0.014 
BF ROI 1 
(um2) 
56100.0 35320.1 60441.7 135005.8 83266.4 86367.0 0.102 
 
BF ROI 2 
(um2) 
 
242244.2 
 
175432.4 
 
227753.3 
 
239145.3 
 
70833.7 
 
212553.3 
 
0.971 
TB (um2) 298344.1 195318.3 261322.0 374151.1 116841.1 392656.7 0.460 
Bridging  
(%) 
40.0 25.5 37.1 51.8 7.8 49.7 0.345 
Week 8 
Rem. 
Imp.  (%) 
 
94.7 
 
2.3 
 
94.5 
 
87.6 
 
4.6 
 
87.9 
 
0.006 
BF ROI 1 
(um2) 
147688.5 99006.3 110244.6 199148.7 233756.7 104586.7 0.627 
BF ROI 2 
(um2) 
345724.5 262734.6 262916.7 234034.4 169231.5 255713.3 0.374 
TB (um2) 493413.0 354917.3 434582.0 433183.1 326254.5 489356.7 0.756 
Bridging  
(%) 
55.0 24.0 63.6 42.0 27.2 48.8 0.382 
Week 12 
Rem. 
Imp.  (%) 
 
94.8 
 
2.1 
 
93.9 
 
89.4 
 
4.4 
 
89.1 
 
0.026 
BF ROI 1 
(um2) 
160414.4 130655.6 164968.6 457085.4 320027.1 315698.3 0.108 
BF ROI 2 
(um2) 
525351.5 541371.6 472108.3 460518.0 196864.0 457171.7 0.805 
TB (um2) 685765.9 625601.5 701414.7 917603.3 365808.3 808620.2 0.478 
Bridging 
(%) 
65.0 20.0 61.5 70.5 16.2 74.0 0.635 
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using an ultrasonic device instead of a trephine bur. However, in line with the 
previous studies [12, 21], after 12 weeks of implantation, complete fusion of the 
calvarial bone and implant occurred in both groups indicating that the CaP/PLGA 
cement discs are bioactive and capable to close the gap between the calvarial bone 
and the implant without an intervening fibrous tissue. In addition, over time an 
increased amount of newly formed bone was observed at the dura side along the 
cement surface in both groups, which shows the bioactive characteristic of the 
cement. 
In comparison with previous studies [12, 21], the present study showed large 
differences regarding the degradation of PLGA-containing CaP cement with equal 
and even higher amounts of PLGA. This difference in degradation and bone 
formation at 12 weeks postoperatively is remarkable, but likely related to the 
aforementioned change in defect preparation method, and further to issues 
involving PLGA-microparticle properties and/or the CaP cement composition. Due 
to a more standardized production procedure of PLGA-microparticles, the size 
distribution in the current study was minimized (20.6 ± 4 μm) as compared to the 
other studies (66 ± 25 μm [12] or 21 ± 18 μm [21]). In general, it is proposed that a 
pore size of at least 50 to 100 μm (microparticles size) is necessary for cell ingrowth 
[23], although in a previous study a microparticle size of 21 ± 18 μm appeared to be 
sufficient to obtain cellular ingrowth throughout the implant [21]. In the current 
study, the peripherally located PLGA-pores showed ingrowth of bone tissue, 
whereas in the center of the implant no ingrowth was observed, albeit that the 
PLGA-microparticles were degraded already after a 4-week implantation period. It 
is likely that the standardized size of the PLGA-microparticles used in the current 
study may have influenced the porosity and especially the interconnectivity of the 
pores in the material. As standardization of the PLGA-preparation process is 
beneficial to obtain reproducibility, additional research has to be done to 
determine the most favorable size of the PLGA-microparticles in view of biological 
performance. 
Further, it has to be emphasized that the composition of the cement in the current 
study (85% α-TCP, 10% CaHPO4 and 5% precipitated hydroxyl-apatite [24]) differs 
from that in the earlier study of Bodde et al. (61% α-TCP, 26% CaHPO4, 10% CaCO3, 
and 3% precipitated hydroxyl-apatite) [21]. Both calcium phosphate cements 
harden as a calcium deficient hydroxyapaptite (CDHA) due to the hydrolysis of the 
α-TCP [25]. α-TCP transforms after three days into an apatite-like structure that 
remains stable over time, whereas the monotite component (CaHPO4) disappears 
between 2 and 8 weeks [4]. The difference between this novel bone cement 
formula and the previously used cement is mainly dependent on increased levels of 
α-TCP and precipitated hydroxyl-apatite as well as absence of CaCO3. In view of 
that, the different composition of the novel cement leads to a more stable cement 
from a ceramic point of view. However, in vivo experiments in which the effect of 
the difference in composition on degradation and biological responses are 
compared in a direct manner, have not been performed to date and are required to 
justify the assumption on cement stability. 
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As mentioned earlier, the experimental set-up, characteristics of the cement, size 
distribution of the PLGA-microparticles, (micro)porosity and the interconnectivity 
of the material all influence implant degradation and cellular ingrowth and 
therefore the bone forming capacity of the material. If one or all of these factors 
are slightly altered, the outcome of the study can differ from earlier findings. In 
addition, also the implant location may influence the degradation of the implant 
material. For example, material placed in femoral or cranial defects will be exposed 
to different environments, which includes the nature of biomechanical loading, 
surrounding tissue and blood/nutrient supply. Beside the environment, also the 
origin of the bones (i.e. long bone formation (femur) is endochondral while cranial 
bone formation is intramembranous), may play a role in the degradation and bone 
formation due to distinctive signaling properties [26]. Therefore, more research is 
necessary to elucidate the most favorable CaP/PLGA cement composition for 
different sites of application. 
In conclusion, the present study demonstrated that a higher amount of PLGA-
microparticles (30 vs. 20 wt.%) in CaP/PLGA cement composites has significant, 
though minimal effects on degradation. Bone formation showed not to be 
influenced by the amount of PLGA-microparticles within the composite, although a 
significant temporal increase in bone formation was observed only for composites 
containing 30 wt.% PLGA-microparticles. After 12 weeks of implantation, the total 
amount of newly-formed bone was ~20% compared to the amount of calvarial 
bone in healthy rats. Further optimization of CaP/PLGA cement is necessary to 
increase control over degradation and tissue ingrowth. 
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Introduction 
Apatite cements (such as calcium phosphate cement, CPC) represent a promising 
candidate material for bone substitution mainly due to their biocompatibility and 
osteoconductive properties  [1-5]. An additional advantage of such a cement is the 
self-setting nature, which makes them injectable and allows the use of a minimally 
invasive surgical procedure during clinical use [2, 4, 5]. However, CPCs are 
characterized by a very slow degradation rate, which has to be considered as a 
disadvantage for several applications, like sinus elevation and the filling of 
extraction sockets  [1, 5]. 
To enhance the biodegradability and tissue ingrowth of CPC, (micro)porosity can be 
introduced into the already intrinsically nanoporous cement [1, 5]. One promising 
strategy to create porosity into CPC is the introduction of biodegradable polymers, 
e.g. in the form of poly(D,L-lactic-co-glycolic) acid (PLGA) microparticles [6-9]. 
PLGA-microparticles degrade over time and hence create pores within the ceramic 
matrix that increase the surface-to-volume ratio of the CPC and allow tissue 
ingrowth [10, 11]. Many animal studies demonstrated that porosity created by 
degradation of PLGA-microparticles embedded within CPC increases cement 
degradation and accelerates the regeneration of a bone defect [9-12]. However, 
the osteoconductive properties of CPC/PLGA are not be sufficient to achieve 
complete defect filling under critical conditions, like poorly vascularized sites and 
(elderly) patients with metabolic disorders [13]. Consequently, the enrichment of 
CPC/PLGA with osteopromotive or osteoinductive factors is necessary to improve 
their biological performance. 
Bioactive glasses (BGs) are a group of synthetic silica-based bioactive materials with 
the unique ability to bond to living bone by forming a biologically active bone-like 
apatite layer on their surface [14-17] that acts as a template for calcium phosphate 
precipitation and directs new bone formation [14, 17, 18]. In addition, it has been 
reported that BGs attract and stimulate osteoprogenitor cells, which differentiate 
into matrix-producing osteoblasts and subsequently increase the rate of bone 
formation and bone ingrowth into BG-based granular material [19-22]. In view of 
this, the incorporation of BG into CPC seems a safe approach to improve the 
osteopromotive properties of CPC. 
A recent in vitro study demonstrated that BG can successfully be introduced into 
CPC and CPC/PLGA composites, with a maximum of 30wt.% BG, without 
compromising the setting time and mechanical properties of CPC or CPC/PLGA 
composites [23]. These encouraging in vitro data on the introduction of BG into CPC 
composite material formed the basis for the current in vivo study, which aimed to 
evaluate the ectopic and orthotopic in vivo response to CPC/BG composites, with or 
without PLGA microparticles, in rats. Pre-set scaffolds in 4 different formulations (1: 
CPC; 2: CPC/BG; 3: CPC/PLGA; and 4: CPC/PLGA/BG) were implanted 
subcutaneously and in femoral condyle defects of rats. Histocompatibility (ectopic 
implants; histology) and bone responses (orthotopic implants; histology and 
histomorphometry) were evaluated after 2 and 6 weeks of implantation. 
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Materials and methods 
Materials 
Calcium phosphate cement (CPC) consisted of 85% alpha tri-calcium phosphate (α-
TCP; CAM Bioceramics BV, Leiden, The Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; J.T. Baker Chemical Co., USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). 2% Na2HPO4 was used as liquid 
phase for the preparation of the cement. Acid-terminated poly(DL-lactic-co-glycolic 
acid) (PLGA; Purasorb®, Purac, Gorinchem, The Netherlands) with a lactic to glycolic 
acid ratio of 50:50 and a molecular weight (Mw) of 17 kDa was used for 
microparticle preparation. Biosilicate® parent glass was used as type of bioglass 
(particle size: 2,5 μm) and was provided by Vitreous Materials Laboratory (LaMaV), 
Department of Materials Engineering, Federal University of São Carlos, Sao Carlos, 
Sao Paulo, Brasil [24]. 
 
Preparation of dense PLGA microparticles 
Dense PLGA microparticles were prepared by a single emulsion technique, as 
described previously [3]. Briefly, 0.2 g of PLGA was dissolved in 2 mL of 
dichloromethane (DCM) (Merck. Darmstadt, Germany) in a 20 mL glass tube. Two 
mL of this solution was transferred into a stirred beaker containing 100 mL of 0.3% 
poly vinyl alcohol (PVA) (88% hydrolyzed, MW 22000, Acros. Geel, Belgium) 
solution. Subsequently, 50 mL of 2% isopropanol (IPN) (Merck) was added. The 
solution was stirred for 1 h. The microparticles were allowed to settle for 1 h and 
the clear solution was decanted. The suspension left was centrifuged and the clear 
solution on top was aspirated. Finally, the microparticles were washed and 
collected through centrifugation at 1500 rpm for 5 min, lyophilized and stored at -
20 °C until use. The size distribution of the microparticles was determined by image 
analysis (Leica Qwin®, Leica Microsystems, Wetzlar, Germany). The microparticles 
were imaged by scanning electron microscopy (SEM; JEOL6310 at 15kV). 
 
Preparation of the pre-set composites 
Four experimental groups were created: (1) CPC, (2) CPC/BG, (3) CPC/PLGA, and (4) 
CPC/PLGA/BG. Table 1 represents an overview of the composition of these 
materials. 
For both subcutaneous and femoral implants, pre-set composites were made by 
adding different amounts of the base materials inside a 2 ml closed tip syringe (BD 
Plastipakt, Becton Dickinson S.A., Madrid, Spain; Table 1) and pre-mixing the 
powder mixture using a mixing apparatus (Silamat, Vivadent, Schaan, 
Liechtenstein). Subsequently, a Na2HPO4 solution (2 wt%) in a liquid/powder ratio 
of 0.35 was added into the syringe and the mixtures were mixed for another 20s. 
Directly after mixing, the composite cements were injected into Teflon molds (3 
mm x 2.9 mm). After overnight setting at room temperature, the pre-set 
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composites were removed from the molds and analyzed using SEM. Before use, the 
pre-set composites were sterilized by γ-radiation with a minimum dose of 25 kGy 
(Isotron B.V., Ede, The Netherlands). 
 
Table 1 Composition and porosity values of pre-set composite materials 
Groups CaP 
(wt. %) 
BG  
(wt. %) 
PLGA 
(wt. %) 
Macro 
porosity 
Total 
porosity 
CPC 100 0 0 --- 40.6 ± 0.7 
CPC/BG  70 30 0 --- 41.6 ± 0.8 
CPC/PLGA 70 0 30 40.5 ± 1.2 55.7 ± 0.9 
CPC/PLGA/BG 40 30 30 41.2 ± 0.8 56.5 ± 1.5 
CPC, Calcium phosphate cement; BG, Bioactive glass; CPC/BG, BG incorporated into CPC; 
CPC/PLGA, dense PLGA-microparticles incorporated into CPC; CPC/PLGA/BG, dense PLGA-
microparticles and BG incorporated into CPC; wt. %, weight percentage. 
 
Characterization of pre-set composites 
Porosity measurements 
The microporosity (i.e. additional porosity after PLGA-microparticles degradation) 
and total porosity (i.e. intrinsic porosity/microporosity) were determined by 
measuring the weight of pre-set composite cylinders, with and without PLGA-
microparticles. To burn out the PLGA-microparticles, composite scaffolds were 
placed in a furnace at 650oC for 2 h. Subsequently, microporosity and total porosity 
were calculated using the following equations [1]: 
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Surgical procedure 
Twenty-four healthy young adult male Wistar rats (12 weeks old; weight 295 ± 29g) 
were used as experimental animals. The animal experimental plan was reviewed 
and approved by the Experimental Animal Committee of the Radboud University 
(RU-DEC 2011-156) and national guidelines for the care and use of laboratory 
animals were observed. 
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique 
Fine Limited). To minimize post-operative discomfort, buprenorfine (Temgesic; 
Reckitt Benckiser Health Care Limited, Schering-Plough, Hoddesdon, UK) was 
administered intraperitoneally (0.02mg/kg) directly after the operation and 
subcutaneously for 2 days after surgery. 
To insert implants into the femoral condyles, the animals were immobilized on 
their back and both hind limbs were shaved, washed and disinfected with 
povidone-iodine. After exposure of the distal femoral condyle, a 1.0 mm pilot hole 
was drilled. The hole was gradually widened with drills of increasing size until a 
final defect size of 3 mm in width and 3 mm in depth was reached. Low rotational 
drill speeds (max. 450 rpm) and constant physiologic saline irrigation were used. 
After preparation, the defects were thoroughly irrigated and packed with sterile 
cotton gaze to stop bleeding. Surgery was performed in both legs of the rats and 
one defect was created in each condyle. The pre-set implants were placed in the 
created defect, according to a randomization scheme (n=6 per experimental group, 
per time point). Thereafter, the wound was closed with resorbable Vicryl® 5-0 
(Johnson&Johnson, St.Stevens-Woluwe, Belgium) after which the skin was closed 
by staples (Agraven®; InstruVet BV, Cuijk, The Netherlands). 
In addition, half of the animals (12 rats) received 4 pre-set implants placed 
subcutaneously into the back of each rat. To insert the implants, rats were 
immobilized on their abdomen and the skin was shaved, washed and disinfected 
with iodine. Four paravertebral incisions were made (two on each site of the 
vertebral column) and subcutaneous pockets were created by blunt dissection. The 
implants were randomly placed for each group (n=6 per experimental group, per 
time point). Finally, the skin was closed using staples (Agraven®, Instruvet BV). The 
animals were housed in pairs and the intake of water and food was monitored in 
the initial postoperative period. Further, the animals were observed for signs of 
pain, infection and proper activity. After 2 and 6 weeks of implantation, rats were 
sacrificed by CO2 suffocation. 
 
Histological procedures 
After harvesting the specimens (the subcutaneous implants and femoral condyles), 
the specimens were fixated in 4% formaldehyde for 2 days, followed by 
dehydration in a graded series of ethanol and embedding in methylmethacrylate 
(MMA). After polymerization of the specimens, histological analysis was done. 
Therefore, for both subcutaneous implants and femoral condyles, thin sections (10 
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μm) were prepared perpendicular to the medial-lateral drilling axis of the implants 
using a microtome with a diamond blade (Leica Microsystems SP 1600, Nussloch, 
Germany) [25]. At least, three sections of each specimen were stained with 
methylene blue and basic fuchsin.  
 
Histological and histomorphometrical evaluation 
A histological grading scale was used to evaluate the capsule thickness, tissue 
response of the capsule surrounding the subcutaneous implants and the tissue 
directly adjacent to the implant surface in four pre-determined fields using light 
microscopy as previously reported (Table 2) [26, 27]. At least three sections of each 
specimen were examined using light microscopy (Leica Microsystems AG, Wetzlar, 
Germany). Two experienced observers (AR and FW) performed the scoring in a 
blinded manner. 
The femoral condyle defects were quantitatively scored using computer-based 
image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, 
Germany) by defining a 3 mm diameter circular area (i.e. the diameter of the 
created defects) superimposed on the bone defect area as the region of interest 
(ROI). From digital images (magnification 2,5X), the amount of CPC and bone tissue 
within this ROI were determined [9]. 
 
Statistical analysis 
Statistical analyses of material degradation and bone formation were performed 
using SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA). The statistical comparisons 
were performed using a one-way analysis of variance (ANOVA) with a Tukey 
multiple comparison post-test. Differences were considered significant at P-values 
< 0.05. 
 
Results 
Materials characterization 
Morphological examination of BG granulate revealed that the BG particles had an 
irregular structure with an average particle size of around 2.5 μm (Figure 1A). The 
preparation of PLGA-microparticles via the single-emulsion solvent-extraction 
technique resulted in PLGA-microparticles with an average size of 40 ± 4 μm. 
Morphological examination using SEM revealed that the PLGA-microparticles had a 
spherical appearance with a smooth surface (Figure 1B). SEM evaluation of the CPC 
surface showed a nanoporous structure (Figure 1C). Surface examination of 
CPC/BG, CPC/PLGA and CPC/PLGA/BG with SEM showed homogenous distribution 
of BG granulate and/or PLGA-microparticles within CPC, respectively (Figure 1D-F). 
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Table 2 Modified Histological Grading Scale for Soft Tissues 
Evaluation Response Score 
Capsule 
thickness 
1–4 cell layers 
5–9 cell layers 
10–30 cell layers 
>30 cell layers 
Not applicable 
4 
3 
2 
1 
0 
Tissue 
response of 
the capsule 
surrounding 
the implants 
Fibrous, mature, not dense, resembling connective 
or fat tissue in the noninjured regions. 
Fibrous, but immature, showing fibroblasts 
and little collagen. 
Granulous and dense, containing both fibroblasts and many 
inflammatory cells. 
Consists of masses of inflammatory cells with little or no signs 
of connective tissue organization. 
Cannot be evaluated because of infection or factors not 
necessarily related to the material. 
4 
 
3 
 
2 
 
1 
 
0 
Tissue 
response 
directly 
adjacent to 
the implant 
surface 
(Interface) 
 
Fibroblasts contact the implant surface without the presence 
of macrophages or foreign body giant cells. 
Scattered foci of macrophages and foreign body cells are 
present. 
One layer of macrophages and foreign body cells is present.  
Multiple layers of macrophages and foreign body cells are 
present. 
Cannot be evaluated because of infection or other factors not 
necessarily related to the material. 
4 
 
3 
 
2 
1 
 
0 
 
Porosity measurements demonstrated total porosity values (due to intrinsic 
nanoporosity) of 40.6 ± 0.7% and 41.6 ± 0.8% for CPC and CPC/BG, respectively. 
Composite cements containing PLGA microparticles showed values of 40.5 ± 1.2% 
(macroporosity) and 55.7 ± 0.9% (total porosity) for CPC/PLGA and 41.2 ± 0.8% 
(macroporosity) and 56.5 ± 1.5% (total porosity) for CPC/PLGA/BG (Table 1). 
 
General observation of the experimental animals 
From the 24 animals used in this study, two animals were lost due to an anesthesia-
induced respiratory depression, of which one animal received 2 femoral condyle 
implants and the second animal received 2 femoral condyle implants and 4 
subcutaneous implants. The remaining animals recovered uneventfully from the 
surgical procedure and remained in good health during the entire implantation 
period. No clinical sign of inflammation or adverse tissue response were observed 
during the implantation period. At the end of the experiment, 44 subcutaneous 
implants were retrieved, of which 43 were used for analysis (1 CPC/PLGA/BG 
implant was excluded from analysis due to implant fracturing during histological 
processing). Furthermore, a total of 44 femoral condyle implants were retrieved 
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and all of them were included for analyses. An overview of the number of implants 
placed, retrieved and used for analysis is presented in Tables 3. 
 
 
Figure 1 SEM micrographs of the (A) BG particles (B) dense PLGA-microparticles, (C) CPC, (D) 
CPC/BG, (E) CPC/PLGA and (F) CPC/PLGA/BG.  BG (arrow) and PLGA-microparticles 
(arrowheads) are indicated in the SEM micrographs. Bar represents 1, 10 or 100 μm.  
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Table 3 Number of implants placed, retrieved and used for histological analyses for the 
subcutaneous implants and femoral condyle defect implants 
 Implants placed Implants retrieved  Implants used  
for analysis 
Week 2 6  2 6  2 6 
Subcuteaneous 
implants 
CPC 
CPC/BG 
CPC/PLGA 
CPC/PLGA/BG 
 
 
6 
6 
6 
6 
 
 
6 
6 
6 
6 
  
 
5a 
5a 
5a 
5a 
 
 
6 
6 
6 
6 
  
 
5 
5 
5 
5 
 
 
6 
6 
6 
5b 
Femoral Condyle 
implants 
CPC 
CPC/BG 
CPC/PLGA 
CPC/PLGA/BG 
 
 
6 
6 
6 
6 
 
 
6 
6 
6 
6 
  
 
5a 
5a 
6 
6 
 
 
6 
6 
5a 
5a 
  
 
5 
5 
6 
6 
 
 
6 
6 
5 
5 
CPC, Calcium phosphate cement; BG, Bioactive glass; CPC/BG, BG incorporated into CPC; 
CPC/PLGA, dense PLGA-microparticles incorporated into CPC; CPC/PLGA/BG, dense PLGA-
microparticles and BG incorporated into CPC; wt. %, weight percentage; a Deviation from 
number of implants placed due to animal dead or b deviation from number of implants 
retrieved due to fracturing of implants during to the histological processing. 
 
Descriptive histology of subcutaneous implants 
Two weeks 
Representative histological sections of all experimental groups 2 weeks after 
implantation are depicted in Figure 2. CPC and CPC/BG revealed no sign of material 
degradation and the implants were visual as a dense material (Figure 2A and C). 
CPC/PLGA showed PLGA-microparticle degradation, which was visualized by the 
formation of pores within the material (Figure 2E). CPC/PLGA/BG revealed clear 
degradation and changes in the morphological shape of the implants (Figure 2G). 
At a higher magnification, CPC, CPC/BG, CPC/PLGA/BG implants were found to be 
surrounded by a medium-thick granulous capsule of 10-30 cell layers containing 
moderate numbers of inflammatory cells and fibroblasts (Figure 2B, D and H). 
CPC/PLGA showed the presence of a granulous capsule consisting of more than 30 
cell layers and large numbers of inflammatory cells were present within the capsule 
(Figure 2F).  Directly adjacent to the surface  of the CPC, CPC/BG, and CPC/PLGA/BG 
implants (interface), moderate numbers of multinucleated giant-cells were 
bserved, while at the interface of CPC/PLGA, many multinucleated giant-cells were 
seen. 
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Figure 2 Representative histological sections of subcutaneous implants of the four 
experimental groups after two weeks of implantation; CPC (A-B), CPC/BG (C-D), CPC/PLGA 
(E-F) and CPC/PLGA/BG (G-H). Bar represents 1 mm. Composite material (C), Fibrous tissue 
(F), degraded PLGA-pores (P), and multi-nucleated giant cells (arrows) are indicated in the 
sections. Bar represents 100 μm. Methylene blue and basic fuchsin staining. 
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Six weeks  
Representative histological sections of all experimental groups 6 weeks after 
implantation are depicted in Figure 3. 
CPC and CPC/BG revealed no sign of material degradation and the implants were 
visual as dense material (Figure 3A and C). Implant degradation had continued for 
CPC/PLGA and CPC/PLGA/BG, showing most degradation in the periphery of 
CPC/PLGA (Figure 3E) with the larger extent of degradation for CPC/PLGA/BG 
(Figure 3G. Additionally, CPC/PLGA and CPC/PLGA/BG showed tissue ingrowth in 
the degrading areas of the implant. 
At higher magnification, all experimental groups revealed a thinner capsule 
surrounding the implant compared to their 2-weeks implanted equivalents with a 
capsule thickness of 5-9 cell layers for CPC and 1-4 cell layers for the other 
formulations. The capsules surrounding CPC and CPC/BG consisted of fibroblasts 
(Figures 3B and 3D). CPC/PLGA and CPC/PLGA/BG implants were surrounded by a 
mature fibrous capsule which resembled connective tissue in the non-injured 
regions (Figures 3F and 3H). For CPC, CPC/BG and CPC/PLGA implants, still multi-
nucleated giant-cells were present at the interface. For CPC/PLGA/BG, the fibrous 
capsule was in close contact with the implant surface without the presence of 
macrophages or multi-nucleated giant cells. 
 
Quantitative histological evaluation of subcutaneous implants 
Two weeks after implantation, statistical analysis of the quantitative histological 
data revealed a significantly thicker capsule for CPC/PLGA compared to all other 
formulations (Figure 4A; p < 0.05). In addition, a significantly more mature capsule 
and interface was observed for CPC/BG and CPC/PLGA/BG compared to CPC/PLGA 
(Figures 4B and 4C, respectively; p < 0.05). With increasing implantation time, the 
capsule thickness, capsule quality and interface quality significantly improved for all 
experimental groups (p< 0.01). At 6 weeks, a significantly thinner capsule 
surrounding CPC/PLGA/BG was observed compared to CPC and CPC/BG (Figure 4A; 
p< 0.05). Moreover, the quality of the capsule and interface was significantly more 
mature for CPC/BG/PLGA compared to CPC and CPC/BG (Figures 4B and 4C 
respectively; p< 0.05). 
 
Descriptive histology of femoral condyle implants 
Two weeks 
An overview of representative histological sections of all experimental groups after 
a 2 week implantation period is depicted in Figure 5. Although the majority of the 
implants within the femoral condyle defect were placed correctly, implantation was 
occasionally imprecise as the bone defect crossed the growth plate or somewhat 
too much toward the edge of the femoral condyle. 
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Figure 3 Representative histological sections of subcutaneous implants of the four 
experimental groups after six weeks of implantation; CPC (A-B), CPC/BG (C-D), CPC/PLGA (E-
F) and CPC/PLGA/BG (G-H). Bar represents 1 mm. Composite material (C), Fibrous tissue (F), 
degraded PLGA-pores (P), and multi-nucleated giant cells (arrows) are indicated in the 
sections. Bar represents 100 μm. Methylene blue and basic fuchsin staining. 
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Figure 4 Histological evaluation of capsule thickness (A), the quality of the capsule (B) and 
the quality of the interface (C) of the different subcuteanous implants i.e. CPC, CPC/BG, 
CPC/PLGA and CPC/PLGA/BG after 2 and 6 weeks implantation using the histological grading 
scale. Error bars represent means ± standard deviation. (a) p<0.05 compared to CPC; (b) 
p<0.05 compared to CPC/BG; (c) p<0.05 compared to CPC/PLGA; (*) p<0.05 compared to 2-
weeks equivalent. 
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Both CPC and CPC/BG showed no signs of degradation, but rather a tight 
interaction with the surrounding bone (Figures 5A-D). For CPC/PLGA, the integrity 
of the implant was slightly affected peripherally, with soft tissue in the contact area 
between the edges of the bone defect and the implant. Limited newly formed bone 
was observed in the periphery of the implant (Figure 5E and F). For CPC/PLGA/BG, 
the integrity of the implant was completely affected. Degradation of the material 
allowed the ingrowth of soft  tissue accompanied by some bone formation in the 
central defect region. The region between the implant and the edges of the original 
defect was either filled with soft tissue or a close contact between bone tissue and 
implant was observed throughout the degraded material (Figure 5G and 5H). 
 
Six weeks 
An overview of representative histological sections of all experimental groups after 
a 6 week implantation period is depicted in Figure 6. 
A limited degradation at the peripheral area of the implants was noticed for CPC. In 
the contact area between the defect border and CPC, fibrous tissue was observed 
and, occasionally, bone remodeling was found (Figure 6A and B). For CPC/BG, very 
limited degradation of the material was seen in the peripheral region of the 
implant, with newly formed bone in the areas where CPC/BG had degraded (Figure 
6C and D). For CPC/PLGA, material degradation had continued leaving lower 
amounts of material in the defect area compared to the 2 week implantation 
period. Moreover, in the created PLGA-pores located in the central region of the 
implants soft tissue and some bone ingrowth was observed. The peripherally 
located PLGA-pores were always filled with bone tissue (Figure 6E and F). The 
degradation of CPC/PLGA/BG had continued and the material was almost 
completely degraded after 6 weeks. In addition, throughout the defect area bone 
ingrowth was found (Figure 6G and H). 
 
Histomorphometry of tissue response to femoral condyle implants 
Scaffold degradation 
Quantitative results on scaffold degradation are presented in Figure 7A. After 2 
weeks of implantation, CPC/PLGA and CPC/PLGA/BG revelaed significantly lower 
amounts of material within the ROI compared to CPC and CPC/BG (p< 0.05). With 
increasing implantation time, CPC/BG, CPC/PLGA and CPC/PLGA/BG 
showedsignificantly more scaffold degradation (p< 0.05), while no temporal 
differences were observed for CPC. At 6 weeks, the material amount for CPC/BG, 
CPC/PLGA and CPC/PLGA/BG were significantly lower compared to CPC (p< 0.05).  
In addition, the amount of material for CPC/PLGA/BG was significantly decreased 
compared to CPC/BG and CPC/PLGA. No differences were observed between 
CPC/BG and CPC/PLGA (p=0.75; the amount of material in ROI ranged for CPC from 
92 ± 4% to 96 ± 4%  after 6 weeks; for CPC/BG from 78 ± 9% to 52 ± 2% after 6 
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weeks; for CPC/PLGA from 56 ± 13% to 47 ± 2% after 6 weeks; for CPC/PLGA/BG 
from 35 ± 14% to 10 ± 3% after 6 weeks). 
 
Bone formation  
Quantitative results on bone formation within the ROI are depicted in Figure 7B. 
After 2 weeks of implantation, no significant differences in bone formation were 
observed between the different scaffolds. With increasing implantation time, the 
amount of bone for CPC/BG, CPC/PLGA and CPC/PLGA/BG had significantly 
increased (p<0.05). At 6 weeks, histomorphometrical analysis revealed significantly 
more bone formation for CPC/PLGA/BG compared to the other formulations (p< 
0.05) as well as for CPC/BG and CPC/PLGA compared to CPC (p<0.05; amount of 
bone formation ranged for CPC from 6 ± 4% to 13 ± 4% after 6 weeks; for CPC/BG 
from 11 ± 4% to 29 ± 3% after 6 weeks; for CPC/PLGA from 6 ± 5% to 32 ± 7% after 
6 weeks; for CPC/PLGA/BG from 10 ± 3% to 42 ± 10% after 6 weeks). 
 
Discussion 
This study aimed to evaluate the effects on in vivo tissue response after 
incorporating BG into CPC (with or without PLGA-microparticles) using 
subcutaneous implantation and implantation into femoral condyle defects in rats 
after 2 and 6 weeks. It was hypothesized that addition of BG would not negatively 
affect the biocompatibility of CPC and CPC/PLGA and would have a positive effect 
on the formation of bone. The main findings of the subcutaneous implantation 
showed that BG incorporation had indeed a favorable effect on soft tissue 
responses in terms of capsule thickness, capsule quality and interface quality. In 
addition, the femoral condyle defect model revealed that incorporation of BG into 
CPC or CPC/PLGA significantly accelerated material degradation and enhanced 
bone formation. 
Severe inflammatory response and tissue irritation caused by biomaterials can 
result in a delay of healing processes [28]. It is well known that the tissue response 
to an implanted biomaterial is determined by its chemical composition, which will 
dictate the intensity of the foreign body reaction and inflammatory process [28]. 
Several studies demonstrated that CPC, CPC/PLGA and BG alone are non-toxic and 
biocompatible [6, 9, 18, 27, 29-32]. In addition, Lee et al. (2010) observed 
enhanced soft tissue adaption after implantation of titanium implants coated with 
BG in combination with hydroxy-apaptite (HA). These findings are in line with the 
results of the current study, which demonstrated that CPC, either pure or 
combined with PLGA-microparticles and/or BG, does not evoke any severe 
inflammatory responses. Moreover, in the early post-implantation period, the 
incorporation of BG into CPC or CPC/PLGA enhanced the soft tissue reaction, 
evidenced by a thinner fibrous capsule with a better interface.  
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Figure 5 Representative histological sections of four experimental groups after two weeks of 
implantation in the femoral condyle defect; CPC (A-B), CPC/BG (C-D), CPC/PLGA (E-F) and 
CPC/PLGA/BG (G-H). Bar represents 1 mm. Composite material (C), Bone formation (B) and 
degraded PLGA-pores (P) are indicated in the sections. Bar represents 100 μm. Methylene 
blue and basic fuchsin staining. 
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Figure 6 Representative histological sections of four experimental groups after six weeks of 
implantation in the femoral condyle defect; CPC (A-B), CPC/BG (C-D), CPC/PLGA (E-F) and 
CPC/PLGA/BG (G-H). Bar represents 1 mm. Composite material (C), Bone formation (B) and 
degraded PLGA-pores (P) are indicated in the sections. Bar represents 100 μm. Methylene 
blue and basic fuchsin staining. 
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Figure 7 Results of histomorphometrical evaluation of the different formulations, i.e. CPC, 
CPC/BG, CPC/PLGA and CPC/PLGA/BG. (A) The amount of remained implant  and (B) the 
amount of newly formed bone after 2 and 6 weeks are expressed as percentage of ROI (i.e. a 
standardized region of interest with similar dimensions as created defect). Error bars 
represent means ± standard deviation. (a) p<0.05 compared to CPC; (b) p<0.05 compared to 
CPC/BG; (c) p<0.05 compared to CPC/PLGA; (*) p<0.05 compared to 2-weeks equivalent. 
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With increasing implantation time, the different CPC-formulations facilitated a 
relatively mild soft tissue reaction with a superiority for the CPC-formulation with 
BG incorporated into CPC/PLGA.  
For the replacement of bone, resorption of the bone substitute material (e.g. 
biodegradation of the material) is required, since formation of new bone tissue and 
ingrowth thereof in the defect area needs the liberation of space [29, 33, 34]. The 
results of the current study indicate that the degradation rate of the material 
indeed substantially influences the formation of bone, as with increasing implant 
degradation higher amounts of newly-formed bone were observed. The inclusion 
of dense PLGA-microparticles within CPC has been previously demonstrated to 
result in improved CPC degradation and hence bone formation due to the release 
of lactic and glycolic acidic monomers, which produce an acidic environment that 
acts as a stimulus for CPC dissolution [3, 9]. The increased implant degradation 
observed for BG-supplemented CPC might be related to the increased BG 
dissolution immediately after contact with fluids [35, 36] resulting in lower amount 
of remaining implant material at an earlier time point compared to the slow 
degradable pure CPC. It is likely that the superior biological performance of BG 
combined with PLGA-microparticles supplemented CPC is determinde by the 
positive effects of both BG and PLGA on the material degradation. Additionally, 
upon implantation, ionic dissolution products of BG have been shown to 
beneficially affect osteogenesis by attracting osteoprogenitor cells and by 
stimulating the differentiation into matrix-producing osteoblasts [14-18].  
Furthermore, it has reported that BG has a stimulatory effect on neovascularisation 
by stimulating the secretion of angiogenic factors [35, 37], which together with the 
osteopromotive properties of BG might further influence bone formation when 
using BG-supplemented CPC, either pure or supplemented with PLGA. However, 
the current study addressed the effect of BG inclusion in CPC based on histological 
analysis rather than at cell level. Consequently, direct evidence of osteopromotion 
and angiogenesis by BG are not available from the current study. Nevertheless, the 
outcome of the current study confirmed our hypothesis that BG can improve the 
biological performance of CPC and CPC/PLGA after 6 weeks of implantation. 
Consequently, BG-supplemented CPC might be promising to improve the 
performance of CPC required for compromised conditions. However, in view of the 
differences in bone metabolism in healthy compared to compromised conditions 
(e.g. osteoporosis), the biological performance of BG-supplemented CPC might be 
different. As this study was limited to relatively short-term evaluation of the 
performance of preset BG-supplemented CPC under optimal conditions to provide 
full control over the complete filling of the defect, information on the long-term 
performance of the (injectable) material and under compromised conditions 
remains to be provided. 
In conclusion, BG incorporation into CPC (or CPC/PLGA) improved the soft tissue 
response upon ectopic implantation compared to pure CPC (or CPC/PLGA). In 
addition, incorporating BG within CPC accelerated material degradation and 
increased bone formation in a femoral condyle defect in rats. Consequently, these 
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data highlight the potential of BG to be used as an additive to CPC to improve the 
biological performance for bone regeneration applications. Further long-term 
studies should be carried out to provide additional information concerning the late 
stages of material degradation and bone regeneration induced by the CPC/PLGA 
cements including BG. In addition, further research is required to evaluate the 
biological performance of BG supplemented CPC in compromised situations. 
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Introduction  
Bone tissue is one of the most frequently transplanted tissues in many fields, 
including dentistry and orthopedics [1]. Autologous bone grafts are still considered 
as the golden standard, albeit that several major drawbacks are related to the 
transplantation of autologous bone, such as postoperative morbidity, low 
availability and lack of functional shape of the transplantable tissue. Consequently, 
research is focusing on the development and evaluation of (synthetic) materials to 
replace autologous bone in grafting procedures. 
Alternative (synthetic) materials for bone grafting are predominantly explored 
within calcium-based ceramics or cements [2, 3], bioactive glasses [4], polymer-
based materials [5], and combinations thereof [6, 7]. Preferably, such synthetic 
bone substitute materials have osteogenic, osteoinductive, and osteoconductive 
properties meaning that similar to autologous bone grafts, bone substitute 
materials are capable of forming new bone tissue, inducing cells to differentiate 
into osteoblasts, acting as a three-dimensional structure onto which new tissue can 
grow, respectively. However, many bone substitute materials do not possess all of 
these characteristics. This makes that such materials are suitable for use in small, 
well-vascularized areas, but not for bone regenerative treatments in large, critical-
sized defects or under compromised medical conditions. Consequently, strategies 
to enrich (synthetic) materials with biological factors (e.g. cytokines, chemokines, 
and growth factors) are necessary in order to improve their biological performance. 
Several members of the transforming growth factor-β family are renowned for 
their capacity to induce bone formation [8-10], of which the so-called bone 
morphogenetic proteins (BMPs) are frequently used in bone tissue engineering [8, 
11]. BMPs, more specifically BMP-2, play a significant role in the regulation of many 
steps in bone morphogenesis due to their biological functions that include 
chemotaxis, differentiation, and mitosis of bone forming cells [11]. For the delivery 
of BMP-2 to a defect site, suitable carriers are necessary to provide effective 
availability of BMP-2 to induce differentiation of bone regenerative cells and 
contribute to bone defect healing [12]. It has been reported that addition of BMP-2 
to natural and synthetic polymers [13-15], hydrogels [16], ceramics [17, 18] or 
composites materials [19, 20] as a carrier results in sustained release and bone 
formation. It is assumed that the scaffold material needs to be loaded with an 
“above threshold” amount of exogenous BMP to actuate bone regenerative cells to 
contribute to bone formation [12, 21, 22]. However, the absolute BMP-2 amounts 
required to stimulate bone formation vary among the different scaffold materials, 
emphasizing the lack of consensus on suitable loading amounts [12]. For example, 
the BMP-2 amounts used in calcium phosphate cement-based materials range from 
2 [20] to 30 μg [23]. Either from a biological point of view as well as cost 
effectiveness, research is focusing on the reduction of the included growth factor. 
Native BMPs and recombinant equivalents produced in mammalian cells are post-
translationally modified through N-linked glycosylation [24], which is a major factor 
affecting the solubility of BMP-2. Bacterially produced BMPs lack this glycosylation, 
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leading to a decrease in solubility. Hence, the use of the less soluble non-
glycosylated BMP-2 might allow the application of lower BMP doses to induce bone 
formation [25]. 
In the present study, the bioactivity and osteoinductive properties of non-
glycosylated BMP-2 (ngBMP-2) and glycosylated BMP-2 (gBMP-2) were 
comparatively evaluated. In vitro bioactivity assays, an in vitro release assay and an 
in vivo rat subcutaneous model using pre-set calcium phosphate cement (CPC) with 
adsorbed BMP-2, were used to assess the in vitro bioactivity, in vitro release profile 
and to evaluate the ectopic osteoinductive potential of a carrier loaded with 
ngBMP-2 compared to gBMP-2. It was hypothesized that ngBMP-2 was biologically 
active and capable of inducing differentiation and mineralization of osteoblast-like 
cells. In addition, it was hypothesized that due to the effects of glycosylation on 
solubility the retention of ngBMP-2 to CPC would be higher, resulting in the 
induction of bone at an ectopic site at lower concentrations compared to gBMP-2 
loaded equivalents. 
 
Materials and Methods 
Materials  
Calcium phosphate cement (CPC) consisted of 85% alpha tri-calcium phosphate (α-
TCP; CAM Bioceramics BV, Leiden, The Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; J.T. Baker Chemical Co., USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). The CPC powders were ball-
milled and had particle sizes of 9.7 ± 2.0 μm, 4.5 ± 1.9 μm, and 5.0 ± 1.9 μm for α-
TCP, pHA, and DCPA, respectively [26]. The cement liquid applied was a sterilized 2 
wt.% aqueous solution of Na2HPO4. Acid terminated poly(DL-lactic-co-glycolic acid) 
(PLGA; Purasorb®, Purac, Gorinchem, the Netherlands) with a lactic to glycolic acid 
ratio of 50:50 and a molecular weight (Mw) of 17 ± 0.02 kg/mol was used for 
microparticle preparation. Recombinant human ngBMP-2 was kindly provided by 
dr. P. Hortschansky (Hans Knoell Institute, Jena, Germany). Commercially available 
recombinant human glycosylated BMP-2 (gBMP-2; R&D Systems MN, USA) was 
used for comparison. 
 
In vitro studies  
Bioactivity assay with C2C12 cell line 
The biological activity of both gBMP-2 and ngBMP-2 was tested by the induction of 
alkaline phosphatase (ALP) activity in C2C12 cells, as described before [27]. C2C12 
cells were plated at a density of 2 x 104 cells/cm2 and grown for 24 h in Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco BRL Life Technologies B.V., Breda, The 
Netherlands) supplemented with 10 % fetal calf serum (FCS; Gibco). Subsequently, 
medium was replaced by DMEM containing 5% FCS either in the presence or 
absence of 1-1000 ng/ml ngBMP-2 or gBMP-2.After 72 hours ALP enzymatic activity 
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was quantified by measuring the formation of p-nitrophenol from p-nitrophenyl 
phosphate (PNPP, Sigma-Aldrich, St. Louis, MO, USA) as described previously [28]. 
ALP enzymatic activity was corrected for differences in cell number as determined 
by a Neutral Red assay [29].  
 
Bioactivity assay with primary rat bone marrow-derived osteoblast-like cells 
Two independent runs were performed, with for each run freshly isolated primary 
rat bone marrow-derived osteoblast-like cells (OBLCs) following the procedure 
described by Maniatopoulos et. al (1988) [30]. All procedures were conducted in 
accordance with ISO-standards (9001:2008) and National Guidelines for care and 
use of laboratory animals after approval of the Experimental Animal Ethical 
Committee (RU-DEC 2008-199). In short, bone marrow was harvested from femora 
of male Wistar rats weighing between 120 g and 150 g. Femora were washed 3 
times in α-minimal essential medium (α-MEM; Gibco) containing 0.5 mg/ml 
gentamycin (Gibco) and 3.0 μg/ml Fungizone (Gibco). Epiphyses were cut off and 
diaphyses flushed out with 9 ml non-osteogenic medium (i.e. α-MEM 
supplemented with 10% FCS (Gibco) and 50 mg/ml gentamycin (Gibco)). The cells 
were divided into 2 groups; one group cultured in non-osteogenic medium and the 
other group in osteogenic medium (i.e. α-MEM supplemented with 10% FCS 
(Gibco), 50 μg/ml ascorbic acid (Sigma), 10 mM Na β-glycerophosphate (Sigma),10-8 
M dexamethasone (Sigma) and 50 μg/ml gentamycin (Gibco)). The cells were 
incubated in culture flasks at 37 °C in a humidified atmosphere of 95% normal air 
and 5% carbon dioxide. The medium was changed 3 times per week. After 7 days of 
primary culture, the cells were detached using trypsin/ethylenediaminetetraacetic 
acid (EDTA) (0.25% w/v trypsin/0.02% EDTA), concentrated via centrifugation, re-
suspended in either non- or osteogenic medium, and seeded at a concentration of 
1 x 104 cells/cm2 in 24-well plates (medium volume: 1 ml). Cell culture was 
maintained using 4 different conditions: (1) non-osteogenic medium(-O); (2) 
ngBMP-2-supplemented non-osteogenic medium (500 ng/ml) (-OBMP); (3) 
osteogenic medium (+O); and (4) ngBMP-2 supplemented osteogenic medium (500 
ng/ml) (+OBMP). The medium was changed 3 times a week. For respective groups, 
ngBMP-2 was added during the first week at medium refreshments at days 0, 1, 3 
and 5.  
 
Protein assay: To determine cell amounts, total protein measurements were 
performed using the bicinchoninic acid (BCA) assay (Sigma) on day 4, 8, 12 and 16 
(n=3). The culture medium was removed and the cells were washed twice with PBS. 
After washing, one ml of MilliQ was added to each sample and the samples were 
stored at -80°C. Just before analysis, the samples were subjected to two freeze-
thaw cycles. A standard curve was made using serial dilutions of bovine serum 
albumin in MilliQ (range: 0-40 μg/ml). Then, 100 μl of sample or standard was 
added to the wells of a 96-wells plate and 100 μl of work solution (1% copper 
sulphate, 25% BCA in MilliQ and 24% sodium carbonate, sodium bicarbonate, 
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sodium tartrate in 0.2 N NaOH) was added to all the wells. The samples were 
incubated at 37 °C for 2 hours and left to cool down at room temperature. The 96-
wells plate was read (Bio-Tek Instruments, Abcoude, the Netherlands) at 570 nm, 
and the protein concentrations were calculated from the obtained standard curve.  
 
Alkaline Phosphatase Activity (ALP) assay: ALP was used as a marker for early 
osteoblast differentiation. For determination of ALP-activity, the same samples as 
for the protein assay were used. ALP-activity was determined by adding 80 μl of the 
samples and 20 μl of buffer solution (5mM magnesium chloride, 0.5M 2-amino-
2methyl-1-propanol) to a 96-wells plate. A standard curve was prepared via serial 
dilutions of 4-nitrophenol (range: 0-25 nM), after which 100 μl was added to a 96-
wells plate. 100 μl of substrate solution (5mM p-nitrophenylphosphate) was added 
to all wells and the plate was incubated for 1 hour at 37°C. The reaction was 
stopped by adding 100 μl of stop solution (0.3M sodium hydroxide) to all the wells. 
The plate was read at 405 nm, and ALP-activity values were normalized to the 
amount of cellular protein present in the samples.  
 
Calcium assay: To assess the formation of mineralized matrix, culture plates were 
washed with PBS and one ml of 0.5 N acetic acid was added to the samples for 
overnight incubation during gentle agitation. A standard curve was made using 
serial dilutions of CaCl2·2H2O in acetic acid (range: 0-100 μg/ml). Then, 10 μl of the 
sample or standard was added to the wells of a 96-wells plate and 300 μl of work 
solution (5% o-cresolphtalein complexone, 5% 14.8 M ethanolamine, 2% 
hydroxyquinoline and 88% MilliQ) was added to all wells. Samples were incubated 
for 5 to 10 minutes at room temperature after which the plate was read at 570 nm. 
 
Release experiment and in vivo studies  
Preparation of PLGA-microparticles, pre-set CPC scaffolds and loading with BMP-2 
PLGA-microparticles (~40 μm diameter) were prepared using a double-emulsion-
solvent-extraction technique (water-in-oil-in-water), as described previously [31]. 
In brief, microparticles were produced by adding 500 μl of distilled water to 1400 
mg PLGA in 2 ml dichloromethane. The mixture was emulsified using a Turrax® 
emulsifier for 60 seconds at 6000 rpm. Then, 6 ml 0.3% aqueous poly (vinyl alcohol) 
(PVA, Acros Organics, Geel, Belgium) solution was added and emulsified for 
another 60 sec at 6000 rpm to produce a second emulsion. The emulsion was 
transferred to a stirred beaker, after which 394 ml 0.3% PVA solution and 400 ml of 
2% isopropylic alcohol solution was added slowly. After 1 hour of stirring, the 
microparticles were allowed to sediment for 15 min and the solution was decanted. 
Then, the microparticles were washed and collected through centrifugation at 1500 
rpm for 5 min, lyophilized  and stored at -20 °C until use. Pre-set CPC scaffolds were 
prepared by adding 300 mg PLGA microspheres to 700 mg CPC powder into a 
closed tip 2 mL plastic syringe (BD PlastipakTM, Becton Dickinson S.A., Madrid, 
Spain), after which the content was stirred vigorously for 20 seconds to achieve 
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homogenous distribution of microparticles within the cement powder (Silamat® 
mixing apparatus, Vivadent, Schaan, Liechtenstein). Subsequently, 2 wt.% Na2HPO4 
was added to the mixture in a liquid/powder ratio of 0.35 and mixed for 20 seconds 
using a mixing apparatus. After mixing, the cement was immediately injected in a 
Teflon mould to ensure a standardized shape of the scaffolds (Ø 7.8 mm, height 2.8 
mm) and placed overnight at 37°C. To create an instantaneous open porous 
structure, the pre-set scaffolds were placed in a furnace at 650°C for 2 h to burn 
out the polymer. Finally, CPC scaffolds were sterilized by autoclavation and 
characterized using scanning electron microscopy (SEM; JEOL6310 at 15kV). The 
total porosity of the samples was calculated by the following equation [31]:   
 
To measure the open interconnective porosity of the burned-out pre-set CPC 
scaffolds, mercury (Hg) porosimetry was performed using PoreMaster® GT mercury 
intrusion porosimeter (Quantachrome instruments, Odelzhausen, Germany). 
Burned-out pre-set CPC scaffolds were placed into the system and the intrusion of 
Hg was analyzed under low pressure conditions. Loading of the burned-out pre-set 
CPC scaffolds with BMP-2 was performed via adsorption. Therefore, a volume of 30 
μl growth factor solution containing 1, 5 or 10 μg gBMP-2 or ngBMP-2 was applied 
to the surface of each side of the scaffold to obtain final amounts of 2, 10 or 20 μg 
BMP-2/scaffold. Thereafter, the scaffolds were frozen and lyophilized. To visualize 
the distribution of the added drugs within the burned-out pre-set CPC scaffolds, 
albumin from bovine serum (BSA) labeled with alexa fluor 488 (Invitrogen, Life 
Technologies Europe BV, Bleiswijk, The Netherlands) was used as model protein. 
The loading of labeled BSA (2, 10 or 20 μg BSA/scaffold) to the CPC was similar as 
described previously. Thereafter, the scaffolds were frozen and lyophilized. The 
BSA loaded CPC were overnight fixed in 4% formalin. Subsequently, the tissue 
blocks were embedded in methylmethacrylate. Perpendicularly through the 
implants, thin sections (10 μm) were prepared using a microtome with diamond 
blade (Leica Microsystems SP 1600, Nussloch, Germany) [32].  The sections were 
visualized using a reflectant fluorescence microscope with a Zeiss filter set 00, 
consisting of a 530–585 nm band-pass excitation filter (Carl Zeiss B.V., Sliedrecht, 
The Netherlands). 
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Release experiment 
gBMP-2 and ngBMP-2 were labeled with 125I, as described previously [33]. Briefly, in 
a 500 μl eppendorf tube coated with 100 ug iodogen, 10 ul of 0.5 M phosphate 
buffer saline (PBS) was added. Growth factor (25 μg) and 10-15 MBq 125I (Perkin-
Elmer, Boston, MA) was added and incubated at room temperature for 10 min, 
after which 100 μl of saturated tyrosine solution in PBS was added. The labeling 
efficiency of the reaction was 67.6% and 23% for gBMP-2 and ngBMP-2, 
respectively. To remove the non-bound 125I, the reaction mixture was eluted using 
0.1% BSA in PBS on a pre-rinsed disposable Sephadex G25M column (PD-10; 
Pharmacia, Uppsala, Sweden). The specific activity of the labeled protein was 18.7 
μCi/μg for gBMP-2 and 9.1 μCi/μg for ngBMP-2. CPC scaffolds were loaded similarly 
as described above with either 125I-gBMP-2 or 125I-ngBMP-2 solutions using a 
hot/cold mixture of BMP-2, containing 1 μCi per scaffold (for gBMP 1 μCi ~ 0.053 μg 
BMP-2; for ngBMP 1 μCi ~ 0.110 μg BMP-2). A volume of 30 μl 125I-gBMP-2 or 125I-
ngBMP-2 hot/cold solution containing 1, 5 or 10 μg BMP-2 was carefully loaded 
onto the surface of each side of the scaffold to obtain final amounts of 2, 10 or 20 
μg BMP-2/scaffold. Thereafter, the scaffolds were frozen and lyophilized. CPC 
scaffolds loaded with 125I-labeled BMP-2 (n=3) were placed in 10 ml glass vials for 
evaluation of in vitro BMP-2 release kinetics and incubated in 3 ml PBS at 37 °C on 
an orbital shaker at low rotational speed (60 rpm) for 28 days. At days 1, 4, 7, 14, 
21 and 28, the samples were carefully transferred to new vials containing fresh 
PBS, after which gamma emission of the samples was measured in a shield well-
type gamma counter (Wizard, Pharmacia-LKB, Uppsala, Sweden). Standards were 
measured simultaneously to correct for radioactive decay. The remaining activity in 
the scaffolds was expressed as percentage of the initial dose. 
 
Surgical procedure 
Twenty-four healthy young adult (8 weeks old) male Wistar rats were used as 
experimental animals. National guidelines for the care and use of laboratory 
animals were observed. The research was reviewed and approved by the 
Experimental Animal Committee of the Radboud University (RUDEC 2010-062). 
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique 
Fine Limited, Avonmouth, Bristol, UK). To minimize post-operative discomfort, 
Rimadyl (Carprofen, Pfizer Animal Health, New York, USA) was administered 
intraperitoneally (5 mg/kg) before the surgery, directly after the surgery and 
subcutaneously for two days after surgery.  Four CPC scaffolds were 
subcutaneously implanted into the back of each rat. To insert the scaffolds, rats 
were immobilized on their abdomen and the skin was shaved and disinfected with 
chlorhexidine. On both sides of the vertebral column, two small paravertebral 
incisions were made through the full thickness of the skin. Lateral to the incisions, a 
subcutaneous pocket was created using blunt dissection. Subsequently, one 
implant was inserted into each pocket. Finally, the skin was closed using staples 
(Agraven, Instruvet, Boxmeer, the Netherlands). In total, ninety-six implants were 
CHAPTER 4 
 88 
placed according to a randomization scheme (n=8 for each group per implantation 
period). The animals were housed in pairs. In the initial postoperative period, the 
intake of water and food was monitored. Further, the animals were observed for 
signs of pain, infection and proper activity. At the end of the implantation time, the 
rats were sacrificed by CO2-suffocation. 
 
Implant retrieval and histological preparations 
Implants were retrieved after a 4 or 12 week implantation period. After sacrifice, 
implants with surrounding tissue were excised and fixed in 4% formalin. 
Subsequently, the tissue blocks were dehydrated in increasing ethanol 
concentrations (70–100%) and embedded in methylmethacrylate. Perpendicularly 
through the implants, thin sections (10 μm) were prepared using a microtome with 
diamond blade (Leica Microsystems SP 1600, Nussloch, Germany) [32]. Three 
sections of each implant were stained with methylene blue and basic fuchsin and 
examined using light microscopy (Leica Microsystems AG, Wetzlar, Germany). From 
the control, 20 μg/cement ngBMP-2 and gBMP-2 12 weeks implantation groups, 
MMA samples were polished and gold sputter-coated prior to analysis with 
Scanning electron microscopy (JEOL 6330) using Back-Scattered Electron (BSE) 
mode for histomorphometrical analysis. Using BSE mode, it possible to distinguish 
bone from the implanted scaffold based on the respective densities of the two 
substances. In addition, two samples of the 20 μg/cement ngBMP-2 and gBMP-2 12 
weeks implantation group were deplastified, decalcified (Sakura Finetek, Syntec 
Scientific, Dublin, Ireland) for 16 hours, dehydrated through a series of graded 
ethanol and embedded in paraffin. Using a microtome (Leica RM 2165, Leica 
Microsystems, Nussloch, Germany), 6 μm thick sections were prepared and stained 
with Goldner Trichrome. 
 
Histological and histomorphometrical evaluation 
Sections of MMA-embedded specimens (at least 3 sections per specimen) were 
quantitatively assessed using computer-based image analysis techniques (Leica® 
Qwin Pro-image analysis system, Wetzlar, Germany). From digital images 
(magnification: 5x), the total amount of newly-formed bone surrounding the CPC 
scaffold was determined and expressed in area measures (mm2). Sections of 
decalcified, paraffin-embedded specimens stained with Haematoxyline-eosine and 
Goldner trichrome (at least 3 sections per specimen) were qualitatively examined 
for tissue ingrowth.  
 
Statistical analyses  
Statistical analysis of the in vitro bioactivity assay measurements was performed 
using GraphPad Instat 3.05 software (GraphPad Software Inc., San Diego, CA) using 
one-way analysis of variance with a Tukey multiple comparison post test. 
Differences were considered significant at p-values less than 0.05. Statistical analysis 
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of the release experiment measurements was performed using SPSS, version 16.0 
(SPSS INC., Chicago, Illinious USA). The statistical comparisons were performed 
using 2-tailed Student's t-test. Differences were considered significant at p-values 
less than 0.05. Statistical analysis of bone formation measurements was performed 
using SPSS, version 16.0 (SPSS INC., Chicago, Illinious USA). The statistical 
comparisons were performed using a one-way analysis of variance (ANOVA) with a 
Tukey multiple comparison post-test. Differences were considered significant at p-
values less than 0.05. 
 
Results  
In vitro studies  
Two independent runs of the bioactivity assay with C2C12 cells showed similar 
results. C2C12 cells cultured in the presence of the different types of BMP-2 
demonstrated a dose-dependent ALP-activity. The threshold for the detection of 
ALP-activity was ~125 ng/ml for gBMP-2 and 250 ng/ml for ngBMP-2 with 
significant higher values (p<0.001) for gBMP-2 at each concentration (Figure 1). 
Two independent runs of cell culture experiments with primary rat bone marrow 
derived OBLCs showed similar results. OBLCs cultured in all types of medium 
showed an increase in the cellular protein content between day 4 and 12 after cell 
seeding, with higher maximum values for -O and -OBMP. Thereafter, the protein 
content in all experimental groups decreased (Figure 2a). For all experimental 
groups, ALP-activity was observed from day 4 onwards, showing maximum values 
at day 8 (Figure 2b). In general, ngBMP-2 addition significantly increased ALP-
activity in -O as well as +O in the first 8 days of culture. For mineralization (Figure 
2c), a gradual increase in calcium amounts was observed from day 4 onward for +O 
and +OBMP. Significantly higher values (p<0.001) were observed for +OBMP 
compared to +O at each individual time point. For -O and -OBMP, no increase in 
calcium amounts was observed. 
 
CPC scaffolds, drug loading and release experiment  
CPC scaffolds were characterized using SEM (Figure 3) and demonstrated different 
types of porosity: intrinsic microporosity (pore size ~10 nm - 100 nm) related to 
material setting and crystallization, and macroporosity (pore size: ~40 μm) resulting 
after burning out PLGA-microparticles. The total porosity (consisting of the intrinsic 
porosity of material and additional porosity after PLGA-microparticle degradation) 
was determined by measuring the weight of pre-set composite discs (with and 
without PLGA-microparticles) and comparing it to a fictitious, solid hydroxyapatite 
disc with the same dimensions. The porosity measurements demonstrated a total 
porosity of 75.5 ± 1.3 %. The interconnective porosity as analyzed by Hg intrusion 
porosimetry revealed a porosity of 21.3 %. Drug loading was visualized using cross-
sections of CPC-scaffolds loaded with different amounts of alexa fluor 488 labeled 
BSA (Figure 3). In all concentrations, the distribution of the protein is only observed 
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peripherally and not in the center of the implants. However, a dose-dependent 
effect is observed whereby with increasing BSA concentrations the protein 
infiltration is enlarged. The release and retention after 28 days of 125I-gBMP-2  and 
125I-ngBMP-2 for the low (2 μg), middle (10 μg), and high (20 μg) dose implants are 
depicted in Figure 4 and Table 1. In general, all scaffolds retained their integrity 
during the entire experiment and showed an initial burst release within 1 day, 
followed by a sustained release till day 28 (Figure 4A). For gBMP-2, the burst 
release (Figure 4B) was 17.4 ± 7.8, 14.3 ± 5.8 and 11.7 ± 1.0 %  for low, middle and 
high dose loaded scaffolds, respectively. For ngBMP-2, the burst release was 16.1 ± 
2.4, 22.0 ± 0.7 and 16.0 ± 3.8 for low, middle and high dose loaded scaffolds, 
respectively. The overall sustained release (Figure 4B; % per day) from day 1-28 of 
ngBMP-2 compared to gBMP-2 was significantly lower (p<0.001, overall sustained 
release of 0.63 ± 0.07% and 0.88 ± 0.17%  for ngBMP-2 and gBMP-2, respectively). 
Separately, the sustained release from day 1 to day 28 was significantly lower for 
the low ngBMP-2 loaded scaffolds compared to gBMP-2 loaded scaffolds (p<0.05, 
sustained release of 0.86 ± 0.15 and 0.56 ± 0.07 %/day for gBMP-2 and ngBMP-2, 
respectively). A similar tendency was observed for the middle and high ngBMP-2 
loaded scaffolds compared to the high gBMP-2 loaded scaffolds (for the middle 
dosage p=0.146, sustained release of 0.90 ± 0.26 and 0.63 ± 0.03 %/day for gBMP-2 
and ngBMP-2, respectively; for the high p=0.130, sustained release of 0.87 ± 0.161 
and 0.69 ± 0.03 %/day for gBMP-2 and ngBMP-2, respectively). After 28 days, the 
total release (Figure 4B) for gBMP-2 was 40.6 ± 4.0, 38.7 ± 3.4 and 35.1 ± 4.5 % for 
low, middle and high dose loaded scaffolds, respectively. For ngBMP-2, the total 
release was 31.4 ± 2.4 , 39.1 ± 0.5 and 34.6 ± 3.6 % for low, middle and high dose 
loaded scaffolds, respectively. These release results show significantly increased 
protein retention for ngBMP-2 in the low loaded groups compared to low gBMP-2 
(p<0.05), whereas no significant differences were observed for the middle and high 
loaded groups. 
 
 
Figure 1 ALP activity of the C2C12 cells after 72 h stimulation with gBMP-2 or ngBMP-2. 
C2C12 cells demonstrate a dose-dependent ALP-activity. ALP-activity was significantly 
increased by gBMP-2, and ngBMP-2. Results are shown as means ± SD of triplicate samples 
for one representative experiment out of two. (***) p<0.001. 
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Figure 2 (A) Cellular protein content and (B) Alkaline phosphatase (ALP) activity of and (C) 
mineralization (calcium deposition) by rat osteoblast-like cells cultured in non-osteogenic  (-
O) or osteogenic (+O) medium in the presence or absence of ngBMP-2. Results are shown as 
mean ± SD of triplicate samples for one representative experiment out of two. (***)p<0.001. 
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Figure 3 Characterization of porous CPC scaffolds. Microscopic SEM micrographs of 
composite material before (A) and after (B) burning out the PLGA-microparticles. Bar 
represents 100 μm. (C) The distribution of low, middle or high dose of the model protein 
alexa fluor 488 labeled BSA within porous CPC scaffolds. Bar represents 500 μm. 
 
Table 1 The release in percentage of gBMP-2 and ngBMP-2 from porous CPC 
Low (L), middle (M) and high (H): 2 μg, 10 μg or 20 μg loaded carrier with either gBMP-2 or 
ngBMP-2, *; p<0.05 as compared between both groups at the specific time point. 
 Burst  
release (%) 
Cumulative sustained release (%) 
D 1 D 4 D 7 D 14 D21 D28 
gBMP-2       
L 17.4 ± 7.8 24.7 ± 1.3 29.4 ± 2.69 33.7 ± 3.8 36.5 ± 5.7 40.6 ± 4.0 
M 14.3 ± 5.8 22.2 ± 1.8 25.7 ± 2.3 26.5 ± 9.2 35.5 ± 3.2 38.7 ± 3.4 
H  11.7 ± 1.1 17.9 ± 2.5 23.7 ± 3.4 27.9 ± 3.5 31.3 ± 3.2 35.1 ± 4.5 
ngBMP-2       
L  16.1 ± 2.4 20.1 ± 3.2 23.6 ± 4.1 28.2 ± 5.9 29.3 ± 3.7 31.4 ± 2.4* 
M  22.0 ± 0.7 26.4 ± 0.5 31.5 ± 2.9 * 33.6 ± 0.3 36.5 ± 0.8 39.1 ± 0.5 
H  16.0 ± 3.8 21.9 ± 3.5 25.2 ± 2.5 28.1 ± 5.4 31.2 ± 5.1 34.6 ± 3.6 
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Figure 4 Longitudinal scintigraphic assement of low (L), middle (M) and high (H) dose gBMP-
2 and ngBMP-2 (A) released from loaded porous CPC scaffolds during 28 days and (B) the in 
vitro burst release (after 1 day), sustained release (the release per day from day 1-28) and 
the retention after 28 days. The release and retention is expressed as percentage of the ratio 
of initial loading amount. Error bars represents the mean ± SD (n=3). (*) p<0.05. 
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Descriptive light microscopy  
All specimens showed a fibrous capsule surrounding the scaffold after both 4 and 
12 weeks of implantation, without the presence of inflammatory cells at the 
interface. Figure 5 presents an overview of histological sections of the specimens 
after each implantation period as well as higher magnifications of the newly-
formed bone tissue at the interface between CPC scaffold and tissue. Bone 
formation was observed for all BMP-2 loaded implants after both 4 and 12 weeks 
of implantation, but was absent for unloaded controls. Bone formation and fibrous 
tissue were only observed peripherally and not in the center of the implants in any 
of the sections (Figure 5 and 6). Bone formation was most pronounced for high 
dose ngBMP-2 loaded scaffolds after 12 weeks of implantation.  
 
 
 
Figure 5 Histological sections of the low dose gBMP-2 and ngBMP-2 loaded porous CPC 
scaffolds after 4 and 12 weeks implantation. Bar represents 500 μm. Magnifications of the 
boxes show low dose gBMP-2 and ngBMP-2 loaded porous CPC scaffolds after 12 weeks of 
implantation. Bar represents 100 μm. Methylene blue and basic fuchsin staining. 
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Figure 6 Cross-sections of Control (A, D) and high dose gBMP-2 (B, E, G) and ngBMP-2 (C, F, 
H) loaded porous CPC scaffolds after 12 weeks implantation observed with SEM, back 
scattering SEM and histological with Goldner trichrome staining, respectively. Bone (+) and 
CPC scaffold (-) are indicated in the back scattering SEM micrographs and Goldner trichrome 
stained sections. 
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Histomorphometrical evaluation  
Quantitative results of ectopic bone formation are shown in Figure 7. After 4 weeks 
of implantation, a dose-dependent amount of bone formation was observed for 
both gBMP and ngBMP, whereas no bone formation was observed for controls. A 
significant higher amount of newly-formed bone (p<0.001) was found for low dose 
ngBMP scaffolds compared to gBMP equivalents. The amount of newly-formed 
bone significantly increased in time (for gBMP-2 loaded scaffolds p<0.01; for 
ngBMP-2 loaded scaffolds p<0.001) for all types of scaffolds (except controls) with 
a maximum of ~1mm2 after 4 weeks to a maximum of ~7mm2 after 12 weeks. 
Similar to week 4 observations, significant higher amounts of newly-formed bone 
(p<0.001) were found for low dose ngBMP scaffolds compared to gBMP equivalents 
after 12 weeks of implantation. 
 
Figure 7 Osteoinductive capacity of gBMP-2 and ngBMP-2 loaded carriers at an ectopic 
location after 4 (A) and 12 (B) weeks implantation period. Bone formation is only observed in 
the BMP-2 loaded carriers. In addition, ngBMP-2 can significantly induce more bone at lower 
concentrations compared to gBMP-2 at both implantation periods. Error bars represent 
means ± standard deviation. (***) = p < 0.001; n>7. 
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Discussion  
For clinical application, the availability of recombinant human BMP-2 at acceptable 
costs is mandatory. In view of that, large-scale BMP-2 production via a bacterial 
hosts might be a good alternative for mammalian cells for reasons of cost 
effectiveness [34]. However, bacterially produced BMP-2 lacks a glycosylation site 
and hence is structurally different to and less soluble than the native, post-
translationally modified mammalian BMP-2. Consequently, this study 
comparatively evaluated the bioactivity of non-glycosylated (ng) and glycosylated 
(g) BMP-2 using in vitro bioactivity and release assays and an ectopic animal model, 
in which different amounts (2-20 ug) BMP-2 were loaded onto a porous calcium 
phosphate cement (CPC) carrier. It was hypothesized that less soluble ngBMP-2 
was biologically active and would induce more bone ectopically compared to more 
soluble gBMP-2. In vitro bioactivity assays revealed that ngBMP-2 is less active than 
gBMP-2, however ngBMP-2 was still capable of inducing differentiation and 
mineralization of primary rat osteoblast-like cells. The overall sustained release 
from day 1-28 of ngBMP-2 was significantly lower as compared with gBMP-2. 
Separately, a significant decrease in sustained release for low ngBMP-2 loaded 
scaffolds as compared with gBMP-2 loaded scaffolds was observed leading to an 
increased amount of retained protein after 28 days. In vivo ectopic bone formation 
demonstrated that ngBMP-2 is capable of inducing significant more bone at low 
dosage (2 μg/CPC) from four weeks onward compared to gBMP-2. 
The regenerative capacity of BMP-2 is dependent on its ability to stimulate the pre-
osteoblastic cells to differentiate into bone forming cells leading to the formation 
of new bone. In the current study, a difference in levels of the activity of early 
osteoblastic differentiation marker ALP in C2C12 cells cultured in the presence of 
ngBMP-2 compared to gBMP-2 was observed. Nevertheless, ngBMP-2 
demonstrated to be capable of inducing differentiation and mineralization of 
primary rat osteoblast-like cells. In contrast, several studies reported equal levels of 
ALP-activity for cells cultured in the presence of gBMP-2 or ngBMP-2 [35, 36] 
indicating a comparable in vitro potency of both types of BMP-2 as osteoinductive 
factor. Due to inconsistency in different reports on the efficacy of both types of 
BMP-2 in in vitro experiments, the precise effect of glycosylation on bioactivity 
remains unclear. 
The release profiles of adsorbed ngBMP-2 and gBMP-2 showed an initial burst 
release (within 1 day) followed by a sustained release (from day 1-28) of in total 
approximately ~35% for the ngBMP-2 loaded scaffolds and ~38% for the gBMP-2 
loaded scaffolds, which were similar to earlier reported ones, describing a release 
up to ~40% [37]. Despite similar release profiles of both BMPs,  the sustained 
release per day for the low ngBMP-2 loaded scaffolds was significantly reduced and 
a tendency was observed in the middle and high ngBMP-2 loaded scaffolds 
compared to gBMP-2 loaded scaffolds. These results are in line with the data of the 
amounts of BMP-2 retained onto the implants after 28 days, showing significantly 
higher amounts for low ngBMP-2 compared to low gBMP-2, whereas for middle 
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and high loaded implants similar amounts were observed for ngBMP-2 and gBMP-
2. Although after 28 days the BMP-2 retention is only significantly different for the 
low dosages, the overall sustained release of ngBMP-2 compared to gBMP-2 is 
significantly lower, indicating an effect of glycosylation on protein release. 
Interestingly, after a similar implantation period in vivo, low dosages of ngBMP-2 
induced significantly more ectopic bone formation compared to low gBMP-2 
dosages. As it is likely that the biological process of bone formation is related to the 
presence of BMP-2 at the implant and its solubility, the significantly increased 
amounts of ngBMP-2 retained onto the implants are suggested to be responsible 
for this observation. This higher retention of ngBMP-2 corroborates earlier findings 
[25] that indicated a decreased solubility of ngBMP-2 in fibrin matrices. 
Additionally, this indicates that the biological activity of BMP-2 is not directly 
depending on release but rather on availability and solubility, in either released or 
bound form, in a specific area. 
The sustained release and thus bone formation is carrier dependent due to altered 
release rates of BMP-2 from the different carriers [12]. For example, the retention 
of gBMP-2 within an alginate mesh is significantly increased compared to a collagen 
sponge in the first week after which the difference diminishes [38]. Together with 
the finding of Brown et al. (2011), who reported a positive effect on bone 
formation after a BMP-2 burst release and a subsequent sustained release, it was 
suggested that a combination of relatively high initial release and a low sustained 
release thereafter may be beneficial for growth factor efficacy [39]. The release 
kinetics observed in the current study corroborate earlier findings and indicate a 
similar effect [37]. However, the BMP-2 activation in relation to the bioactivity of 
BMP-2 needs to be observed as a complex factor. It is assumed that BMP-2 not only 
acts in released form, but also when it is presented in an adsorbed form to the 
target cells [20, 40]. However, up to date the ability to discriminate the 
contribution of adsorbed and released forms of BMP-2 is not available. 
The induction of ectopic bone tissue by BMP-2 adsorbed to pre-set CPC scaffolds 
showed to be both dose- and time-dependent with significantly higher bone 
formation induced by ngBMP-2 at low dosage compared to gBMP-2. The amount of 
ectopic bone formation was comparable to previous experiments with 
subcutaneous implantation of scaffolds containing adsorbed glycosylated (rh)BMP-
2 [18, 41]. Bone tissue was predominantly formed in the periphery of the porous 
CPC scaffolds as well as at the material/tissue interface. This observation is likely 
related to the rapid and strong interaction between proteins (e.g. BMP-2) and the 
pre-set CPC scaffolds and the limitations micrometer-scale porosity brings along 
regarding cell penetration. In general, proteins rapidly adsorb to CaP-based 
materials due to electrostatic interactions [42], which even can become stronger 
upon conformational changes of adsorbed proteins. More particularly, Ruhé et al. 
studied the effect of albumin pre-treatment of pre-set, porous CPC scaffolds on 
BMP-2 release under different conditions [43] and demonstrated that albumin pre-
treatment only had a marginal effect on the limited release of BMP-2, emphasizing 
the capacity of pre-set CPC scaffolds to retain adsorbed proteins. Penetration of 
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(bone) tissue into a porous relies on the size of the pores and their 
interconnectivity. In relation to CPC, Link et al. demonstrated that tissue ingrowth 
into pre-set CPC scaffolds containing PLGA microspheres occurred when pore size 
exceeded 50 μm and interconnectivity was obtained by incorporating sufficient 
porogen, in their case at least 20 wt% PLGA-microspheres [44]. The pre-set porous 
CPC scaffolds used in the present study were made using smaller PLGA 
microparticles (i.e. 40 μm) and a higher amount (i.e. 30 wt%). Based on the 
observations that bone formation and tissue ingrowth were limited to the 
periphery of the pre-set CPC scaffolds, as additionally shown using paraffin-
embedded decalcified sections, the created porosity within these scaffolds 
apparently was insufficient for cell penetration.  
In summary, the present study revealed that ngBMP-2 is less biologically active in 
vitro compared to gBMP-2, however still capable of inducing osteoblast-like cells to 
differentiate and mineralize. In addition, ngBMP-2 showed slower release from a 
CaP-based implant compared to gBMP-2. Despite lower biological activity and 
release in vitro, ngBMP-2 significantly increased ectopic bone formation at low 
dosages. This observation provides strong evidence that the efficacy of ngBMP-2 in 
vivo is enhanced compared to gBMP-2 and reflects its value for enrichment 
strategies for biomaterials, bone tissue engineering and bone regenerative 
treatments. 
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Introduction 
Calcium phosphate (CaP) based materials are widely used as bone substitute 
materials in orthopedic, reconstructive and oral surgery due to their performance 
[1, 2]. CaP-based materials are available in various forms, for example as granules 
or blocks. More interestingly, injectable CaP-based pastes (e.g. of brushite or 
apatitic nature [3]) are also available and have the advantage of optimal bone 
defect filling through minimally invasive surgery. Injectable CaP-based cements 
have shown biocompatibility and osteoconductivity, although in vivo degradation 
and tissue ingrowth were difficult to control [1, 4, 5]. 
To enhance material degradation, different approaches have been explored to 
introduce porosity within CaP cement (CPC), including the use of sodium 
bicarbonate to obtain CO2-gas bubbles during cement setting and mixing 
biodegradable polymer microparticles (e.g. gelatin [6] or poly(D,L-lactic-co-glycolic) 
acid (PLGA) [7-10]) as porogens homogeneously through the cement powder. 
Although porosity is instantaneous when using the CO2-gas bubble method, the 
lack of control on pore size and distribution is disadvantageous [11]. In contrast, 
PLGA-microparticles create a delayed porosity, after the PLGA-microparticles are 
degraded by means of hydrolysis in a process called bulk erosion [10],  
with, importantly, homogeneously dispersed pores of desired size. In addition, Felix 
Lanao et al. (2011) reported that the hydrolysis of PLGA-microparticles can be 
controlled depending on the PLGA molecular weight, end-group chemistry, and/or 
morphology [12]. In view of this, CPC degradation and bone formation were shown 
to be highest when dense acid-terminated PLGA-microparticles were incorporated 
in CPC [13]. 
Further empowerment of CPC for biological performance can be achieved by 
incorporating biologically active compounds, including growth factors. Previously, it 
has been reported that biologically active additives can be absorbed on preset CPC. 
For example, CPC surface loading of the growth factor bone morphogenetic 
protein-2 (BMP-2) demonstrated to induce bone formation at ectopic locations in 
rats [14] and rabbits [15] and increased bone formation at orthotopic locations in 
rabbits [16]. However, the clinical application of CPC is in an injectable form, for 
which the loading of additives on the surface of preset CPC is not feasible. 
Consequently, a biologically active compound needs to be incorporated during the 
CPC setting (i.e. included into the powder or the liquid phase of CPC). In view of 
this, growth factor loading onto included porogens (e.g. PLGA-microparticles) 
represents an approach to introduce biologically active compounds for the 
injectable CPC. It has been reported that incorporation of BMP-2 adsorbed PLGA-
microparticles into CPC results in a sustained in vivo release of the growth factor at 
both ectopic [17] and orthotopic locations [18] in rats, and an increased bone 
formation was observed compared to non-loaded scaffolds at orthotopic locations 
[18]. Another approach is to add biologically active compounds to the liquid phase 
of CPC. It has been reported that the inclusion of transforming growth factor (TGF)-
β1 to the liquid phase of CPC increased the formation of bone in rat calvarial bone 
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defects [19]. Since growth factor release and related biological effect are likely to 
be carrier dependent, the release kinetics and osteoinductive capacity of different 
loading approaches need to be evaluated. 
In the present study, different loading methods for BMP-2 into CPC were evaluated 
in terms of in vitro and in vivo release and in vivo osteoinductive capacity. For 
injectable CPC, BMP-2 was either adsorbed onto dense PLGA-microparticles or 
added to the liquid phase of CPC. For comparison, BMP-2 was loaded onto the 
surface of pre-set, porous CPC. Radiolabeled BMP-2 was used to monitor release 
profiles in vitro as well as in vivo using a subcutaneous rat model, in which growth 
factor retention was analyzed via single-photon emission computed tomography 
(SPECT). BMP-2 loaded scaffolds without radiolabel were histologically analyzed for 
osteoinductive capacity of the different loading methods in a rat subcutaneous 
implantation model. It was hypothesized that in view of an injectable CPC, the 
addition of BMP-2 via incorporated PLGA-microparticles would result in an 
increased BMP-2 release and subsequent improved osteoinductive properties in 
CPC/PLGA compared to CPC/liquid due to a faster degradation of the PLGA-
microparticles compared to that of the ceramic matrix of CPC. 
 
Materials and Methods 
Materials 
Calcium phosphate cement (CPC) consisted of 85% alpha tri-calcium phosphate (α-
TCP; CAM Bioceramics BV, Leiden, The Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; J.T. Baker Chemical Co., USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany), and was sterilized using 
gamma irradiation (>25 kGy; Isotron BV, Ede, the Netherlands). The cement liquid 
applied was a sterilized 2 wt.% aqueous solution of Na2HPO4. Acid terminated 
poly(DL-lactic-co-glycolic acid) (PLGA; Purasorb®, Purac Biomaterials BV, 
Gorinchem, the Netherlands) with a lactic to glycolic acid ratio of 50:50 and a 
molecular weight (Mw) of 17 ± 0.02 kg/mol was used for microparticle preparation. 
Commercially available recombinant human BMP-2 (BMP-2; R&D Systems MN, 
USA) was used. 
 
Analysis of the BMP-2 secondary structure 
Circular dichroism (CD) spectra of BMP-2 (0.1 mg/ml) dissolved in 2 wt.% aqueous 
solution of Na2HPO4 or BMP-2 (0.1 mg/ml) dissolved in PBS were recorded in the 
range 195–260 nm at a scan rate of 2s per nm with a Jasco J-810 
spectropolarimeter (Oklahoma City, OK) to visualize protein conformation. A quartz 
cell of 0.1 cm thickness was used. CD spectra values were expressed as mean 
residue ellipticities (in degrees cm−2 dmol−1). The results were further subjected to 
a non-linear regression analysis to illustrate the secondary structure using the 
Gauss–Newton algorithm method. 
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Preparation of hollow and dense PLGA-microparticles 
To prepare hollow PLGA-microparticles of around 50 μm in diameter, a double-
emulsion-solvent-extraction technique (water-in-oil-in-water) was used, as 
described previously [10]. Microparticles were produced by adding 500 μl of 
distilled water to 1400 mg PLGA in 2 ml dichloromethane (DCM). The mixture was 
emulsified using a Turrax® emulsifier for 60 seconds at 6000 rpm. Then, 6 mL 0.3% 
aqueous poly(vinyl alcohol) (PVA, Acros Organics, Geel, Belgium) solution was 
added and emulsified for another 60 sec at 6000 rpm to produce the second 
emulsion. The emulsion was transferred to a stirred beaker, after which 394 mL 
0.3% PVA solution and 400 mL of 2% isopropylic alcohol solution was added slowly. 
After 1 hour of stirring, the microparticles were allowed to settle for 15 min and 
the solution was decanted. Then, the microparticles were washed and collected 
through centrifugation at 1500 rpm for 5 min, lyophilized and stored at -20 °C until 
use. The size distribution of the microparticles was determined by image analysis 
(Leica Qwin®, Leica Microsystems). The microparticles were imaged by scanning 
electron microscopy (SEM; JEOL6310 at 15kV). 
To prepare dense PLGA-microparticles of around 50 μm in diameter, a single-
emulsion technique was used, as described before [12]. Microparticles were 
produced by dissolving 0.4 g of PLGA in 4 mL DCM. The solution was transferred 
into a stirred beaker containing 150 mL of 0.3% PVA solution and 50 mL of 2% IPN 
solution. After 1 hour of stirring, the microparticles were allowed to settle for 1 
hour min and the solution was decanted. Then, the microparticles were washed 
and collected through centrifugation at 1500 rpm for 1 min and lyophilized. 
Subsequently, the microparticles were sterilized by gamma irradiation (>25 kGy; 
Isotron BV, Ede, the Netherlands) and stored at -20 °C until use. The size 
distribution of the microparticles was determined by image analysis (Leica Qwin®, 
Leica Microsystems). The microparticles were imaged by scanning electron 
microscopy (SEM; JEOL6310 at 15kV). 
 
125I-labeling of BMP-2 
BMP-2 was labeled with 125I, as described previously [20]. Briefly, in a 500 μl 
eppendorf tube coated with 100 μg iodogen, 10 μl of 0.5 M phosphate buffer saline 
(PBS) was added. Growth factor (75 μg) and 3 mCi 125I (Perkin-Elmer, Boston, MA) 
was added and incubated at room temperature for 10 min. To remove the non-
incorporated 125I, the reaction mixture was loaded onto a pre-rinsed disposable 
Sephadex G-25 column (NAP5; GE healthcare Bio-Sciences AB, Uppsala, Sweden) 
that was eluted with PBS, 0.1% BSA. The labeling efficiency of the procedure was 
55% and the specific activity of the labeled protein was 22.0 μCi/μg. 
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Experimental groups 
The following experimental groups were generated (for composition see Table 1): 
1. CPC/control (pre-set dense CPC scaffold containing dense PLGA-
microparticles)  
2. CPC/porous  (pre-set instant porous CPC scaffold; PLGA-
microparticles burnt out) 
3. CPC/PLGA (CPC/control scaffold with BMP-2 adsorbed onto 
dense PLGA-microparticles) 
4. CPC/liquid (CPC/control scaffold with BMP-2 added to the 
liquid phase) 
5. CPC/surface (CPC/porous scaffold with BMP-2 loaded on the 
surface) 
 
Table 1 Overview of the different compositions 
Group  CPC 
(wt.%) 
 PLGA (wt.%) 
Hollow or 
Dense 
 PLGA burnt 
out 
 BMP-2 
added to 
CPC/porous  70  30 (H)  yes  --- 
CPC/control  70  30 (D)  no  --- 
CPC/PLGA  70  30 (D)  no  PLGA-
porogens 
CPC/liquid  70  30 (D)  no  Liquid 
phase 
CPC/surface  70  30 (H)  yes  Surface 
 
Preparation of CPC/PLGA scaffolds 
For the in vitro release experiment, the scaffolds were loaded with 125I-BMP-2 
solutions using a hot/cold mixture of BMP-2, containing 0.5 μCi per scaffold. For 
the in vivo release experiment, the scaffolds were loaded with 125I-BMP-2 solutions 
using a hot/cold mixture of BMP-2, containing 15 μCi per scaffold. For the 
evaluation of the osteoinductive capacity of the different loading methods, BMP-2 
without radiolabel was used.  
The different experimental groups were generated as previously reported (for 
CPC/porous and CPC/surface see [14]; for CPC/control, CPC/PLGA and CPC/liquid 
see [12]; for composition see Table 1). In short, 0.69 g dense or 0.3 g hollow PLGA-
microparticles was added to 0.7 g sterile CPC, after which sterile Na2HPO4 solution 
was added to the CPC/PLGA in a liquid/powder ratio of 0.40 and mixed for 20 
seconds. After mixing, the cement was immediately injected into a Teflon mould to 
ensure a standardized shape of the scaffolds (Ø 7.8 mm, height 2.8 mm).  For 
CPC/porous and CPC/surface, an instantaneous open porous structure was created 
by placing the pre-set scaffolds in a furnace at 650°C for 2 h to burn out the 
polymer. 
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For the adsorption of BMP-2 to the PLGA-particles, a volume of 240 μl 0.1% 
BSA/PBS solution containing 10 μg BMP-2 was added to the sterile dense PLGA-
microparticles, after which the microparticles were frozen, lyophilized and used. To 
include BMP-2 in the liquid phase of CPC, a Na2HPO4 solution containing 10 μg 
BMP-2 was used. For surface-loaded BMP-2, a volume of 30 μl growth factor 
solution containing 5 μg BMP-2 was applied to the surface of each side of the 
instantaneous open porous scaffold to obtain 10 μg BMP-2/scaffold. Thereafter, 
the scaffolds were frozen and lyophilized. 
 
Characterization of scaffold material 
Porosity measurements 
To determine total porosity of the scaffolds,  CPC/control and CPC/porous (n=6) 
were placed in a furnace at 650°C for 2 h to burn out the polymer. Subsequently, 
the microporosity and total porosity were calculated using the following equations 
[10]: 
 
Scanning Electron Microscopy (SEM) 
CPC/control and CPC/porous scaffolds were sputter-coated with gold and examined 
and photographed using SEM (Jeol 6310, Nieuw-Vennep, The Netherlands) at an 
acceleration voltage of 10 kV. 
 
Distribution of protein in the different formulations 
To visualize the distribution of added protein when adsorbed or included in the 
different scaffolds, albumin from bovine serum (BSA) labeled with Alexa Fluor 488 
(Invitrogen, Life Technologies Europe BV, Bleiswijk, The Netherlands) was used as a 
model protein. The loading of labeled BSA (10 μg BSA/scaffold) to the different 
CPCs was similar as described previously, resulting in group 3, 4 and 5. The 
scaffolds were frozen, lyophilized and fixed in 4% formalin overnight. Subsequently, 
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the tissue blocks were embedded in methylmethacrylate (MMA). Perpendicular to 
the scaffold diameter, thin sections (~10 μm) were prepared using a microtome 
with diamond blade (Leica Microsystems SP 1600, Nussloch, Germany) [21]. The 
MMA sections were visualized using a fluorescence microscope with a Zeiss filter 
set 00, consisting of a 530–585 nm band-pass excitation filter (Carl Zeiss B.V., 
Sliedrecht, The Netherlands). 
 
In vitro release experiment 
The different CPC scaffolds loaded with 125I-BMP-2 (n=6; 0.5 μCi/scaffold ) were 
placed in 10 ml glass vials for evaluation of the in vitro BMP-2 release kinetics and 
incubated in 3 ml PBS at 37 °C for 28 days. At days 1, 3, 7, 14, 21 and 28, the 
samples were carefully transferred to new vials containing fresh PBS, after which 
gamma emission of the scaffolds was measured in a shielded well-type gamma 
counter (Wizard, Pharmacia-LKB, Uppsala, Sweden). Standards were measured 
simultaneously to correct for radioactive decay. The remaining activity in the 
scaffolds was expressed as percentage of the initial dose. 
 
In vivo experiment 
Animals 
Fifteen healthy young adult (8 weeks old) male Wistar rats were used as 
experimental animals, of which 9 animals were used for the in vivo release 
experiment (two implants per animal) and 6 animals were used to evaluate the 
osteoinductive capacity of the different CPC formulations (4 implants per animal). 
The research was reviewed and approved by the Experimental Animal Committee 
of the Radboud University (RUDEC 2011-186) and national guidelines for the care 
and use of laboratory animals were observed. 
 
Surgical procedure 
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique 
Fine Limited, Avonmouth, Bristol, UK). To minimize post-operative discomfort, 
Rimadyl (Carprofen, Pfizer Animal Health, New York, USA) was administered 
subcutaneously (5 mg/kg) before the surgery. CPC scaffolds were subcutaneously 
implanted into the back of each rat. To insert the scaffolds, rats were immobilized 
on their abdomen and the skin was shaved and disinfected with chlorhexidine. On 
both sides of the vertebral column, two small paravertebral incisions were made 
through the full thickness of the skin. Lateral to the incisions, a subcutaneous 
pocket was created using blunt dissection. Subsequently, one implant was inserted 
into each pocket. Finally, the skin was closed using staples (Agraven, Instruvet, 
Boxmeer, the Netherlands). In total, for the in vivo release experiment eighteen 
implants (two implants per animal; n=6 for each experimental group) and for the 
osteoinductive capacity evaluation twenty-four implants (4 implants per animal; 
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n=3 for groups 1-2 and n=6 for groups 3-5) were placed according to a 
randomization scheme. 
The animals were housed in pairs. In the initial postoperative period, the intake of 
water and food was monitored. Further, the animals were observed for signs of 
pain, infection and proper activity. At the end of the implantation time, the rats 
were sacrificed by CO2-suffocation. 
 
In vivo release experiment 
At days 0, 1, 3, 7, 14 and 21 after implantation of the CPC scaffolds, rats were 
scanned using a small-animal SPECT scanner (U-SPECT II, MILabs, The Netherlands). 
Anesthesia was induced and maintained by Isoflurane inhalation (Rhodia Organique 
Fine Limited, Avonmouth, Bristol, UK). On day 28, rats were sacrificed and scanned 
post mortem followed by a CT scan for anatomic reference. The animals were 
placed prone in the SPECT scanner and scanned for 40 min using a rat 1.0-mm-
diameter-pinhole collimator tube. Scans were reconstructed with MILabs 
reconstruction software, which uses an ordered-subset expectation maximization 
algorithm, with a voxel size of 0.375 mm. The amount of radioactivity in a specified 
volume of interest around the implants was quantified and expressed as 
percentage of original dose per scaffold (PMOD software, version 3.15, PMOD 
Technologies Ltd.). To achieve accurate quantification, standards containing 0, 1, 3, 
10 or 30 μCi 125I were scanned at the same days. 
Implant retrieval and histological preparations 
The specimens without radiolabeled BMP-2 (n=6) were retrieved after a 4-week 
implantation period. After sacrifice, scaffolds with surrounding tissues were excised 
and fixed in 10% phosphate-buffered formaldehyde solution (pH 7.4). 
Subsequently, the tissue blocks were dehydrated in increasing ethanol 
concentrations (70 – 100%) and embedded in methylmethacrylate (MMA). 
Perpendicular to the diameter of the scaffolds, thin sections (10 μm) were 
prepared using a microtome with diamond blade (Leica Microsystems SP 1600, 
Nussloch, Germany) [21]. Three sections of each scaffold were stained with 
methylene blue and basic fuchsin and examined using light microscopy (Leica 
Microsystems AG, Wetzlar, Germany). 
For CPC/PLGA, CPC/liquid and CPC/surface, two MMA samples were polished and 
gold sputter-coated prior to analysis with scanning electron microscopy (JEOL 6330) 
using Back-Scattered Electron (BSE) mode for histomorphometrical analysis. 
 
Histological and histomorphometrical evaluation 
Sections of MMA-embedded specimens (at least 3 sections per specimen) were 
quantitatively assessed using computer-based image analysis techniques (Leica® 
Qwin Pro-image analysis system, Wetzlar, Germany). The analysis technique is 
based on color recognition depending on staining intensity. From digital images 
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(magnification: 5x), the total amount of newly-formed bone surrounding the CPC 
scaffold was determined and expressed in area measures (mm2). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Instat 3.05 software (GraphPad 
Software Inc., San Diego, CA) using one-way analysis of variance with a Tukey 
multiple comparison post test. Differences were considered significant at p-values 
less than 0.05. 
 
Results 
Analysis of the BMP-2 secondary structure 
CD spectra of BMP-2 dissolved in PBS or 2% Na2HPO4 were comparatively analyzed, 
showing only limited differences in molar CD values at 200–235nm. Additionally, 
secondary structure analysis based on the obtained CD spectra revealed no 
significant differences in α-helix, β-sheet or random coil structure of BMP-2 
dissolved in 2% Na2HPO4 compared to BMP-2 dissolved in PBS (Table 2). 
 
Table 2 Secondary structure analysis of BMP-2 dissolved in 2% Na2HPO4 or PBS 
 α-Helix β-Sheet Random coil (%) 
BMP-2 dissolved in PBS 14 40 40 
BMP-2 dissolved in 2% Na2HPO4 14 40 40 
The analysis was conducted based on the CD spectrum using the Gauss–Newton algorithm 
method. 
 
Characterization of scaffold material 
The preparation of hollow PLGA-microparticles with a double-emulsion-solvent-
extraction technique and dense PLGA-microparticles with a single-emulsion 
technique resulted in microparticles with a similar average size of 58.4 ± 35.0 μm 
and 62.4 ± 28.9 μm (p>0.05), respectively. 
Since the principle of CPC preparation was based on either combination of CPC 
with hollow PLGA-microparticles (CPC/porous and CPC/surface) or CPC with dense 
PLGA-microparticles (CPC/control, CPC/PLGA and CPC/liquid), surface examination 
of the scaffolds was carried out for only CPC/porous and CPC/control. Surface 
examination showed that for CPC/control, a homogenous distribution of PLGA-
microparticles within the implant material was observed (Figure 1A). For 
CPC/porous, PLGA-microparticles were completely burnt out and an instant porous 
scaffold material was observed (Figure 1B). Porosity measurements of CPC/porous 
and CPC/control scaffolds demonstrated a microporosity of 42.5 ± 3.0 % and 59.9 ± 
2.9% and a total porosity of 72.3 ± 1.4 % and 80.7 ± 1.4% for CPC/porous and 
CPC/control, respectively. 
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Protein distribution was visualized using Alexa Fluor 488-labeled BSA as a model 
protein (Figure 1C). The protein in CPC/surface was only observed peripherally and 
not in the center of the implants. In contrast, the protein in CPC/PLGA and 
CPC/liquid was distributed throughout the entire scaffold, showing localization of 
protein on the PLGA-microparticles for CPC/PLGA and a more dispersed pattern for 
CPC/liquid. 
 
 
Figure 1 Characterization of scaffold material. Microscopic SEM images of scaffold material 
(A) CPC/control and (B) CPC/porous. Original magnification 75x, bar represents 25 μm. PLGA-
microparticles (arrows) and created pores after burning out PLGA-microparticles 
(arrowheads) are indicated. (C) Protein distribution using alexa fluor 488 labeled BSA as a 
model protein. BSA was loaded on PLGA-microparticles and incorporated in CPC (CPC/PLGA), 
included in liquid phase of CPC (CPC/liquid) or absorbed onto the surface of instant porous 
preset CPC (CPC/surface), Bar represents 500 μm. 
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In vitro release 
The in vitro release for CPC/PLGA, CPC/liquid and CPC/surface, during 28 days is 
depicted in Figure 2. All scaffolds retained their integrity during the entire 
experiment. CPC/surface showed an initial burst release within 1 day (~40%), 
followed by a sustained release till day 28 (Figure 2A). Both CPC/PLGA and 
CPC/liquid showed a limited burst release within 1 day (~10%), followed by a 
sustained release from day 1 till day 28 with a similar pattern compared to 
CPC/surface  (Figure 2A). 
The cumulative BMP-2 release was significantly higher for CPC/surface compared 
to CPC/PLGA and CPC/liquid, reaching after 28 days a release of 70.0 ± 2.2%, 45.7 ± 
1.7% and 48.4 ± 1.5%, respectively (p<0.0001; Figure 2A). From day 3 onward, the 
cumulative BMP-2 release from CPC/liquid was significantly higher compared to 
CPC/PLGA (p<0.01; Figure 2A). 
The relative amounts of BMP-2 released during the different phases (i.e. burst 
release, sustained release, and retained BMP-2 after 28 days) are depicted in Figure 
2B. For CPC/surface, the burst release was significantly higher compared to 
CPC/PLGA and CPC/liquid (Figure 2B; p<0.001; for CPC/PLGA 10.5 ± 2.3% and for 
CPC/liquid 13.1 ± 2.7%; for CPC/surface 40.4 ± 4.6 %). The release rate per day from 
day 1-28 (Figure 2B) of CPC/surface compared to CPC/PLGA and CPC/liquid was 
significantly lower (p<0.0001, release rate of 0.53 ± 0.02%, 0.52 ± 0.02% and 0.40 ± 
0.03% per day for CPC/PLGA and CPC/liquid, CPC/surface, respectively). After 28 
days, the retention for CPC/surface was significantly lower compared to CPC/PLGA 
and CPC/liquid (p<0.0001, retention of 54.3 ± 1.7%, 51.6 ± 1.5% and 30.0 ± 2.2% for 
CPC/PLGA, CPC/liquid and CPC/surface, respectively). 
 
In vivo experiment 
General observation of the experimental animals 
All 6 animals used for the evaluation of the osteoinductive capacity of the different 
formulations, recovered uneventfully from the surgical procedure and remained in 
good health. From the 9 animals used for the in vivo release experiment, one 
animal died after 21 days. Clinical examination indicated that the cause of death 
was an anaesthetic-induced respiratory depression during in vivo scanning. All 
remaining 8 animals recovered uneventfully from the surgical procedure and 
remained in good health. The total number of implants placed, retrieved and used 
for histomorphometrical evaluation is depicted in Table 3.  
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Figure 2 Longitudinal in vitro scintigraphic assement (A) CPC/PLGA, CPC/liquid and 
CPC/surface during 28 days and (B) the in vitro burst release (after 1 day), sustained release 
(the release per day from day 1-28) and the retention after 28 days. The release and 
retention is expressed as percentage of the ratio of initial loading amount. Error bars 
represents the mean ± SD (n=6). (a) p<0.001 compared to CPC/PLGA and CPC/liquid, (b) 
p<0.01 compared to CPC/PLGA.  
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Table 3 Overview of implants placed, retrieved and used for histomorphometrical evaluation 
  Implants  
placed 
 Implants  
retrieved 
 Implants used for analysis 
CPC/porous  3  3  3 
CPC/control  3  3  3 
CPC/PLGA  6  6  5* 
CPC/liquid  6  6  5* 
CPC/surface  6  6  5* 
*deviations from the number of implants retrieved due to fracturing of implants during 
histological processing. 
 
In vivo release 
The in vivo release during 28 days from CPC/PLGA, CPC/liquid and CPC/surface, is 
depicted in Figure 3. CPC/surface showed an initial burst release within 1 day 
followed by a sustained release from day 1 till day 28 (Figure 4A). Both CPC/PLGA 
and CPC/liquid showed a limited burst release within 1 day (~10%), followed by a 
sustained release from day 1 till day 28 with a similar pattern compared to 
CPC/surface (Figure 4A). The cumulative BMP-2 release was significantly higher for 
CPC/surface compared to CPC/PLGA and CPC/liquid reaching up to 90.1 ± 1.3%, 
61.3 ± 4.7 and 65.2 ± 1.9% after 28 days, respectively (p<0.0001; Figure 4A). 
The relative amounts of BMP-2 released during the different phases (i.e. burst 
release, sustained release, and retained BMP-2 after 28 days) are depicted in Figure 
4B. For CPC/surface, the burst release was significantly higher compared to 
CPC/PLGA and CPC/liquid (Figure 4B; p<0.001; for CPC/PLGA 10.3 ± 8.5%, for 
CPC/liquid 8.5 ± 3.0 and for CPC/surface 51.8 ± 7.1%). The release rate per day 
from day 1-28 (Figure 4B; % per day) of CPC/surface compared to CPC/liquid was 
significantly lower (p<0.01, release rate of 1.4 ± 0.3% and 2.1 ± 0.1% per day for 
CPC/surface and CPC/liquid, respectively). Between CPC/surface and CPC/PLGA 
(p=0.47; for CPC/PLGA 1.8 ± 0.4%) and between CPC/PLGA and CPC/liquid (p=0.14) 
no differences were observed. 
After 28 days, a significant lower protein retention for CPC/surface was observed 
compared to CPC/PLGA and CPC/liquid (Figure 4B; p<0.0001; for CPC/PLGA 39.2 ± 
4.2%, for CPC/liquid 36.0 ± 3.2% and for CPC/surface 9.9 ± 1.3%). 
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Figure 3 (A) Representative U-SPECT/CT-scan of rat implanted with CPC scaffolds. (B) 
Representative U-SPECT scans of CPC/PLGA, CPC/liquid or CPC/surface during 28 days.  
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Figure 4 Longitudinal in vivo (A) release assessment analyzed via a small animal U-SPECT II 
scanner of CPC/PLGA, CPC/liquid and CPC/surface during 28 days and (B) the in vitro burst 
release (after 1 day), sustained release (the release per day from day 1-28) and the retention 
after 28 days. The release and retention is expressed as percentage of the ratio of initial 
loading amount. Error bars represents the mean ± SD (n=4). (a) p<0.01 compared to 
CPC/PLGA and CPC/liquid; (b) p<0.05 compared to CPC/liquid. 
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 Osteoinductive capacity of the different formulations 
The structural integrity of the scaffolds was maintained in all experimental groups. 
A fibrous capsule surrounding CPC/control and CPC/porous, without the presence 
of inflammatory cells at the interface was observed (data not shown). Ingrowth of 
soft tissue was observed peripherally in CPC/control and throughout the implants 
in CPC/porous and no bone formation was observed in the vicinity of these 
scaffolds. A fibrous capsule surrounding CPC/PLGA, CPC/liquid and CPC/surface, 
without the presence of inflammatory cells at the interface was observed (data not 
shown). In 4 out of 5 CPC/surface, a limited amount of bone was formed at the 
periphery of the scaffold, while no bone formation was observed in the vicinity of 
CPC/PLGA and CPC/liquid scaffolds (Figure 5B). Back-scatter SEM micrographs 
confirmed the observed peripheral bone formation in CPC/surface (Figure 5C). 
Quantitative results of ectopic bone formation revealed a total amount of bone in 
the periphery of CPC/surface of 3.6 ± 3.0 mm2. 
 
Discussion 
To enhance the biological performance of CPC biologically active compounds, such 
as BMP-2, can be introduced. The clinical application of CPC in an injectable form 
requires an integrated loading of BMP-2 via either PLGA-microparticles or the liquid 
phase of the cement. In view of this, the current study comparatively evaluated the 
in vitro and in vivo release profiles as well as the osteoinductive potential of CPC 
scaffolds in a rat subcutaneous implantation model, in which BMP-2 was (i) loaded 
onto dense PLGA-microparticles (CPC/PLGA), (ii) added to the liquid phase of the 
cement (CPC/liquid), or (as a control) (iii) adsorbed onto the surface of preset 
scaffolds (CPC/surface). It was hypothesized that in view of an injectable CPC, the 
addition of BMP-2 via incorporated PLGA-microparticles would result in an 
accelerated BMP-2 release leading to improved osteoinductive properties for 
CPC/PLGA compared to CPC/liquid. The in vitro and in vivo release assays revealed 
that the BMP-2 burst release from CPC/surface was significantly increased 
compared to CPC/PLGA and CPC/liquid. The BMP-2 retention for CPC/surface was 
significantly lower after 28 days compared to CPC/PLGA and CPC/liquid, despite a 
significantly increased sustained release rate for CPC/PLGA and CPC/liquid. The 
ectopic rat model demonstrated that only CPC/surface is capable of inducing 
ectopic bone formation. 
The release profiles of the different scaffold formulations revealed similar patterns 
consisting of a burst release followed by a sustained release. However, the 
cumulative release was significantly increased at all time points for surface-loaded 
BMP-2 compared to that for incorporated BMP-2 (via either PLGA-microparticles or 
the liquid phase of the CPC). This difference in cumulative release is mainly 
dependent on the large difference (~30% in vitro, ~40% in vivo) in burst release 
observed for surface-loaded BMP-2 compared to that for incorporated BMP-2. 
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Figure 5 (A) Histological overview sections of CPC/control and CPC/porous. Bar represents 
1000 μm. Histological sections are stained with methylene blue and basic fuchsin. (B) 
Magnification of histological sections of CPC/PLGA, CPC/liquid and CPC/surface. Bone (b) is 
indicated in the sections. Original magnification is 20x. Bar represents 100 μm. Histological 
sections are stained with methylene blue and basic fuchsin. (C) Cross-sections observed with 
back scattering SEM of CPC/PLGA, CPC/liquid and CPC/surface. For back scattering SEM 
micrographs bone appears dark gray (+) while the CPC scaffold is lighter (-). 
 
The difference in burst release is likely to be related to the manufacturing process 
of the different scaffolds, which results in an evidently distinct protein distribution. 
Surface loaded BMP-2, was located peripherally and hence in direct contact with 
the surrounding environment in which BMP-2 could be released fast and freely. In 
contrast, incorporated BMP-2 was located throughout the CPC and hence any 
released BMP-2 had to diffuse out of the scaffold. In addition, the protein diffusion 
within CPC is dependent on the scaffold porosity, for which differences existed 
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regarding the temporal presence of porosity (i.e. directly for CPC/surface and after 
degradation of PLGA-microparticles for CPC/PLGA and CPC/liquid). Previous studies 
have demonstrated that the dense acid terminated PLGA-microparticles degrade in 
vitro between 2-6 weeks [12] and are completely degraded in vivo after 4 weeks 
(current manuscript) at ectopic locations. In vitro degradation of  plain CPC 
(without PLGA microparticles)  starts from week 1 [12, 22] and is limited, but can be 
substantially increased via the effect of acidic degradation products of PLGA. The 
fact that all 3 experimental groups still show a linear sustained release indicates 
that degradation (of the CPC) is governing release. However, a relationship 
between release and porosity is not univocally established. Remarkably, similar 
release kinetics were observed for CPC/PLGA and CPC/liquid, where it was 
expected that the rapid degradation of PLGA-microparticles would evoke a faster 
release of adsorbed BMP-2. In view of this, it appears that liberated BMP-2 
molecules from the degraded PLGA-microparticles readily adsorbs to the ceramic 
matrix of CPC, after which overall release kinetics show large similarity to scaffolds 
with BMP-2 loaded via the liquid phase of the cement [23, 24]. 
The in vivo release of BMP-2 in the current study was ~10-20% higher compared to 
the in vitro release of the different formulations. However, the observed in vitro 
and in vivo release kinetics of the different scaffolds followed a similar pattern. 
These findings corroborate earlier observations, in which despite similar release 
patterns (i.e. a burst release followed by a sustained release) differences regarding 
the amounts between the in vitro and in vivo release kinetics of BMP-2 from CPC 
were observed ranging from 50% [24] to 80% [25]. This difference is likely 
dependent on the availability of proteins within body fluid and the large buffering 
capacity of the body, which can be responsible for the difference in release 
amounts, re-adsorption of the protein and BMP-2 clearance from the vicinity of the 
scaffold [26]. Therefore, Ruhé et al. (2005) and Li et al. (2003) suggested to perform 
the in vitro release experiment in protein-rich buffer solution to simulate more the 
body fluid and therefore simulating more the in vivo release of the growth factor 
[24, 25]. However, for the extrapolation of in vitro data to the in vivo situation 
protein-rich buffer solution alone was not sufficient because the in vitro release 
profile of BMP-2 loaded CPC performed in a protein-rich-buffer still underestimated 
the in vivo release profile with ~20% [24]. Therefore, the predictive value of in vitro 
release patterns implicates an underestimation of the in vivo situation. 
In the current study, the in vivo release of BMP-2 from the different CPC scaffolds 
was analyzed noninvasively with SPECT imaging. With SPECT the pharmacokinetic 
profile of 125I-labelled proteins could be monitored quantitatively and the 
(localization of the) 125I-labelled proteins could be visualized in the rats [27, 28]. 
However, tracking the released 125I-BMP-2 molecules could not be visualized due to 
limitations in the sensitivity. Nevertheless, due to a fixed implant position, 
concentrated 125I-BMP-2 molecules in the different scaffolds could be visualized 
and analyzed accurately and reliably. 
Although it seems straightforward to assume that the biological activity of BMP-2 
upon loading onto the surface of or into the scaffolds might be compromised, 
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earlier reports and side-experiments in the current study provide evidence to proof 
this assumption wrong. For example, in the current study as well as previously 
reported [14], the addition of surface-loaded BMP-2 increased the osteoinductive 
properties of CPC, indicating no effect on the bioactivity of BMP-2 upon surface 
loading. In addition, several reports showed that the different loading methods to 
incorporate BMP-2 into CPC used in the current study (i.e. adsorption of BMP-2 to 
PLGA-microparticles or addition of BMP-2 to the liquid phase of CPC) are capable to 
evoke either osteoinductive responses [17, 18] or enhance osteogenic responses 
[19]. Further indirect proof for retained biological activity of BMP-2 was obtained 
via secondary structure analysis of dissolved BMP-2, which revealed no 
conformational changes of the protein upon dissolution in the liquid phase of 
cement. Unfortunately, direct evidence for retained biological activity of BMP-2 
upon loading into CPC via adsorption to PLGA-microparticles or addition to the 
liquid phase remains unavailable, since cell culture experiments with CPC scaffolds 
or releasate are impossible in view of the effects of calcium release from CPC [29, 
30]. Taken together, the indirect evidence indicates that the lack of an 
osteoinductive effect of BMP-2 incorporated within CPC is mainly dependent on an 
insufficient amount of (burst) released BMP-2 rather than to an altered BMP-2 
bioactivity. 
Previous reports assumed that for clinical applications in a bone environment, a 
burst release is needed to result in an “above threshold” amount of exogenous 
BMP-2 to trigger bone regenerative cells to stimulate bone formation [31-33]. 
However, lack of consensus exists regarding appropriate amounts of BMP-2 [18, 
34]. In view of that, the BMP-2 loading methods for injectable CPC used in this 
study appeared unable to induce bone formation ectopically. This observation is 
likely to be related to the release profile as mentioned earlier, but also to the 
spatial distribution of BMP-2 throughout the entire scaffold (in contrast to 
condensed availability at the periphery of the scaffold following surface-loading, 
which showed osteoinductive capacity). Still, BMP-2 loading for CPC via adsorption 
to PLGA-microparticles or addition to the liquid phase might be a feasible means to 
accomplish the stimulation of bone regeneration at orthotopic locations. Further, it 
has to be emphasized that addition of BMP-2 to the liquid phase of CPC is preferred 
above adsorption to PLGA-microparticles, since the manufacturing process is more 
straightforward and less labor-intensive. 
In conclusion, the present study demonstrated that BMP-2 loading is feasible for 
injectable CPC via adsorption to PLGA-microparticles or addition to the liquid phase 
of CPC. These loading methods resulted in a similar release profile over the course 
of 28 days, despite distinct protein distribution patterns. Compared to CPC-
scaffolds with surface-loaded BMP-2, these loading methods showed a similar 
release profile, except for a significantly decreased burst release. As such, the 
observed osteoinductive capacity for only CPC-scaffolds with surface-loaded BMP-2 
is likely to be related to this difference in burst release. It remains unclear to what 
extent the differential BMP-2 loading methods for injectable CPC can affect the 
biological response in a bone environment. 
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Introduction 
Currently, over 75 million people in Europe, USA and Japan are affected with 
osteoporosis according the International Osteoporosis Foundation (IOF) [1]. 
Osteoporosis is characterized by a decrease in bone mass (i.e. osteopenia) and a 
decline in bone micro-architecture, which leads to an enhanced fragility of the 
skeleton and hence an increased risk of fractures [2]. The decreased amount of 
bone mass and the loss of bone architecture is due to an excessive osteoclastic 
bone resorption and a reduced capacity of osteoblasts to replace the resorbed 
bone [3]. Together, the prevalence and increased risk of fractures make that in the 
world population over 50 years of age, 1 in 3 women and 1 in 5 men will experience 
an osteoporotic fracture [1]. 
In view of the differences in bone morphology and metabolism between 
osteoporotic patients and healthy humans, presumably the biological performance 
of bone implants in osteoporotic patients is different. For the evaluation of bone 
implant performance under such compromised conditions, several pre-clinical 
animal models are available [2, 4]. Osteoporosis can be introduced either via 
chemical stimulation, for example by the administration of prednisolone to rabbits 
[5] or via an ovariectomy in female animals or an orchidectomy in male animals [2, 
4]. The removal of the ovaries or testis induces a decline in estrogen and androgen 
levels, respectively, which leads to a reduced bone mineral density and bone 
mineral content. The most well-established osteoporosis animal model is the 
ovariectomized (OVX) rat. Following ovariectomy, a rapid decrease in bone mass 
and strength occurs that mimics the bone changes following oophorectomy or 
menopause in humans [2]. In general, bone loss occurs first in trabecular bone, 
after which cortical bone is affected [2]. Furthermore, the degree of bone loss for 
the various trabecular bone sites occurs in different time lapses after OVX surgery. 
For example, bone loss becomes obvious already after 14 days in the proximal tibial 
metaphysis, whereas the femoral neck starts to show bone loss after approximately 
30 days [2]. Consequently, studying bone implant performance in OVX rats requires 
proper selection of an adequate implant location, as in this animal model not all 
trabecular and cortical bone sites are affected to a similar extent. 
Calcium phosphate cements (CPCs) represent reliable candidates for the 
substitution of bone due to their similar chemical composition compared to the 
mineral phase of bone and their biocompatibility and osteoconductive properties. 
From an application point of view, CPCs offer the advantage of using minimally 
invasive surgical techniques due to their injectability [6, 7]. The main disadvantage 
of CPC is its low degradation rate mainly due to the inadequate intrinsic porosity of 
the material (i.e ~50% with pore sizes ~10 nm - 100 nm) [8, 9]. This porosity is 
insufficient for substantial material degradation and tissue ingrowth [7-11]. The 
degradation rate of CPC can be enhanced in a controllable manner by the 
homogeneous inclusion of biodegradable polymeric microparticles, such as gelatin 
[12] or poly(D,L-lactic-co-glycolic) acid (PLGA) [13-16], in the cement powder. After 
microparticle degradation, the ceramic matrix of CPC contains a homogeneously 
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dispersed porosity that accelerates the ingrowth of bone as observed in different 
animal models [8, 9, 17-19]. However, the outcome of these studies is only based 
on healthy subjects and consequently does not provide information on bone 
substitute material performance in a compromised situation, such as in 
osteoporotic patients. 
In the present study, the performance of CPC containing PLGA microparticles 
(CPC/PLGA) was comparatively evaluated in healthy and osteoporotic rats (OVX). 
The biological performance of CPC/PLGA was studied in a rat femoral condyle 
defect over a time period of 4 and 12 weeks. It was hypothesized that the 
degradation of CPC would be increased due to a higher osteoclastic activity in 
osteoporotic animals and that the obtained space would be filled with newly 
formed bone at an earlier time point. 
 
Materials and Methods 
Materials 
Calcium phosphate cement (CPC) consisted of 85% alpha tri-calcium phosphate (α-
TCP; CAM Bioceramics BV, Leiden, The Netherlands), 10% dicalcium phosphate 
anhydrous (DCPA; J.T. Baker Chemical Co., USA) and 5% precipitated 
hydroxyapatite (pHA; Merck, Darmstadt, Germany). The cement liquid applied was 
a sterilized 2 wt.% aqueous solution of Na2HPO4. Acid-terminated poly(DL-lactic-co-
glycolic acid) (PLGA; Purasorb®, Purac, Gorinchem, the Netherlands) with a lactic to 
glycolic acid ratio of 50:50 and a molecular weight (Mw) of 17 ± 0.02 kg/mol was 
used for microparticle preparation. 
 
Preparation of PLGA-microparticles 
To prepare hollow PLGA-microparticles, a double-emulsion-solvent-extraction 
technique (water-in-oil-in-water) was used, as described previously [16]. 
Microparticles were produced by adding 500 μl of distilled water to 1400 mg PLGA 
in 2 ml dichloromethane. The mixture was emulsified using a Turrax® emulsifier for 
60 seconds at 6,000 rpm. Then, 6 ml 0.3% aqueous poly(vinyl alcohol) (PVA, Acros 
Organics, Geel, Belgium) solution was added and emulsified for another 60 sec at 
6,000 rpm to produce the second emulsion. The emulsion was transferred to a 
stirred beaker, after which 394 ml 0.3% PVA solution and 400 ml of 2% isopropylic 
alcohol solution was added slowly. After 1 hour of stirring, the microparticles were 
allowed to settle for 15 min and the solution was decanted. Then, the 
microparticles were washed and collected through centrifugation at 1500 rpm for 5 
min, lyophilized and stored at -20 °C until use. The size distribution of the 
microparticles was determined by image analysis (Leica Qwin®, Leica Microsystems, 
Wetzlar, Germany). 
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Preparation of CPC/PLGA 
CPC/PLGA was prepared by weighing 0.7 g of cement powder and 0.3 g of PLGA-
microparticles in a 2 ml injection syringe (BS Plastipak, Becton Dickinson S.A., 
Madrid, Spain). This powder component was sterilized by gamma radiation with a 
minimum dose of 25 kGy (Isotron B.V., Ede, The Netherlands). A sterile aqueous 
solution of 2% Na2HPO4 was used as the liquid phase, with a liquid-to-powder ratio 
of 0.35 mL/g. 
From preset CPC/PLGA disks, the microporosity and the total porosity was analyzed 
by placing the composite materials in a furnace at 650°C for 2 h to burn out the 
polymer. Subsequently, microporosity and total porosity were calculated using the 
following equations[16]: 
 
Animals 
Thirty-two healthy adult (16 weeks old) female Wistar rats were used as 
experimental animals, which underwent several procedures during the course of 
the experiment (Figure 1). Sixteen rats underwent an ovariectomy (OVX) and the 
other sixteen animals underwent a sham surgery (SHAM). From 4 OVX and 4 SHAM, 
in vivo computed tomography (CT) images were acquired at multiple time points to 
quantify the bone architecture (i.e. bone volume, trabecular thickness and 
trabecular spacing) in the femoral condyle: (i) before OVX or SHAM surgery, (ii) 
before creation of a condyle bone defect, and (iii) before sacrifice (at 4-week or 12 
weeks). The studies were reviewed and approved by the Experimental Animal 
Committee of the Radboud University (RUDEC 2010-242) and carried out in 
accordance with national guidelines for the care and use of laboratory animals. 
 
Surgical procedure to induce osteoporosis 
The rats underwent acclimatization to laboratory conditions for 1 week after which 
a bilateral ovariectomy or sham surgery was performed. In short, anesthesia was 
THE BIOLOGICAL PERFORMANCE OF CPC/PLGA CEMENT IN OSTEOPOROTIC RATS 
 
 129 
induced and maintained by Isoflurane inhalation (Rhodia Organique Fine Limited). 
To minimize post-operative discomfort, Rimadyl (Carprofen, Pfizer Animal Health, 
New York, USA) was administered intraperitoneally (5 mg/kg) before the surgery. In 
addition, immediately and four hours after the surgery buprenorfine 
(Temgesic£;Reckitt Benckiser Health Care Limited, Schering-Plough, UK) was 
administered intraperitoneally (0.02 mg/kg). Sixteen animals underwent an 
ovariectomy (OVX) through two separate incisions in the lateral abdominal wall. 
The remaining 16 animals underwent a sham surgery (SHAM), in which the ovaria 
were exposed but not removed using an identical surgical approach as for the other 
animals. The 16 SHAM rats had free access to normal pellet food containing 1.17% 
calcium (Ca) and 0.91% phosphorus (P) and water, while the 16 OVX rats had free 
access to a low-calcium diet in which pellet food contained 0.01% Ca and 0.77% P. 
The rats were housed in pairs at a constant temperature of 23 °C and 60% 
humidity. 
 
Surgical procedure to create femoral condyle bone defects 
Six weeks after the OVX or SHAM surgery, one femoral condyle defect per animal 
was created (n=8 per experimental group, per time point). Anesthesia was induced 
and maintained by Isoflurane inhalation (Rhodia Organique Fine Limited). To 
minimize post-operative discomfort, Rimadyl (Pfizer Animal Health) was 
administered intraperitoneally (5 mg/kg) before the surgery. In addition, directly 
and 12 hours after the surgery buprenorfine (Reckitt Benckiser Health Care Limited) 
was administered intraperitoneally (0.02 mg/kg). First, the left hind limb of the rats 
were shaved, washed and disinfected with povidone-iodine, after which the rats 
were immobilized on their back. A longitudinal incision was made on the medial 
surface of the left femur. After exposure of the medial side of the distal femoral 
condyle, a bone defect (Ø 2.5 mm, depth 3 mm) was created perpendicular on the 
bone surface, using a dental drill (Elcomed 9927 SPS; W&H Dentalwerk Burmoos 
GmbH, Burmoos, Austria). A series of increasing bur diameters (1.5–2.0–2.3–2.5 
mm) was used under constant saline cooling at a speed of 800 rpm. The drilled 
cavity was then washed with saline and dried using sterile cotton gaze. At the same 
time, 2% Na2HPO4 solution was added to the CPC/PLGA powder component in the 
syringe and mixed for 30 seconds using a dental amalgam mixer (Silamat®; 
Vivadent, Schaan, Liechtenstein). Subsequently, the material was injected into the 
cavity. After initial setting of the cement, the subcutaneous tissue layer was closed 
with resorbable Vicryl® 5-0 (Johnson&Johnson, St.Stevens-Woluwe, Belgium) after 
which the skin was closed by staples (Agraven®; InstruVet BV, Cuijk, The 
Netherlands). 
After surgery, both experimental groups (SHAM and OVX) had free access to 
normal pellet food containing 1.17% calcium (Ca) and 0.91% phosphorus (P) and 
water. The animals were housed in pairs. In the initial postoperative period, the 
intake of water and food was monitored. In addition, the animals were observed 
for signs of pain, infection and proper activity.  
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Implant retrieval and histological processing 
The treated left condyles (i.e. femoral condyles with a filled defect) and the 
untreated femoral condyles from the right leg of both experimental groups were 
retrieved after a 4- or 12-week implantation period. After sacrifice by CO2-
suffocation, the specimens were excised and fixed in phosphate-buffered 
formaldehyde solution (pH 7.4). Subsequently, the tissue blocks were dehydrated 
in increasing ethanol concentrations (70–100%). 
From both OVX and SHAM animals, 7 out of 8 treated condyles and 3 untreated 
condyles of each implantation time were embedded in methylmethacrylate 
(MMA). After polymerization, thin sections (10 μm) were prepared in a cross-
sectional direction perpendicular on the longitudinal direction of the implants using 
a microtome with diamond blade (Leica Microsystems SP 1600, Nussloch, 
Germany) [20]. Three sections of each specimen were stained with methylene blue 
and basic fuchsin and examined using light microscopy (Leica Microsystems AG, 
Wetzlar, Germany). 
The remaining specimens (1 out of each experimental group) were decalcified in 
ethylenedinitrilotetraacetic acid (EDTA, Merck KGaA, Darmstadt, Germany) for 10 
days, dehydrated through a series of graded ethanol and embedded in paraffin. 
Using a microtome (Leica RM 2165, Leica Microsystems, Nussloch, Germany), 6 μm 
thick sections were prepared and stained with hematoxylin-eosin (HE). In addition, 
tartrate-resistant acid phosphatase (TRAP) staining was applied to determine 
osteoclastic activity. To perform a TRAP staining, the sections were deparaffinized 
and preincubated in 0.2 M TRIS-HCl buffer (pH 9.0) for 2 h at 37 °C. After rinsing 
with distilled water, the sections were incubated in a solution consisting of 
hexazotized pararosaniline and MgCl2 (pH 5.0) at 37 °C. Positive staining developed 
within 30 min, after which the sections were counterstained for 1 min with 
hemotoxylin, rinsed in water, dehydrated and mounted with DPX (BDH Laboratory 
supplies, Poole, England). Paraffin sections of rat skulls were included as positive 
controls. 
 
Histological and histomorphometrical evaluation 
The MMA histological sections (n=3) were assessed quantitatively using computer-
based image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, 
Germany). From digitalized images of treated femoral condyles (magnification: 5x), 
a circular region of interest (ROI) was determined with a diameter equal to that of 
the final drill to create the defect (2.5 mm diameter circular area). Within this ROI, 
the amount of remained CPC, newly formed bone and trabecular spacing (i.e. the 
surface area between adjacent trabeculae) was determined.  
In addition, from digitalized images of the untreated right femoral condyles 
(magnification: 5x), a circular region of interest (ROI) with a diameter equal to the 
created defects was positioned. Within this ROI, the percentage of bone formation 
and trabecular spacing was determined and compared to the amount of newly 
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formed bone and trabecular spacing observed within the created defect of the 
corresponding left femoral condyle. 
 
Validation of the OVX rat model 
In vivo computed tomography (CT) scanning 
From 4 OVX and SHAM animals, in vivo CT images of both femoral condyles (i.e. left 
femur with defect 6 weeks and right femur without defect) were acquired with an 
animal CT scanner (Inveon, Siemens Preclinical Solutions, Knoxville, TN) at multiple 
time points (Figure 1) [21]. To acquire CT images, anesthesia was induced and 
maintained by isoflurane inhalation (Rhodia Organique Fine Limited, Avonmouth, 
Bristol, UK). The animals were placed in supine position in the scanner and images 
were acquired (spatial resolution 30 μm, 80 kV, 500 μA, exposure time 1000 ms). 
Projected files were then reconstructed using a cone beam algorithm. The bone 
architecture was analyzed using image analysis software (Inveon Research 
Workplace 3.0, Siemens Medical Solutions USA Inc, Knoxville, USA). From 
reconstructed CT scans, 3D models were built for visualization and morphometric 
analysis. For the morphometric analysis, a subregion of the femoral condyle was 
selected, which included the entire femoral condyle head from the top (without 
cortical bone layer) until 70 micro-tomographic slices down. By auto-interpolation 
of the layers, a volume of interest (VOI) was obtained. Within this VOI, the amount 
of trabecular bone and bone marrow were determined on basis of the density in 
Houndsfield units. Thereafter, bone morphometric parameters (bone volume, 
trabecular spacing and trabecular thickness) were calculated using the Inveon 
Research Workplace Bone Morphometry tool (Siemens Medical Solutions USA Inc). 
 
 
 
Figure 1 Schematic overview of experimental set-up. Six weeks after the ovariectomy (OVX), 
one femoral condyle bone defect per animal was created. Implants and non-treated femoral 
condyles were retrieved after a 4 or 12 week implantation period. To quantify the bone 
mineral density animals were scanned before inducing osteoporosis, before creating the 
bone defect and before each implantation time. 
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Histological and histomorphometrical evaluation 
At both implantation periods, the MMA histological sections of untreated femoral 
condyles of both SHAM and OVX (n=3) were assessed quantitatively using 
computer-based image analysis techniques (Leica® Qwin Pro-image analysis 
system, Wetzlar, Germany). From digitalized images of the untreated right femoral 
condyles (magnification: 5x), a circular region of interest (ROI) with a diameter 
equal to the created defects was positioned. Within this ROI, the percentage of 
bone and trabecular spacing was determined. The amount of bone and trabecular 
spacing observed in OVX was compared to SHAM.  
 
Ex vivo micro computed tomography (μCT) scanning 
From one SHAM and OVX rat, the non-treated right femoral condyle was isolated 
to visualize the bone structure. For visualization, microcomputed tomography (μCT) 
at a voltage of 100 kV and an intensity of 98 μA and a resolution of 9.4 μm was 
performed (Skyscan-1072 X-ray microtomograph, TomoNT version 3N.5, Skyscan®, 
Belgium).  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Instat 3.05 software (GraphPad 
Software Inc., San Diego, CA) via one-way analyses of variance with a Tukey multiple 
comparison post test. Differences were considered significant at p-values less than 
0.05. 
 
Results 
Characterization of PLGA-microparticles and CPC/PLGA composite 
The preparation of PLGA-microparticles with the double-emulsion-solvent-
extraction technique resulted in hollow microparticles with an average size of 35.7 
± 19.8 μm. The size distribution is shown in Figure 2A. Morphological examination 
using SEM revealed that the PLGA-microparticles had a spherical appearance with a 
smooth surface (Figure 2B). 
For pre-set CPC/PLGA composite discs, examination by SEM showed homogeneous 
distribution of PLGA-microparticles throughout the entire ceramic matrix (Figure 
2C). Porosity calculations demonstrated that microporosity (i.e. additional porosity 
after PLGA-microparticles degradation) and total porosity (consisting of intrinsic 
porosity and microporosity) demonstrated microporosity and total porosity values 
of 48.7 ± 2.7% and 75.5 ± 1.3%, respectively. 
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Figure 2 (A) The size distribution PLGA-microparticles prepared by the double-emulsion-
solvent-extraction technique (n=471). The microparticles had an average size of  37.7 ± 19.9 
μm (B) SEM evaluation revealed spherical PLGA-microparticles with a smooth surface. Bar 
represents 10 μm (C) SEM picture of CPC with incorporated PLGA-microparticles. Bar 
represents 50 μm. 
 
General observation of the experimental animals 
All 32 animals recovered uneventfully from the surgical procedure for OVX or 
SHAM and neither signs of wound complications nor signs of adverse tissue 
response were observed post-operatively. The creation of femoral bone defects 
resulted in loss of 1 SHAM animal due to an anesthesia-induced respiratory 
depression. The remaining 31 animals recovered uneventfully from the surgical 
procedure and remained in good health during the remaining experimental period, 
except for 1 OVX that suffered from inflammation at the defect location (i.e. 
swelling and pus formation). At the end of the experiment, a total of 31 implants 
were retrieved, of which 27 were included for analyses. The exclusion of 3 implants 
from analysis was due to specimen fracturing during histological processing and 1 
implant was excluded due to an adverse tissue response that became apparent 
after microscopic evaluation. An overview of the number of implants placed, 
retrieved, and used for evaluation is presented in Table 1. 
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Validation of the osteoporotic rat model 
Six weeks after OVX and SHAM surgery, the morphometric analyses of the in vivo 
CT scans of the femoral condyles revealed a significant decrease in bone volume 
(BV; p<0.001) and trabecular thickness (TT; p<0.001) and a significant increase in 
trabcular spacing (TS; p<0.05) in OVX compared to SHAM (Table 2). In the period 
from defect creation till sacrifice at 4 or 12 weeks, a significantly decreased BV 
(p<0.001) and TT (p<0.001) and a significantly increased TS (p<0.046) in OVX 
compared to SHAM were maintained in the femoral condyle (Table 2).  
Representative 3D reconstructions obtained via ex vivo μCT of the untreated 
femoral condyle of SHAM and OVX after periods of 4 and 12 weeks and histological 
sections of the untreated femoral condyle of SHAM and OVX after implantation 
periods of 12 are shown in Figure 3A and B, respectively. Histomorphometrical 
evaluation of untreated femoral condyles of SHAM and OVX showed a significant 
decrease in BV (at 4 weeks p=0.008; at 12 weeks p=0.002) and a significant increase 
in TS (at 4 weeks p=0.008; at 12 weeks p=0.002) in OVX compared to SHAM at both 
time points (Table 2). 
 
Descriptive light microscopy of bone defects 
Figure 4 presents an overview of the ROI in histological sections of the two 
experimental groups after implantation periods of 4 and 12 weeks.After 4 weeks, 
the structural integrity of the CPC was lost in both SHAM (Figure 4A) and OVX 
(Figure 4B), and newly-formed bone was observed throughout the degrading 
implant material. CPC degradation rate in OVX was increased compared to SHAM. 
For both SHAM and OVX, the newly-formed bone was trabecular-like, as 
characterized by the presence of an open porous structure (spacing) with bone 
marrow formation. The amount of newly-formed bone in OVX was lower compared 
to SHAM. In addition, the open porous structure in the newly-formed bone in OVX 
was enlarged compared to SHAM. TRAP staining revealed a similar osteoclastic 
activity for SHAM (Figure 5A and E) and OVX (Figure 5 B and F) within the ROI. 
After 12 weeks, CPC in both SHAM (Figure 4C) and OVX (Figure 4D) was almost 
completely degraded, showing less implant material in OVX. The formation of new 
bone had continued in SHAM and a complete interconnected bone network could 
be observed at the defect area. In contrast, the amount of newly-formed bone and 
trabecular spacing in OVX appeared similar to that observed at week 4. TRAP 
staining revealed absence of osteoclastic activity within the boundaries of the 
defect in both SHAM and OVX (Figure 5C and D). 
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Table 1 Number of implants placed, retrieved and used for histomorphometrical analyses 
 Implants placed Implants retrieved Implants used for analysis 
Week 4 12 4 12 4 12 
SHAM 8 7 8 7 7a 7a 
OVX 8 8 8 8 7a 6a, b 
a Deviation from number of implants retrieved due to fracturing of implants during 
to the histological processing or b due to adverse tissue response. 
 
 
Table 2 The bone architecture of SHAM and OVX animals evaluated with in vivo CT scanning 
and histomorphometrical evaluation 
 
  Before 6 wks after OVX Week 4 Week 12 
   SHAM OVX SHAM OVX SHAM OVX 
In
 v
iv
o 
CT
 s
ca
nn
in
g 
BV/TV 0.890  
± 0.010 
0.920 
± 
0.004 
0.821 
± 
0.014
a 
0.913 
± 
0.009 
0.834 
± 
0.019 
a, b 
0.921 
± 
0.005  
0.874 
± 
0.019 
b, c 
Trabecular 
Spacing 
0.016  
±  
0.003 
0.012 
± 
0.002 
0.026 
± 
0.002
a 
0.012 
± 
0.001 
0.024 
± 
0.004 
a, b 
0.012 
± 
0.001   
0.016 
± 
0.004 
b, c  
Trabecular 
Thickness 
0.135 
±  
0.015 
0.156 
±  
0.01  
a 
0.119 
± 
0.005
a 
0.146 
± 
0.020 
0.121 
± 
0,004 
a, b 
0.139 
± 
0.009 
0.112 
± 
0.011
b 
H
M
M
 
ev
al
ua
ti
on
 Bone 
formation 
(%) 
- - - 42.9 ± 
3.2 
32.0 ± 
2.1 b 
35.9 ± 
2.6 c 
19.9 ± 
2.6  
b, c 
Spacing 
(%) 
- - - 57.1 ± 
3.2 
68.0 ± 
2.1  
b 
64.1 ± 
2.6  
c 
80.0 ± 
2.6  
b, c 
BV/TV, Bone volume/total volume; OVX, Ovariectomy; HMM evaluation,  
Histomorphometrical evaluation; a; p< 0.05 compared to before; b , p< 0.05 compared to 
SHAM group; c, p < 0.05 compared to week 4. 
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Figure 3 Representative (A) 3D-reconstructed images of ex vivo μCT scanning after 
implantation periods of 4 and 12 weeks and (B) histological sections after 12 weeks 
implantation period of SHAM and OVX. Methylene blue and basic fuchsin staining. Bar 
represents 1000 μm.  
 
Figure 4 Representative histological sections of SHAM (A, C) and OVX (B, D) after 4 and 12 
weeks, respectively. Bar represents 500 μm. Methylene blue and basic fuchsin staining.  
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Figure 5 Representative histological sections of SHAM (A, E) and OVX (B, F) after 4 and 12 
weeks, respectively. Bar represents 1 mm. Defect area is marked with yellow dashed line and 
osteoclast activity after 12 weeks (→) are indicated in the sections. Magnifications of blue 
boxes depicted in A and B are shown in C (SHAM) and D (OVX). Bone (B), trabecular spacing 
(S) and osteoclast activty after 12 weeks (→) are indicated in the sections. Bar represents 
100 μm. Tartrate-resistant acid phosphatase (TRAP) staining. 
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Histomorphometrical evaluation 
Comparative evaluation of CPC performance in SHAM and OVX 
Quantitative results on the amount of remained CPC are presented in Figure 6A. 
For both SHAM and OVX, the amount of remained CPC was low, but without 
significant temporal progress (SHAM: from 7.2 ± 2.7% at week 4 to 7.2 ± 9.5% after 
week 12, p=0.979; OVX: from 1.9 ± 2.2% at week 4 to 0.4 ± 0.4% after week 12, 
p=0.224). Statistically significant differences in the amount of remained CPC 
between the SHAM and OVX (p=0.016) were observed after a 4 week implantation 
period. 
Quantitative results on bone formation in the ROI are depicted in Figure 6B. 
Significantly more bone was formed in SHAM compared to OVX at both time points 
(SHAM: from  35.2 ±  11.5% at week 4 to 52.6 ± 7.2% after week 12 ; OVX: from  
18.6 ±  5.7% at week 4 to 23.3 ± 7.6% after week 12; for week 4 p=0.026 and for 
week 12 p=0.016). For SHAM, a significant temporal increase in bone formation 
was observed between 4 and 12 weeks of implantation (p=0.027), but not for OVX 
(p=0.329). 
Quantitative results of the amount of trabecular spacing are shown in Figure 6C. 
Significantly more spacing was observed in OVX compared to SHAM at both time 
points (SHAM: from  57.6 ±  10.0% at week 4 to 79.4 ± 7.8% after week 12 ; OVX: 
from 40.1 ± 13.4% at week 4 to 76.3 ± 7.5% after week 12; for week 4 p=0.008 and 
for week 12 p=0.016). No significant temporal progress in spacing was observed 
between implantation periods of 4 and 12 weeks (for SHAM p=0.066; for OVX 
p=0.569). 
 
Comparative evaluation of bone amounts and trabecular spacing in the defect 
and contralateral femoral condyle 
Since physiologically maximal bone amounts differ between OVX and SHAM 
animals (see Table 1), a comparative evaluation of bone amount and trabecular 
spacing was carried out between newly-formed bone in the defect area (left 
femoral condyles) and bone in the untreated fictitious area in the contralateral 
femoral condyle. 
Quantitative results on bone amounts are represented in Figure 7A. At week 4, the 
amount of newly-formed bone in SHAM was comparable to untreated SHAM 
(p=0.29), whereas the amount of newly-formed bone in OVX was significantly 
decreased compared to untreated OVX (p=0.01). After 12 weeks, the amount of 
newly-formed bone in SHAM was significantly increased compared to untreated 
SHAM (p=0.01), whereas OVX showed similar bone amounts compared to 
untreated OVX (p=0.83). 
Quantitative results on trabecular spacing are represented in Figure 7B. At week 4, 
the amount of trabecular spacing in SHAM was similar to that in untreated SHAM 
(p=0.98), whereas OVX showed significantly more trabecular spacing compared 
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untreated OVX (p=0.003). After 12 weeks, trabecular spacing in SHAM and OVX was 
similar to untreated SHAM and OVX, respectively (SHAM p=0.053; OVX p=0.46). 
 
 
 
Figure 6 Results of histomorphometrical evaluation of SHAM and OVX in femoral condyle 
defects. The amount of (A) CPC, (B) bone formation and (C) trabecular spacing after 4 and 12 
weeks of the two experimental groups are expressed as percentage of ROI (i.e. a 
standardized region of interest within the boundaries of the implant). Error bars represent 
means ± standard deviation. (*) p< 0.05; (**) p< 0.01; n≥6. 
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Figure 7 Results of histomorphometrical evaluation of bone amounts (A) and trabecular 
spacing (B) in the defect area (left femoral condyles) of SHAM and OVX. The amount of 
newly formed bone and trabecular spacing present in the defect area of SHAM and OVX was 
related to the amount of bone and trabecular spacing present in untreated fictitious area 
(with the same dimensions as the defect) of the right femoral condyle of SHAM and OVX. 
The amount of bone and trabecular spacing in the untreated right femoral condyles was set 
at 100% and indicated with dashed line. Error bars represent means ± standard deviation. (*) 
p< 0.05; n>3. 
 
Discussion 
In the present study, the degradation and bone forming capacity of injectable 
CPC/PLGA was comparatively evaluated in healthy (SHAM) and osteoporotic (OVX) 
rats using a rat femoral condyle defect after implantation periods of 4 and 12 
weeks. It was hypothesized that OVX would accelerate CPC degradation due to a 
higher osteoclastic activity present in osteoporotic animals. Additionally, this 
accelerated CPC degradation was hypothesized to allow more new bone formation 
in the created space. The results revealed a significantly increased material 
degradation and decreased bone formation at both implantation periods in OVX 
compared to SHAM. In addition, the amount of bone formed in the femoral 
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condyle defects in OVX was significantly decreased compared to the amount of 
bone present in untreated OVX condyles at 4 weeks, although this effect was 
diminished after 12 weeks. In contrast, the amount of newly formed bone in the 
femoral condyle defect in SHAM was similar at 4 weeks and significantly increased 
after 12 weeks of implantation compared to the original amount of bone present in 
untreated SHAM condyles. 
The ovariectorized rat is generally accepted as a suitable preclinical animal model 
for human postmenopausal osteoporosis [2, 4, 22]. However, according to the 
definition of the WHO, the observed bone changes in ovariectorized rats are 
denoted as osteopenia rather than osteoporosis (i.e. bone mass reduced but no 
increased risk in fractures) [1]. Nonetheless, in line with previous reports [2, 4, 22, 
23], the present study demonstrated that over the course of the experiment OVX 
rats exhibited most of the characteristics as observed in human postmenopausal 
osteoporosis, including a significant decrease in trabecular bone mass and 
thickness and an increase in trabecular spacing, compared to healthy individuals as 
analyzed with histomorphometrical analysis and in vivo CT scanning indicating the 
presence of osteoporosis. 
To obtain replacement of bone, new bone formation and resorption of the bone 
substitute material, e.g. biodegradation of the material, is required. The 
degradation rate and the formation of bone should be in balance to maintain 
mechanical stability and to allow a gradual takeover of mechanical strength by 
newly-formed bone tissue. In the current study, the material degradation was 
significantly increased in OVX compared to SHAM, but no increased amount of 
newly-formed bone in OVX was observed. This is in line with Wang et al. (2008), 
who reported an accelerated resorption and altered osteoconductive responses for 
calcium sulphate-based bone substitute materials in an osteoporotic spine model in 
OVX rats compared to healthy control animals [24]. The biodegradation of calcium 
phosphate-based bone substitute materials can occur in an active manner, where 
osteoclastic activity is necessary for the bioresorbabillity [25-28]. Although an 
increased osteoclastogenesis and osteoclastic activity can be observed in human 
postmenopausal osteoporosis caused by the lack of estrogen [3], the current study 
failed to show an apparent difference in osteoclastic activity within the boundaries 
of the defect between SHAM and OVX after 4 weeks implantation period. 
Furthermore, after a 12-week implantation period, osteoclastic activity appeared 
absent within the boundaries of the defect in OVX and SHAM. This indicates that 
the lack of bone formation in OVX after 4 weeks is mainly due to a reduced capacity 
of the osteoblasts to replace the material with bone rather than to excessive 
osteoclastic activity. In view of this, additional empowerment via the inclusion of 
drugs and/or growth factors, such as bone morphogenetic proteins (BMPs), into 
CPC for the use in osteoporotic conditions might be promising, since BMP-2 has 
been reported to increase the osteoinductive properties of the materials in healthy 
animals [29, 30] as well as stimulating the healing of osteoporotic rat fractures 
after BMP-7 injection [31]. Also, the use of antiresorptive agents (i.e. 
biphosphonates) to inhibit osteoclastic activity might not be recommended in OVX 
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receiving CPC, since reduced osteoclastic activity might slow down the CPC 
degradation process and thus the creation of available space for the formation of 
bone. In addition to a potential negative effect on the CPC degradation, 
bisphosphonate treatment was shown before not to influence the healing of an 
OVX closed midshaft femoral fracture [31].  
Furthermore, it needs to be emphasized that besides material properties of the 
bone substitute material also the implantation site is known to influence the bone 
forming capacity of a material: for example similar CPC as used in the current study 
placed in a cranial defect in healthy rats resulted in less CPC degradation and bone 
formation compared to the current study [32]. The straightforward explanation for 
this phenomenon is that at different locations materials will be exposed to 
different environments, which includes the nature of biomechanical loading, 
surrounding tissue and blood/nutrient supply. Besides environment, also the origin 
of the bones (i.e. long bone formation is endochondral while cranial bone 
formation is intramembranous), may play a role in the degradation and bone 
formation due to distinctive signaling properties [33]. Therefore, the most 
favorable CPC for use in osteoporotic patients is, similar to its application in healthy 
individuals, dependent on the local bone condition and the specific host response. 
In conclusion, accelerated degradation of CPC/PLGA was observed in osteoporotic 
animals, but less bone formation was induced compared to healthy animals at  4 
and 12 weeks after implantation. In addition, the amount of newly-formed bone 
under osteoporotic conditions after 4 weeks was less in the femoral condyle defect 
compared to that present at a non-defect, osteoporotic control femoral condyle, 
but equal after 12 weeks. On the other hand, in healthy conditions, the amount of 
newly-formed bone in the femoral condyle defect was equal to that present at a 
non-defect control femoral condyle at 4 weeks, while higher after 12 weeks. This 
indicates that bone regeneration at a defect site is slower, but can reach native 
amounts after longer time periods. Consequently, bone regenerative treatments in 
osteoporotic conditions seem to require additional empowerment of bone 
substitute materials to achieve equal bone amounts.  
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Summary and address to the aims 
Calcium phosphate-based, apatitic cements (CPC) represent a high-potential 
candidate material for application as a bone substitute material to fill up bone 
defects in the field of dental, orthopaedic and reconstructive surgery, because of 
their biocompatible, osteoconductive and injectable properties. A disadvantage of 
CPC, however, is the poor biodegradation, which impedes replacement by bone 
tissue and hence full regeneration of the defect. The biodegradation of CPC 
depends on different factors, including cement properties (e.g. chemical 
composition, setting reaction, porosity, crystallinity and particle size of the calcium 
phosphate compounds) and the patient (e.g. medical condition and implantation 
site). The biodegradation of the CPC and thus the ingrowth of bone has been 
shown to be improved by altering the porosity. The porosity can be increased via 
different approaches, for example the use of sodium bicarbonate to obtain CO2-gas 
bubbles during CPC setting, mixing water-soluble crystals or biodegradable polymer 
microparticles (e.g. gelatin or poly(D,L-lactic-co-glycolic acid) (PLGA) as porogens 
homogeneously through the ceramic powder. To further empower the biological 
performance of CPC biologically active compounds can be introduced. However, 
many variables such as type of additive, additive dosage, release and retention 
need to be investigated to generate an effective injectable CPC for the 
reconstruction of different types of bone defects in a variety of patients. 
 
In view of the above mentioned, the research described in this thesis focused on 
addressing the efficacy of CPC in healthy conditions, exploring the effect of various 
incorporated additives on CPC performance, and evaluating differences between 
CPC performance in healthy and osteoporotic conditions. 
  
1. To what extent can addition of PLGA-microparticles improve the biological 
performance of CPC/PLGA? 
 
Chapter two of this thesis provided temporal information on the biological 
performance of CPC containing different amounts of PLGA-microparticles in terms 
of material degradation and bone formation. Preset CPC supplemented with 20 or 
30 wt.% PLGA-microparticles were implanted in a rat critical-sized cranial defect 
model. In forty-eight rats, a critical-sized cranial defect was created and C20% and 
C30% were implanted for 4, 8 and 12 weeks (n=8). Histological analysis of the 
retrieved specimens revealed that implant degradation for C30% was significantly 
faster compared to C20%, albeit that overall degradation was limited for both types 
of implants. Although bone formation was limited for both experimental groups, 
C30% showed a significant temporal increase of total bone formation. The 
percentage of defect bridging was comparable for C20% and C30% at all 
implantation periods. Based on the results of Chapter 2, the amount of PLGA-
microparticles in CPC demonstrated to increase material degradation, while bone 
formation was found not to be influenced. The biological performance of CPC 
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supplemented with PLGA-microparticles is insufficient to fully regenerate a critical 
sized defect and therefore requires additional empowerment with biological active 
compounds. 
 
2. Can the biological performance of CPC be improved by the addition of 
bioactive glass? 
 
CPC supplemented with PLGA-microparticles represents a promising candidate 
material for bone substitution mainly due to their biocompatibility and 
osteoconductive properties however, the biological performance of CPC 
supplemented with PLGA-microparticles under healthy conditions is insufficient to 
fully regenerate critical sized bone defects (Chapter 2). Therefore, the enrichment 
of CPC/PLGA with biological active compounds is necessary in order to stimulate 
bone healing under critical conditions, including large bone defects, poorly 
vascularized sites, and (elderly) patients with metabolic disorders. In view of this, 
the incorporation of Bioactive glasses (BGs) into CPC seems a promising approach 
to improve the biological performance of CPC since BGs are known for their unique 
ability to bond to living bone which acts as a template for calcium phosphate 
precipitation and directs new bone formation. In addition, it has been reported 
that BGs attract and stimulate osteoprogenitor cells, which differentiate into 
matrix-producing osteoblasts and subsequently increase the rate of bone 
formation and bone ingrowth into BG-based granular material. Previous, it was 
demonstrated that BG could successfully be introduced into CPC, either pure or 
supplemented with PLGA-microparticles. Although in vitro data on the introduction 
of BG to CPC composite material were encouraging, the biocompatibility and in vivo 
bone response to these formulations remained unknown. Therefore, Chapter 3 
aimed to evaluate the in vivo response of BG supplemented CPC, either pure or 
supplemented with PLGA-microparticles, via both ectopic and orthotopic 
implantation models in rats. Pre-set scaffolds in 4 different formulations (1: CPC; 2: 
CPC/BG; 3: CPC/PLGA; and 4: CPC/PLGA/BG) were implanted subcutaneously and in 
femoral condyle defects of rats for 2 and 6 weeks. The results of Chapter 3 
revealed that BG incorporation improved the histocompatibility upon ectopic 
implantation compared to pure CPC, as demonstrated by an improved capsule and 
interface quality surrounding the implants. Additionally, incorporating BG within 
CPC accelerated material degradation and increased bone formation in a femoral 
condyle defect in rats. Consequently, these results highlight the potential of BG to 
be used as an additive to CPC to improve the biological performance for bone 
regeneration applications. Nevertheless, the current favorable data have to be 
confirmed in long-term in vivo studies, which also have to be performed under 
compromised wound healing conditions. 
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3. Does the solubility of BMP-2 influence the bioactivity, release profile of 
and osteoinductive properties of CPC scaffold material? 
 
BMP’s play a significant role in the regulation of many steps in bone morphogenesis 
due to their biological functions that include chemotaxis, differentiation, and 
mitosis of bone forming cells. Similar to native BMP’s, recombinant equivalents 
produced in mammalian cells are post-translationally modified through N-linked 
glycosylation. In contrast, bacterially produced BMP’s lack this glycosylation leading 
to a decrease in solubility. This reduced solubility affects the release kinetics from 
bone substitute materials and hence might allow the application of lower BMP 
doses to induce bone formation. This seems promising for reducing the amount of 
included growth factor in bone substitute materials. Consequently, in Chapter 4, it 
was hypothesized that ngBMP-2 induces more profound ectopic bone formation at 
lower dosages compared to gBMP-2. To that end, gBMP-2 and ngBMP-2 were 
firstly in vitro comparatively evaluated for biological activity and release from pre-
set CPC scaffolds. Thereafter, an ectopic implantation model in rats was used, in 
which gBMP-2 and ngBMP2 were loaded at various dosages (2-20 ug/implant) on 
the pre-set CPC scaffolds and implanted for 4 and 12 weeks. The results revealed 
that both the in vitro biological activity of and the in vitro release of ngBMP-2 are 
lower compared to gBMP2. Upon ectopic implantation, however, ngBMP-2 loaded 
implants induced more bone formation at lower concentrations from 4-weeks 
onward compared to gBMP-2 equivalents. The results of Chapter 4 revealed that 
the solubility of BMP-2 protein influences the bioactivity and release profile of the 
growth factor, resulting in improved osteoinductive properties of scaffold loaded 
with ngBMP-2. Together, this indicates the value of ngBMP-2 as a more powerful 
alternative for mammalian produced recombinant BMP-2 for bone regenerative 
therapies. 
 
4. Does the BMP-2 loading method to CPC influence the release kinetics and 
osteoinductive potential of CPC? 
 
Clinical application of CPC (with incorporated PLGA-microparticles) in an injectable 
form implicates that loading methods for growth factors are limited. In view of this, 
Chapter 5 addressed differential loading methods for BMP-2 and the effects on in 
vitro and in vivo release kinetics via an in vitro release experiment and in vivo using 
microSPECT imaging with 125I-labeled BMP-2 as well as the osteoinductive capacity 
of differentially loaded scaffolds using a subcutaneous rat model. The differential 
loading methods comprised BMP-2 adsorption to PLGA-microparticles (CPC/PLGA), 
BMP-2 addition to the liquid phase of CPC (CPC/liquid), and BMP-2 adsorption to 
the surface of preset, porous CPC (CPC/surface) as a control. Additional controls 
consisted of porous CPC scaffolds (CPC/porous) and CPC/PLGA (CPC/control) 
without BMP-2 loading. The results of Chapter 5 revealed that BMP-2 loading is 
feasible via adsorption to PLGA-microparticles and addition to the liquid phase of 
CPC, for which similar release profile were observed over the course of 28 days, 
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despite distinct protein distribution patterns. Compared to CPC/surface, CPC/PLGA 
and CPC/liquid showed a significantly lower burst release, followed by a similar 
sustained release profile. As such, the observed osteoinductive capacity for only 
CPC-scaffolds with surface-loaded BMP-2 is likely to be related to this difference in 
burst release. It remains unclear to what extent the differential BMP-2 loading 
methods for injectable CPC can affect the biological response in a bone 
environment. 
 
5. What are the differences in biological performance of CPC between 
osteoporotic and healthy rats? 
 
In the previous chapters of this thesis, the performance of CPC (with or without 
additives) was evaluated in healthy animals. As such, the outcome of these studies 
provided no information on the performance of CPC under compromised 
conditions, such as in osteoporotic patients. Consequently, Chapter 6 
comparatively evaluated the performance of injectable CPC/PLGA in healthy 
(SHAM) and osteoporotic rats (OVX) using a rat femoral condyle defect with 
implantation periods of 4 and 12 weeks. It was hypothesized that in OVX rats, the 
degradation of CPC/PLGA would be increased due to a higher osteoclastic activity 
present in osteoporotic animals and that the obtained space would be rapidly filled 
with newly formed bone. The results of Chapter 6 revealed that despite an 
accelerated degradation of CPC/PLGA in osteoporotic animals, bone formation was 
slower compared to healthy animals after implantation periods of 4 and 12 weeks. 
In addition, after 4 weeks, the amount of newly-formed bone under osteoporotic 
conditions was less in the femoral condyle defect compared to that present at a 
non-defect, osteoporotic control femoral condyle, but equal after 12 weeks. On the 
other hand, under healthy conditions, the amount of newly-formed bone in the 
femoral condyle defect was equal to that present at a non-defect control femoral 
condyle at 4 weeks, while higher after 12 weeks. The results of Chapter 6 indicate 
that bone regeneration at a defect site under osteoporotic conditions is slower, but 
can re-establish native amounts after longer time periods. Consequently, bone 
regenerative treatments in osteoporotic conditions seem to require additional 
empowerment of bone substitute materials to achieve equal bone amounts.  
 
Closing remarks and future perspectives  
In our search to optimize the biological performance of apatitic CPC, we 
supplemented CPC with PLGA-microparticles to create a porous scaffold to 
enhance material degradation and tissue ingrowth. To predict the degradation of 
the PLGA-supplemented CPC and hence the bone forming capacity, we considered 
the total porosity of the scaffolds (contributed to the intrinsic porosity of CPC and 
added PLGA-microparticles) to be an important parameter. Although the amount 
and size (distribution) of PLGA-microparticles varied among the different chapters 
of this thesis from 20 to 30 wt.% and from 20 to 60 μm, the total porosity of all 
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scaffolds was similar at around 70%. This indicates that the variations made 
regarding amount and size (distribution) of PLGA-microparticles evoked only 
limited variations in ultimate porosity of the CPC. In vivo experiments, in which the 
effect of different amounts of PLGA-microparticles on degradation and biological 
responses were compared in a direct manner have been performed (Chapter 2). 
However, no direct evidence of the influence of size on biological performance of 
CPC is available to date and requires further investigation. Despite similar porosity 
values, the extent of CPC degradation and subsequent bone forming capacity 
varied among the different chapters of this thesis. This difference is likely to be 
dependent on the experimental set-up (i.e. implant location). In addition, our 
results indicate that the interconnectivity of the material is also of importance. The 
most beneficial interconnective porosity is not yet known, although we showed in 
Chapter 4 that an interconnective porosity of ~20% is insufficient and further 
investigation is required. For clinical applications, reproducibility and 
standardization of the material is important. Many of these factors, such as the 
type and amount of the PLGA-microparticles and the components of the CPC, can 
be controlled. However, still a lot of work has to be done on the standardization of 
PLGA-microparticle size and insight into the relation between their size and amount 
to obtain effective interconnectivity within the CPC. To obtain reproducible 
interconnective porosity, combining different standardized sizes (with only limited 
size ranges) of PLGA-microparticles might be an option as previously described [1]. 
Therefore, future research has to focus on the relation between PLGA-
microparticle size, amount, and interconnectivity, and the performance of these 
CPCs in vivo. Additionally, this relation has to be investigated at different in vivo 
locations and bone defect sizes under healthy as well as compromised conditions.  
Parallel research on CPC degradation revealed that the morphology of PLGA-
microparticles (i.e. hollow or dense) has a stronger effect on degradation than both 
molecular weight and terminal end-group modification [2]. Therefore, in 
chronologically later performed research of this thesis, we supplemented CPC with 
these dense PLGA-microparticles. The objectives of these chapters was based on 
the evaluation of the biological performance of CPC/dense PLGA-microparticles  
supplemented with either osteopromotive BG particles or the osteoinductive 
growth factor BMP-2. Therefore, aside from the proof-of-principle that has recently 
been obtained in a rabbit femoral condyle [3], a biological evaluation of CPC 
incorporating dense PLGA-microparticles for different PLGA-microsphere particle 
sizes, amounts, implant sites, and medical conditions needs to be performed. 
After the realization that the biological performance of CPC was still unsatisfactory 
following optimization approaches based on combinations of the ceramic cement 
matrix and hollow PLGA-microparticles, our research focused on the empowerment 
of CPC by incorporating additives with a certain biological capacity. Candidate 
additives used for this purpose were BG and BMP-2. The loading method of 
additives varied as BG was mixed throughout the ceramic matrix, whereas BMP-2 
was either adsorbed to PLGA-microparticles or added to the liquid phase of CPC. 
We demonstrated that incorporation of BG indeed improved the biological 
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performance at 6 weeks of implantation. Further long-term studies are necessary 
to provide additional information concerning the late stages of the bone matrix 
synthesis and degradation induced by the CPC/PLGA cements including BG. 
Additionally, we demonstrated that it is feasible to include BMP-2 within CPC via 
both methods, although growth factor release and related osteoinductive 
properties of the CPC were insufficient to induce ectopic bone formation 
subcutaneously in rats. It is likely that the lack of an osteoinductive effect was 
dependent on the limited BMP-2 burst release. This illustrates that the release 
kinetics of growth factors are complex and may be influenced by many variables as 
previously reported [4]. It remains unclear to what extent the differential BMP-2 
loading methods for injectable CPC can affect the biological response in a bone 
environment. Taken together, the incorporation of the additives BG and BMP-2 to 
improve the biological performance of CPC showed promising results and could be 
used as a lead toward product development.  
The majority of the patients requiring regeneration of (large) bone defects with 
bone substitute materials have a sub-optimal medical condition and thus bone 
metabolism, of which osteoporotic patients represent a somewhat worst-case 
scenario. Consequently, the need for an efficient CPC to treat bone defects in this 
group of patients is high. The differences in bone morphology and metabolism 
between compromised patients and healthy humans points to a different biological 
performance of CPC. As such, this thesis reported for the first time the biological 
performance of CPC with included PLGA-microparticles in osteoporotic conditions 
and revealed that bone regenerative treatments in osteoporotic conditions require 
additional empowerment of CPC. The investigated additives in this thesis might 
improve the biological performance in compromised conditions. Therefore, 
research has to focus on the potential of additives to improve the biological 
performance of CPC in osteoporotic conditions. 
From a biological and cost-effective point of view (i.e. potential risks of side-effects, 
labor intensiveness and cost price) the use of biological active compounds has 
limitations. It is necessary to find a compromise between the cost prize of 
empowered CPC and its biological efficacy under specific conditions. Preferably, 
clinicians should have the possibility to select the most appropriate CPC for each 
specific clinical application. To reach such an approach, the challenge is to identify 
the accurate combination of (i) standardized ceramic cement matrix, (ii) specific 
type of porogens, and (iii) additives, depending on patient-specific conditions (e.g. 
defect size, location, age, and medical condition). A final prerequisite is that such a 
customized injectable CPC becomes available in a simple, straightforward and 
controllable application system that allows gentle application of the CPC with 
optimal handling properties (i.e. viscosity, setting). 
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Samenvatting en evaluatie van de doelstellingen 
Calcium fosfaat cement (CPC) is een kansrijk materiaal voor de behandeling van 
botdefecten op het gebied van tandheelkundige, orthopedische en reconstructieve 
chirurgie. CPC is veel belovend omdat het veel lijkt op de minerale fase van bot. Het 
bestaat uit een poeder en een vloeibare fase. Na het mengen van deze twee fases 
vormt zich een pasta die gemakkelijk in te spuiten is in een botdefect. Naast deze 
goede injecteerbare eigenschappen van CPC is het materiaal biocompatibel (een 
negatieve lichaamsreactie blijft uit) en osteoconductief (het materiaal fungeert als 
een matrix waarover bestaand bot wordt voorgeleid). Nadat het CPC geïnjecteerd 
is in een botdefect geeft het eerste plaats stabilisatie aan het defect, waarna 
lichaamseigen botweefsel het botdefect kan herstellen. Echter een nadeel van CPC 
is de lage degradatiesnelheid (afbraak) van het materiaal. Het degraderen van CPC 
is noodzakelijk omdat uiteindelijk het botdefect volledig hersteld (dus gevuld) moet 
worden met nieuw gevormd botweefsel. De degradatie van CPC hangt af van 
verschillende factoren, zoals de cement eigenschappen (o.a. chemische 
samenstelling, porositeit, kristalliniteit en de deeltjesgrootte van de 
calciumfosfaatverbindingen) en de patiënt (bijvoorbeeld een mogelijk aanwezige 
medische aandoening en de locatie van implantatie). Het is aangetoond dat de 
degradatie van CPC en daarmee de ingroei van bot sterk verbeterd kan worden 
door verhoging van de porositeit van het materiaal. Het inmengen van biologisch 
afbreekbare polymeer micropartikels (zoals gelatine of poly (melkzuur-co-
glycol)zuur; PLGA) door het CPC poeder leidt tot verhoogde porositeit in het 
materiaal doordat het PLGA micropartikel degradatieproces eerder optreedt dan 
de degradatie van het CPC. De biologische werking van CPC kan verder verbeterd 
worden door toevoeging van biologisch actieve moleculen (zoals groeifactoren) die 
de botvorming kunnen stimuleren. Factoren die de botvorming induceren worden 
ook wel osteoinductieve factoren genoemd. Vele variabelen zijn echter onbekend, 
zoals het type additief, de dosis en de methode waarop de additieven toegevoegd 
kunnen worden aan het injecteerbare CPC. Al deze variabelen moeten onderzocht 
worden om een goede botvervanger te ontwikkelen die gebruikt kan worden voor 
de regeneratie van verschillende type botdefecten. 
 
Het onderzoek in dit proefschrift heeft betrekking op het bestuderen van de 
doeltreffendheid van CPC in gezonde omstandigheden, het effect van diverse 
toegevoegde additieven op de CPC prestatie, en het beoordelen van de verschillen 
tussen de CPC prestaties onder gezonde en osteoporotische omstandigheden. 
 
1. In welke mate kan de biologische werking van CPC/PLGA verbeterd 
worden door toevoeging van PLGA micropartikels? 
Hoofdstuk twee van dit proefschrift verstrekt temporele informatie over de 
biologische werking (o.a. materiaal degradatie en botvorming) van CPC waaraan 
verschillende hoeveelheden PLGA micropartikels zijn toegevoegd. In achtenveertig 
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ratten werd een kritische-grootte craniaal defect gemaakt waarin uitgeharde CPC 
disks aangevuld met 20 of 30 gewichtsprocent PLGA micropartikels (respectievelijk 
C20% en C30%) werden geïmplanteerd voor 4, 8 en 12 weken (n=8). Histologische 
analysemethoden toonden aan dat C30% aanzienlijk sneller degradeert dan C20%, 
maar dat de totale degradatie beperkt is in zowel C20% als C30%. Het percentage 
nieuw gevormd bot dat het botdefect overbrugde was vergelijkbaar voor C20% en 
C30% op alle implantatie periodes. Hoewel de botvorming beperkt was voor beide 
experimentele groepen, vertoonden C30% een significante temporele stijging van 
de totale botvorming. De resultaten van hoofdstuk 2 tonen aan dat de 
materiaaldegradatie verbetert wanneer een grotere hoeveelheid PLGA 
micropartikels aan CPC wordt toegevoegd, terwijl de botvorming niet wordt 
beïnvloed. De biologische werking van CPC aangevuld met PLGA micropartikels is 
onvoldoende om kritische-grootte defecten volledig te regenereren. Hierdoor zijn 
extra toevoegingen van biologisch actieve factoren vereist om de botregeneratie te 
kunnen stimuleren.  
 
2. Kan de biologische werking van CPC worden verbeterd door toevoeging 
van bioactief glas? 
 
De biologische werking van CPC, aangevuld met PLGA micropartikels, is onder 
gezonde omstandigheden niet toereikend om kritische-grootte botdefecten 
volledig te regenereren (hoofdstuk 2). Verrijking van CPC/PLGA met biologisch 
actieve factoren is hierdoor noodzakelijk om botgenezing te stimuleren onder 
kritische omstandigheden, zoals grote botdefecten, slecht gevasculariseerde 
locaties en (oudere) patiënten met metabole stoornissen. De integratie van 
bioactief glas (BG) in CPC lijkt een veelbelovende aanpak om de biologische 
prestatie van CPC te verbeteren. BG’s staan bekend om hun unieke vermogen te 
binden aan levend bot, waardoor er een sjabloon gevormd wordt voor 
calciumfosfaatprecipitatie die de vorming van nieuw bot stuurt. Daarnaast is 
bekend dat BG osteoprogenitorcellen aantrekt en stimuleert te differentiëren tot 
matrix-producerende osteoblasten (botvormende cellen). Hierdoor wordt de 
botvorming versneld en treedt ingroei van bot in BG gebaseerd materiaal op. 
Eerdere studies van de afdeling Biomaterialen toonden aan dat BG succesvol kan 
worden geïntroduceerd in CPC of CPC aangevuld met PLGA micropartikels. 
Ondanks dat de in vitro gegevens over de incorporatie van BG in CPC bemoedigend 
waren, was het onbekend hoe de in vivo respons (o.a. de biocompatibiliteit en 
botvormingseigenschappen) van dit materiaal was. Daarom werd in hoofdstuk 3 de 
in vivo respons op toevoeging van BG aan CPC (puur of aangevuld met PLGA 
micropartikels) geëvalueerd. Uitgeharde CPC disks in vier verschillende 
formuleringen (1: CPC, 2: CPC/BG, 3: CPC/PLGA, en 4: CPC/PLGA/BG) werden 
subcutaan en in gecreëerde botdefecten in de laterale condyle van de femur 
(bovenbeen) van ratten geïmplanteerd voor 2 en 6 weken. Uit de resultaten bleek 
dat BG de histocompatibiliteit verbeterd in subcutaan geplaatste implantaten, 
vergeleken met puur CPC. Bovendien was in orthotopisch geplaatst CPC met 
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toegevoegd BG, de materiaaldegradatie en botvorming verhoogt. De resultaten van 
hoofdstuk 3 suggereren dat BG kan worden gebruikt als een additief om de 
biologische prestaties van CPC te verbeteren, waardoor een betere botregeneratie 
kan worden verkregen. De huidige, gunstige resultaten moeten bevestigd worden 
op de langere termijn. Daarnaast moeten deze studies worden uitgevoerd in slecht 
genezende defecten (zoals in osteoporotische patiënten). 
 
3. Heeft de oplosbaarheid van ‘bone morphogenetic protein-2’ (BMP-2) 
invloed op de bioactiviteit, het afgifteprofiel van en de osteoinductieve 
eigenschappen van CPC? 
 
BMP's spelen een belangrijke rol in de regulatie van de botmorfogenese (o.a. het 
stimuleren van de differentiatie en mitose van osteoblasten). Lichaameigen BMP’s 
en recombinant equivalenten geproduceerd in zoogdiercellen zijn post-
translationeel gemodificeerd door N-gekoppelde glycosylering (gBMP-2). Bacterieel 
geproduceerde BMPs worden niet geglycolyseerd (ngBMP-2), wat leidt tot een 
verminderde oplosbaarheid. Dit heeft invloed op de afgifte van ngBMP-2 en 
daarmee bestaat de mogelijkheid om lagere BMP doses te gebruiken om 
botvorming te induceren. Het verlagen van de hoeveelheid toegevoegd groeifactor 
in botvervangende materialen is uit biologische en kosteneffectief oogpunt (d.w.z. 
potentiële risico's van bijwerkingen, arbeidsintensiviteit en de kostprijs) van groot 
belang. In hoofdstuk 4 werd verondersteld dat ngBMP-2 meer ectopische 
botvorming bij lagere doseringen kan induceren dan gBMP-2. Om dit te evalueren 
werd eerst in vitro de biologische activiteit en afgiftepatroon bestudeerd van 
gBMP-2 en ngBMP-2 geladen dragermateriaal. Daarna werd een ectopisch 
implantatie model in ratten gebruikt, waarin gBMP-2 en ngBMP2 werden geladen 
in verschillende doseringen (2-20 μg/implantaat) op dragermateriaal en subcutaan 
geïmplanteerd voor 4 en 12 weken. De resultaten toonden aan dat zowel de in 
vitro biologische activiteit als de in vitro afgifte van ngBMP-2 lager was dan van 
gBMP2. Echter, vanaf 4 weken na ectopische implantatie van ngBMP-2 geladen 
implantaten vormt zich meer bot bij lagere concentraties dan in gBMP-2-
equivalenten. Uit de resultaten van hoofdstuk 4 blijkt dat de biologische activiteit 
en het afgifteprofiel van BMP-2 wordt beïnvloedt door de oplosbaarheid van het 
eiwit. Dit resulteerde in verbeterde osteoinductieve eigenschappen van 
botvervangend materiaal geladen met ngBMP-2. Tezamen suggereert dit dat 
ngBMP-2 een krachtig alternatief is voor in zoogdieren geproduceerd recombinant 
BMP-2 voor bot regeneratieve therapieën. 
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4.  Heeft de wijze waarop BMP-2 toegevoegd wordt aan het CPC invloed 
op het BMP-2 afgifteprofiel en de osteoinductieve eigenschappen van 
CPC? 
 
De klinische toepassing van CPC (met ingebouwde PLGA micropartikels) is in een 
injecteerbare vorm. Dit impliceert dat de methodes om groeifactoren toe te 
voegen aan CPC beperkt zijn. Het onderzoek in hoofdstuk 5 richtte zich op het 
bestuderen van verschillende ladingsmethoden voor BMP-2 en de gevolgen van 
deze methode op de in vitro en in vivo BMP-2 afgifte. Via een in vitro BMP-2 afgifte 
experiment en in vivo m.b.v. microSPECT (een 3-dimensionale diagnostische 
beeldvormingstechniek waarbij gebruik wordt gemaakt van radioactief gelabelde 
stoffen, in dit geval radioactief gelabeld BMP-2) werd het afgiftepatroon van 
verschillende BMP-2 geladen CPC geanalyseerd. Vervolgens werd de 
osteoinductieve capaciteit van de verschillende implantaten geanalyseerd m.b.v. 
een subcutaan implantatie rat model. De verschillende ladingsmethoden 
bestonden uit BMP-2 adsorptie aan PLGA micropartikels waarna toegevoegd aan 
CPC (CPC/PLGA), en BMP-2 toegevoegd aan de vloeibare fase van CPC/PLGA 
(CPC/vloeistof). Uitgeharde poreuze CPC waaraan BMP-2 is toegevoegd d.m.v. 
adsorptie aan het oppervlak (CPC/oppervlak) diende als controle. Extra controles 
bestonden uit uitgeharde poreuze CPC implantaten (CPC/poreus) en CPC/PLGA 
(CPC/controle) zonder BMP-2. Uit de resultaten van hoofdstuk 5 bleek dat BMP-2 
lading mogelijk was via adsorptie aan PLGA micropartikels en via de vloeibare fase 
van CPC, waarbij hetzelfde afgifteprofiel waargenomen werd gedurende 28 dagen, 
ondanks een duidelijk verschil in de eiwitspreiding van het geladen BMP-2 in de 
twee groepen. De BMP-2 afgifte na 1 dag (de initiële afgifte) was voor zowel 
CPC/PLGA als CPC/vloeistof lager dan voor CPC/oppervlak, terwijl het afgifte 
patroon van dag 2-28 vergelijkbaar was tussen alle groepen. Hierdoor is het 
mogelijk dat het alleen in CPC/oppervlak geobserveerd osteoinductief vermogen 
ontstaan is door een verschil in de initiële afgifte. Het blijft echter onduidelijk of de 
verschillende BMP-2 ladingsmethoden voor een injecteerbaar CPC een effect 
hebben op de biologische prestatie in een botomgeving. 
 
5. Wat zijn de verschillen in de biologische prestatie van CPC tussen 
osteoporose en gezonde ratten? 
 
In de vorige hoofdstukken van dit proefschrift werd de biologische prestatie van de 
CPC (met of zonder additieven) onderzocht bij gezonde dieren. Als zodanig leveren 
de resultaten van deze studies geen informatie op over de biologische prestatie van 
de CPC onder kritische omstandigheden, zoals bij osteoporose patiënten. Hierdoor 
is in hoofdstuk 6 de biologische prestatie van injecteerbaar CPC/PLGA in 
osteoporotische ratten (ovx) onderzocht en vergeleken met de prestatie in 
gezonde (sham) ratten. In de verschillende type ratten werd CPC/PLGA 
geïnjecteerd in botdefecten gecreëerd in de laterale condyle van de femur van 
ratten. De implantatie periodes waren 4 en 12 weken. De hypothese van de studie 
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was dat door een hogere activiteit van de osteoclasten (botafbrekende cellen) 
aanwezig in osteoporotische dieren, de degradatie van CPC/PLGA in ovx ratten 
versneld zal zijn en hierdoor de ontstane ruimte versneld zou worden opgevuld 
met nieuw bot. Uit de resultaten bleek dat op beide implantatieperiodes de 
botvorming trager was in vergelijking met gezonde dieren, ondanks een versnelde 
afbraak van CPC/PLGA in osteoporotische dieren. Bovendien was na vier weken de 
hoeveelheid gevormd bot onder osteoporotische omstandigheden in het 
gecreëerde botdefect minder dan in een intacte osteoporotische knie, maar was dit 
na 12 weken gelijk. Anderzijds, onder gezonde omstandigheden is de hoeveelheid 
nieuw gevormd bot na vier weken in het gecreëerde botdefect gelijk aan de 
hoeveelheid in een intacte gezonde knie en hoger na 12 weken. De resultaten van 
hoofdstuk 6 geven aan dat de regeneratie van bot in een botdefect onder 
osteoporotische condities trager is, maar dat na verloop van tijd botregeneratie 
plaatsvindt tot de oorspronkelijke aanwezige hoeveelheid bot. Dit suggereert dat 
onder osteoporotische omstandigheden extra toevoegingen, of aanpassingen aan 
het botvervangend materiaal nodig zijn om tot een goede botregeneratieve 
behandeling te komen. 
 
Slotopmerkingen en toekomstperspectieven 
In onze zoektocht om de biologische werking van CPC te optimaliseren, hebben we 
aan het CPC PLGA micropartikels toegevoegd om een verhoogd poreus materiaal te 
creëren dat de materiaaldegradatie, en dus de ingroei van (bot)weefsel, verbetert. 
Om de degradatie van het CPC/PLGA te voorspellen en daarmee het vermogen om 
bot te regenereren, beschouwden we de totale porositeit van het materiaal als 
belangrijke parameter. De totale porositeit bestaat uit de intrinsieke porositeit van 
CPC en de toegevoegde porositeit na PLGA micropartikel degradatie. Hoewel de 
hoeveelheid (van 20 tot 30 gewichtsprocent) en de grootte van de PLGA 
micropartikels (van 20 tot 60 μm) varieerden tussen de verschillende hoofdstukken 
van dit proefschrift, was de totale porositeit vergelijkbaar, ongeveer 70%. Dit 
betekent dat de aangebrachte wijzigingen ten aanzien van de hoeveelheid en de 
grootte van PLGA micropartikels slechts beperkte verschillen in uiteindelijke 
porositeit van het CPC opleverden. Ondanks de in vivo experimenten met 
verschillende hoeveelheden PLGA toegevoegd aan CPC (hoofdstuk 2) is er tot op 
heden geen direct bewijs dat de grootte van de PLGA micropartikels invloed heeft 
op biologische werking van CPC. Derhalve vereist dit verder onderzoek. Ondanks 
soortgelijke porositeitswaarden varieert de mate van CPC degradatie en de daarop 
volgende botvormende capaciteit in de studies die beschreven staan in dit 
proefschrift. Dit verschil is waarschijnlijk veroorzaakt door verschillen in de 
proefopzet (bijvoorbeeld een verschil in implantaat locatie). Daarnaast blijkt uit de 
resultaten van dit proefschrift dat het netwerk van de poriën (de 
interconnectiviteit) in het materiaal ook van belang is. De meest gunstige 
interconnectiviteit is nog niet bekend, al komt uit de resultaten van hoofdstuk 4 
naar voren dat een interconnectiviteit van ongeveer 20% niet voldoende is.  
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Voor klinische toepassingen is reproduceerbaarheid en standaardisering van het 
materiaal van cruciaal belang. Veel factoren zoals de aard en hoeveelheid van de 
PLGA micropartikels en de verschillende componenten van het CPC poeder kunnen 
worden gereguleerd. Echter, meer onderzoek is vereist om het productieproces 
van PLGA micropartikels te standaardiseren, zodat de grootte van de partikels 
reproduceerbaar is. Om een reproduceerbare interconnectiviteit te verkrijgen, 
kunnen verschillende gestandaardiseerde PLGA micropartikels gecombineerd 
worden, zoals eerder beschreven [1]. Hierdoor moet toekomstig onderzoek zich 
richten op de relatie tussen de grootte en hoeveelheid van de PLGA micropartikels 
enerzijds, en de ontstane interconnectiviteit en biologische prestatie van het CPC in 
vivo anderzijds. Bovendien is het noodzakelijk om dit te onderzoeken op 
verschillende plaatsen in vivo, met verschillende afmetingen van botdefecten en 
onder gezonde en zieke omstandigheden. 
Uit parallel onderzoek van de afdeling Biomaterialen van het UMC St. Radboud 
bleek dat de morfologie van de PLGA micropartikels (hol of massief) een sterker 
effect heeft op de materiaaldegradatie dan het moleculegewicht en de chemische 
eindgroep modificatie van de partikels [2]. Daarom zijn de experimenten in dit 
proefschrift die na deze constatering zijn gestart, uitgevoerd met deze massieve 
PLGA micropartikels. De doelstellingen van deze studies zijn gebaseerd op de 
evaluatie van de biologische werking van CPC met massieve  PLGA micropartikels, 
aangevuld met ofwel de osteopromotieve factor BG (hoofdstuk 3) ofwel de 
osteoinductieve groeifactor BMP-2 (hoofdstuk 5). Recentelijk is een ‘proof-of-
principle’ verkregen met CPC, waaraan massieve PLGA micropartikels zijn 
toegevoegd [3]. Echter is het noodzakelijk om de biologische prestatie van dit 
materiaal te bestuderen, waarbij CPC met (verschillende groottes en 
hoeveelheden) massieve PLGA micropartikels op verschillende locaties en onder 
verschillende medische condities wordt geïmplanteerd.  
Ondanks optimalisatiemethodes waarbij verschillende combinaties van CPC en 
holle PLGA micropartikels werden gebruikt, bleek de biologische prestatie van dit 
CPC ontoereikend om kritische-grootte defecten te regenereren (hoofdstuk 2). 
Hierdoor richtte het onderzoek in dit proefschrift zich tevens op het versterken van 
CPC door het toevoegen van additieven met een biologische activiteit t.a.v. 
botvorming. Mogelijke kandidaten waren BG (hoofdstuk 3) en BMP-2 (hoofdstuk 4 
4 en 5). De methode waarop de additieven werden toegevoegd varieerde, waarbij 
BG werd gemengd in de keramische matrix (CPC poeder), terwijl BMP-2 ofwel 
geadsorbeerd werd aan de PLGA micropartikels, of wel werd toegevoegd aan de 
vloeibare fase van CPC. In dit proefschrift is aangetoond dat de biologische 
prestaties na 6 weken inderdaad verbeterden wanneer BG werd toegevoegd aan 
CPC of CPC/PLGA. Vervolgstudies met deze materialen zijn noodzakelijk om meer 
informatie te krijgen over de botformatie en afbraak op de langere termijn. 
Daarnaast is in dit proefschrift aangetoond dat BMP-2 toe te voegen is aan 
injecteerbaar CPC d.m.v. adsorptie aan de PLGA micropartikels of via toevoeging 
van BMP-2 aan de vloeibare fase van het injecteerbaar CPC. Echter zijn de 
osteoinductieve eigenschappen van beide materialen ontoereikend om op 
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ectopische locaties in ratten botformatie te stimuleren. Het ontbreken van een 
osteoinductief effect in deze materialen komt waarschijnlijk door de beperkte 
initiële BMP-2 afgifte. Dit illustreert hoe complex de afgiftekinetiek van 
groeifactoren is. De afgiftekinetiek van groeifactoren wordt waarschijnlijk sterk 
beïnvloed door vele variabelen zoals eerder beschreven [4]. Tot op heden blijft het 
onduidelijk in hoeverre de BMP-2 ladingsmethode invloed heeft op de biologische 
prestatie van CPC in een botomgeving. Ondanks de onduidelijkheden ten aanzien 
van het effect van BG op de langere termijn en het effect van BMP-2 
ladingmethodes in een botomgeving, is de integratie van de additieven BG en BMP-
2 in CPC veelbelovend. Daarom kan mogelijk zowel BG als BMP-2 gebruikt worden 
als belangrijke component in de ontwikkeling van goed botsubstitutie materiaal. 
De meerderheid van de patiënten die regeneratie van (grote) botdefecten met 
botvervangend materiaal nodig hebben, hebben een suboptimale medische 
toestand en dus een suboptimaal botmetabolisme. Osteoporose patiënten 
vertegenwoordigen een groep patiënten met een zogenaamd ‘worst-case’ 
scenario, waarbij het botmetabolisme zodanig slecht is dat er een duidelijk effect 
zichtbaar is ten aanzien van de botkwaliteit. Hierdoor is het noodzakelijk om een 
efficiënt CPC te ontwikkelen die de botdefecten in deze groep patiënten goed kan 
herstellen. De verschillen in botmorfologie en metabolisme tussen zieke en 
gezonde individuen duidt op een verschillende biologisch prestatie van CPC. In dit 
proefschrift is voor het eerst de biologische prestatie van CPC/PLGA onder 
osteoporotische omstandigheden gerapporteerd (hoofdstuk 6). Hieruit bleek dat 
om een goede botregeneratie onder osteoporotische omstandigheden te 
verkrijgen extra toevoegingen aan het bestaande CPC/PLGA noodzakelijk zijn. De 
onderzochte additieven, BG en BMP-2, in dit proefschrift zijn goede kandidaten om 
de biologische prestatie van CPC/PLGA onder osteoporotische omstandigheden te 
verbeteren. Hierdoor is het noodzakelijk dat vervolgonderzoek zich richt op 
mogelijkheid van deze en  eventueel andere additieven om de biologische prestatie 
van CPC in osteoporotische patiënten te verbeteren. 
Vanuit een biologisch en kosteneffectief oogpunt (d.w.z. potentiële risico's van 
bijwerkingen, arbeidsintensiviteit en de kostprijs) zou het gebruik van biologisch 
actieve moleculen beperkt moeten worden. Het is noodzakelijk een compromis te 
vinden tussen de kostprijs van CPC en de biologische activiteit van het materiaal. Bij 
voorkeur moeten artsen de mogelijkheid hebben om de meest geschikte CPC te 
selecteren voor elke specifieke klinische toepassing. Voor het bereiken van een 
dergelijke aanpak is de uitdaging om de juiste combinatie van (i) 
gestandaardiseerde keramische cement matrix, (ii) de specifieke aard van 
toegevoegde poriën, en (iii) additieven te identificeren, afhankelijk van de 
patiëntspecifieke omstandigheden (zoals defectgrootte, locatie, leeftijd en 
medische conditie). Een laatste voorwaarde is dat het opmaat gemaakt 
injecteerbare CPC beschikbaar is in een eenvoudig, duidelijk en controleerbaar 
applicatiesysteem dat de toepassing van CPC met optimale 
verwerkingseigenschappen (o.a. goede viscositeit en uitharding van het materiaal) 
mogelijk maakt. 
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verbonden. Het is fijn te weten dat waar ik ook ben en wat ik ook doe jullie er zijn. 
Ik ben zo blij en trots dat jullie mij vriendinnetjes zijn! 
Familie Abbink, Lieve Bas, Bep, Esther en Gerrit bedankt voor alle relaxte 
weekendjes. Het is prettig om een tweede familie te hebben waar je je thuis voelt.  
Oma Martens, Lieve Oma, u bent echt de allerliefste oma van de hele wereld! Als ik 
ook maar iets van uw geheugen had geërfd was ik een genie geworden.  
Mijn broer, Lieve Daan, bedankt voor het zijn van een echte grote broer; eentje die 
af en toe pest, waarmee je een gezellig avond kunt hebben maar waar je ook naar 
toe kan voor advies. Iedereen zou een broer moeten hebben zoals jij! Ohja en na 
jaren van ‘proefjes doen’ is het met gelukt, een hogere academische titel…  
Mijn ouders, Lieve papa en mama, mijn doktors titel is het bewijs van jullie steun, 
stimulatie en vertrouwen in mijn kunnen. Misschien wisten jullie niet precies wat ik 
aan het doen was, maar jullie waren (en zijn) er altijd voor mij. Het is enorm fijn om 
te weten dat je altijd en overal een thuis hebt! 
Als laatste Wout, natuurlijk sta jij ook bij mij op deze plaats… Lieve Woutje, vaak 
denk ik dat ik het wel alleen kan als zelfstandige vrouw maar met jouw arm om mij 
heen is alles zoveel leuker, fijner en vooral mooier. Ik ben zo ontzettend gelukkig 
door jouw liefde en steun aan mij maar vooral ook omdat we enorm met en om 
elkaar kunnen lachen. Je haalt oprecht het beste in me naar boven. Ik vind je lief! X 
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